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ABSTRACT
USING AN IN VITRO-IN VIVO CORRELATION FOR THE
‘BIOEQUIVALENCE BY DESIGN’ DEVELOPMENT OF AN IMMEDIATE RELEASE
CARBAMAZEPINE PRODUCT

By
Douglas G. Steinbach
December 2018

Dissertation supervised by James K. Drennen, III, Ph.D.
The quality of a drug product may be characterized by the consistency with which its indicated
clinical effect, and safety profile, is experienced by the patient. The concept that such quality should
be built into a product is at the core of the United States Food and Drug Administration’s (FDA) quality
by design (QbD) initiative. This vision for pharmaceutical product development emphasizes the riskbased identification of critical quality attributes (CQA) which summarize a product’s performance, the
efficient refinement of critical product/process parameters (CPP) that can affect such attributes, and the
systematic development of CPP limits, which assure appropriate performance of CQAs. For a tableted
drug product, a cornerstone CQA is dissolution.
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Often, a formulation and/or manufacturing process can change during a patient’s course of treatment,
potentially jeopardizing the consistent performance of the drug product. Regulatory agencies typically
require that sponsors demonstrate how the generic/post-change product is bioequivalent to the
reference/pre-change product. While in vivo clinical trials are one strategy for demonstrating this,
sponsors typically prefer in vitro dissolution tests as an alternative. During these in vitro test, the F2
metric is commonly used to assess dissolution profile similarity. This work sought to compare the F2
method with an alternative method, on the basis of errors in bioequivalence. The alternative method was
based on the use of a physiologically based in vitro-in vivo correlation (PB-IVIVC) model that had been
nested within a clinical trial simulation platform. The PB-IVIVC method provides a direct link from
dissolution performance to clinical performance. Thus, when it is used to refine a CPP-vs-dissolution
response surface, based on the performance of reference product, the assurance of clinically defined
bioequivalence can be directly built into a model tablet system.
The model drug product for this work was an immediate release carbamazepine tablet. Carbamazepine
was selected as the model active pharmaceutical ingredient because it has a narrow therapeutic index and
is designated as a class II compound (i.e. high permeability, low solubility) according to the FDA’s
biopharmaceutics classification system (BCS). As such, this compound is identified within the FDA’s
scale-up and post-approval change guidance as possessing elevated risk for biononequivalence when
changes are imposed to its formulation and/or manufacturing process.
After gathering single dose in vitro-in vivo data from the literature, the construction of the PB-IVIVC
began according to a two step process. Here, the respective parameters for the rate and extent of each
product’s absorption were calculated using classical pharmacokinetic modeling and then regressed
against each product’s rate and extent of dissolution. Next, the classically defined clearance parameter
was replaced using a physiologically based clearance model. This allowed routinely available population
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pharmacokinetic data to be combined with first principles of human physiology, for the mechanistic
prediction of intersubject variability via correlated Monte Carlo simulations. This PB-IVIVC was then
used to not only define the CPP ranges for the model carbamazepine tablet system that would directly
provide for bioequivalent performance, but to perform a post hoc assessment of the CPP ranges conferred
by the use of F2 statistic. Ultimately, the results showed that when the product’s CPPs were refined
using the F2 statistic the was higher risk of biononequivalence was higher when comparted to a product
that had been refined using the PB-IVIVC. It is intended that this work support the movement of
product/process optimization practices away from methods that result in rigid factors of unknown clinical
significance, and towards those that are focused on efficiently achieving specific clinical objectives.
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Chapter 1. Introduction
1.1

Bioequivalence Assessment: Current Practice and Associated

Issues
The first pharmaceutical regulations were born from society’s need for quality drug
products. A concept common to most definitions of pharmaceutical quality involves meeting
or exceeding patients’ needs. For individuals on established medication regimens, quality is
largely defined in terms of consistency. The expectation is that the medication will perform
consistently throughout the duration of therapy. Bioequivalence studies are used by sponsors
to assure consistent product performance despite the occurrence of product variations (e.g.
scale up, post approval changes [SUPAC], and therapeutic conversion to generic product).
Drug products are considered bioequivalent by the Food and Drug Administration (FDA)
when there is no statistical difference in the rate or extent of absorption between the
comparators.1 In vivo and in vitro methods may be used to establish bioequivalence
according to the Code of Federal Regulations (CFR) Title 21.2
Generic drug applications typically rely on at least one in vivo clinical trial for
bioequivalence as the cornerstone of their abbreviated new drug application. Such trials have
often been considered the most rigorous means of assessing bioequivalence. The statistical
assessment of bioequivalence requires that inter-subject variability be accounted for
during the calculation of the critical values of a hypothesis test or confidence interval.
Traditionally, inter-subject variability is estimated within the treatment periods of
conventional bioequivalence studies. These studies typically rely on a small cohort (n
≈ 24) of young healthy patient volunteers who generally undergo a single dose of the
test and reference drug products. The reliability of inter-subject variability estimates
1

can be increased by i) using clinical trials in the actual patient population, and ii)
performing them on the scale of trials conducted during the second and third clinical
development phases. The time and overhead demands that such large scale trials place on
pharmaceutical sponsors, however, is substantial. This reality, along with the ethical
limitations associated with the performance of in vivo trials in a clinical population for the
sole purpose of quality assessment results in the avoidance of such measures during the
assessment of bioequivalence. However, this necessary compromise often results in the
tenuous assertion that the inter-subject variance estimates defined by the pharmacokinetic
conditions expressed in the healthy, single-dosed bioequivalence study populations are
representative of those PK conditions expressed by the actual patient population during dayto-day clinical practice. The reliance upon this assertion can lead to erroneous inferences
being drawn in in vivo trials aimed at the assessment of consistent product performance.
Other factors that limit the reliability of bioequivalence testing include: the ethical restrictions
that limit testable strengths, the study design limitation associated with narrow therapeutic
index drugs the often subjective nature of efficacy/toxicity, and the appropriateness of
washout periods.3,4
Brand drug sponsors encounter activities related to the assurance of bioequivalence
during changes to a product or manufacturing process. Unlike generic drug sponsors, the
sponsors of new drugs typically avoid the clinical demonstration of pre-vs-post change
bioequivalence. This avoidance is due, in part, to the minimal amount of information yielded
from traditional in vivo bioequivalence trials (i.e., pass or fail), the absence of long-term
safety data, and the large amount of resources required to run a clinical trial, and the expenses
due to downtime. In vitro approaches are more expedient and resource sparing. Here, the
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similarity of dissolution profiles is typically evaluated using an empirical USP window
criteria, or in the absence thereof, the F2 statistic.5,6 A limitation of this approach is that
inter-subject variability is no longer accounted for by these quality measurements. Such
methods do not provide for the continuous movement toward a risk-based and science-based
approach of pharmaceutical quality as articulated in the Pharmaceutical CGMPs for the 21st
Century and echoed by Dr. Janet Woodcock (the FDA’s acting director for the Center for
Drug Evaluation and Research).7,8 In a perspective article, Woodcock identified the primary
cause of most pharmaceutical quality issues to be a weakly defined link between critical
quality attribute (CQA) measurements and clinical performance citing dissolution based
biowavers as a specific example of where this can occur.9
The concept that a strong link between the surrogates of in vivo performance and
clinical response is essential for the efficient assurance of quality is a foundational principle
this work. An example of the ramifications stemming from a weak link between a quality
measurement and clinical significance can be seen in the 2012 recall of 300mg extended
release generic product of Buproprion (trade name Wellbutrin XL). The generic sponsor
was attempting to bring to market two strengths of an extended release Buproprion product:
150 mg and 300mg. The 150mg generic drug product had a sufficiently wide therapeutic
plasma concentration window. Thus, it was approved for the market following a traditional
in vivo generic-vs-brand in bioequivalence trial. The 300mg dose however, was associated
with an increased risk of seizures, making clinical trials for bioequivalence prohibitive.
Therefore, after the 150mg was approved the FDA approved the 300mg form in 2006 based
on 1) the formulation of the 300mg generic product being proportionally equivalent to the
150 mg generic product, and 2) satisfactory compendial (USP) dissolution tests of the 300
3

mg product. Unfortunately, reports of increased side effects or reduced efficacy (subjectively
defined) began soon after the generic entered the market. In vivo clinical trials were
performed in 2012, showing a significant difference between the performance of brand and
generic formulations, ultimately necessitating a product recall.
A literature review by Desmarais et al. suggests the Bupropion incident may not be
isolated.10 The researchers examined the PubMed database to find works related to adverse
events following the brand-to-generic switching of psychotropic medications. The work
notably excluded pharmacokinetic studies conducted with healthy volunteers unless it
contained data relevant to the clinical population. The researchers expressed significant
concerns when the results indicated a large and growing body of literature reporting an
increased risk of adverse events following switches. Similarly, several large scale (n > 1500)
case-control studies have specifically found that changes in anticonvulsant drug formulation
involving generics was a risk factor for emergency or hospital-level treatment of epilepsy
(OR: 1.78 to 1.81).11-12 The combined evidence in the literature suggests that the origin of
bioequivalence related failures is multifaceted, resulting, in part, from the practical
limitations of conventional clinical methods and the absence of clinically relevant quality
specifications.
While a strong link between the surrogates of in vivo performance and clinical response
is critical for the market entry of generic drug products, it is also important for navigating the
product/process changes that can occur over the lifecycle of a brand or generic product. The
inevitable reality of change events is evident in the focus of recent ‘scale-up/post-approval
change’ regulatory documents (e.g., see ICH Q12 draft guidance). A theme shared by this
and other documents is an emphasis on how a sponsor’s possession of advanced product and
4

process knowledge can contribute to a reduction in the number of subsequent regulatory
submissions. The assurance of such flexibility comes from effectively incorporating
knowledge–driven tools and strategies within the initially approved Pharmaceutical Quality
System. Thus, product/process changes can be made with less need for extensive regulatory
oversight prior to implementation due to prior approval. According to the CFR, one of the
most informative and preferred methods by the FDA for the overall determination of
bioequivalence is one that correlates in vitro tests with human in vivo bioavailability data.
However, current IVIVC (in vitro-in vivo correlation) guidance documents and literature
focus on illustrating best practices for extended release products that are Biopharmaceutical
Classification System (BCS) class I and III. Therefore, research on the development of
adequate surrogates for clinical performance (and the illustration of such practices) is
critical for immediate release products that are BCS class II. This is especially critical for
therapies that are associated with a narrow therapeutic index.
The model drug in this dissertation is carbamazepine. The difference between the toxic
plasma concentrations and the minimum effective plasma concentration for this compound
is approximately three fold and as such is generally considered to have a ‘narrow therapeutic
index’.

Additionally, the release performance of tableted formulations containing

carbamazepine as the active pharmaceutical ingredient (API) has been demonstrated to be
sensitive to product/process variability. These features, combined with the biochemical
properties which place it in the category of a BCS class II compound, makes a solid oral
dosage form of carbamazepine a high-risk product from a bioequivalence perspective.
Therefore, carbamazepine was considered a suitable model system for this project.

5

1.2.

Hypothesis, Specific Aims, and Purpose
The intent of this work is to strengthen the understanding between quality
assessment measurements and clinical performance according to quality by design
(QbD) principles. This dissertation is based on the central hypothesis that,
for an immediate release carbamazepine product,
a physiologically-based IVIVC, coupled with a clinical trial simulation
platform, provides a more accurate estimation of bioequivalence than
the conventional F2 similarity criterion during the comparative
assessment of test vs. reference product performance.
Given this, four specific aims were performed for the assessment of the central
hypothesis of this dissertation.
Specific Aim 1:
Develop an IVIVC for an immediate release carbamazepine product using
a classical pharmacokinetic model
-●The ability of an IVIVC to predict an entire plasma concentration profile given a
product’s dissolution performance enhances its meaningfulness. This is often achieved
by constructing a hierarchical framework around a pharmacokinetic model. The goal
of the first specific aim is to construct an IVIVC that can predict the entire plasma
concentration profile by parameterizing its pharmacokinetic model using mean plasma
concentration profiles of carbamazepine products in a normal healthy population. In
using plasma data as the basis for pharmacokinetic parameterization, the approach is
termed: top down pharmacokinetic modeling (i.e. pharmacokinetic parameters are
solely informed by the plasma concentration profiles).
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Specific Aim 2:
Account for population level pharmacokinetic variance within the
pharmacokinetic model of the in vitro-in vivo correlation by appropriately
integrating physiologically based inter-subject variability
-●Equivalence testing requires that variance of the response be taken into consideration
during the assessment.

The identification of population-level pharmacokinetic

variance typically relies of inefficient large-scale in vivo trials (i.e. top down). In this
work, pharmacokinetic variance will be accounted for from the bottom up by coupling
the results of quantitative pharmacologic assays performed in vitro, with systemic
physiologically based pharmacokinetic modeling and simulation.

Specific Aim 3:
Define a formulation for an immediate release carbamazepine tablet and model
its change in dissolution performance as a function of defined critical attributes
-●The mathematical equations used to model the immediate release dissolution
behavior of a tablet can be manipulated to generate a host of profiles ranging from
mono-exponential curves to sigmoidal shapes. Specific aim three ensures that the two
bioequivalence assurance methods identified in the hypothesis are compared across
a realistic spectrum of dissolution profiles.

Specific Aim 4:
Derive a distribution of clinical responses resulting from use of an F2-based
equivalence criteria and compare with that derived from a physiologically based
IVIVC on the basis of type I/II errors in bioequivalence
-●The fourth specific aim of this work is the culmination of the first three specific
aims. After defining the dissolution performance of the benchmark product, this
specific aim uses the physiologically based IVIVC (developed from specific aims
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one and two) to process the interpolated F2 dissolution profiles (from specific aim
three) and generate a distribution of clinical responses. This F2-distribution of
clinical responses can then be compared against the reference distribution of clinical
responses representing all of the responses that would be bioequivalent to the
benchmark product. This will be performed through integration of the respective
probably density functions.

While IVIVCs are of significant interest to regulatory agencies, and the subject of much
research, their approval rate remains relatively low. This is despite the compounding costs
to society and sponsors that stem from unintended delays to product development timelines
due to a sponsor’s inability to assure that an observed difference in dissolution performance
is inconsequential. The use of an IVIVC provides a path towards avoiding such delays as
they provide a more informative interpretation of pivotal dissolution tests. The intention of
this dissertation is to provide a streamlined framework to facilitate the development of a
population level IVIVC via physiologically-based pharmacokinetic modeling and
simulation for informing clinically-based decision making during product development.
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1.3.

Advancing Pharmaceutical Quality: In vitro-In vivo Correlation
Models
According to an FDA guidance document entitled “Extended Release Oral Dosage

Forms: Development, Evaluation, and Application of In vitro/In vivo Correlations”
there are three in vitro-in vivo correlation (IVIVC) levels: A, B, and C. The differential
criteria for these three levels have been generally accepted by numerous regulatory
agencies and scientific communities. The levels differ primarily in theamount of detail
required of both input and output data. The defining characteristic of a level A IVIVC
is the ability to predict the entire in vivo time course from the in vitro data. A level B
IVIVC uses the principles of statistical moment analysis (e.g., the output is defined in
terms such as the mean residence time); it does not uniquely reflect the actual in vivo
plasma level curve because a number of different in vivo curves will produce similar
mean residence time values. Similarly, a Level C correlation does not reflect the
complete shape of the plasma concentration time curve; instead, it draws a relationship
between an amount dissolved at a given time and some summary pharmacokinetic
parameter such as the area under the curve (AUC), maximum plasma concentration, or
the time of the maximum plasma concentration.
Level A correlations are the most common type of correlation provided in NDAs
submitted to the FDA according to guidance documents and other regulatory
literature.13 This is because the the level A IVIVC is considered the most informative.
The specifics for establishing a level A correlation is left up to the sponsor. Examples
cited in the guidance document make reference to convolution and deconvolution
methods; however, numerous methods for creating a level A IVIVC exist.
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A

subsequent section will detail the areas of commonality and differentiation among these
methods.

1.4.

Theoretical Background for Project
The feasibility of this project is based on the founding principles of the Biopharmaceutical

Classification System established by Amidon et al. and subsequently adopted by the FDA.14,15
This system is based on solubility and permeability and is used, in part, to guide expectations
concerning the rate limiting step of absorption; i.e., dissolution rate limited, permeability
limited, and solubility–permeability limited.

Here, the systemic absorption of a high

permeability, low solubility drug is considered dissolution rate limited. Amidon et al. justified
such expectations by combining the Noyes-Whitney Equation and a first-order absorption rate
model to describe the fraction of drug absorbed (see eq. 1.4.1).

Eq. 1.4.1)
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)]

through the absorption site

The existence of a dissolution rate limited scenario was illustrated by calculating
lim

→

Eq.1.4.2. (see eq. 1.4.2 for result). If the rate of permeation into the systemic

circulation is instantaneous relative to the rate of drug dissolution (i.e., solubilized drug is
immediately absorbed and sink conditions are
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effectively generated; 𝑘

>>𝑘

), systemic absorption can be considered limited by the

rate of dissolution.
Eq. 1.4.2)
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)]

In the seminal work, Amidon et al. describe expectations concerning possibility of
successfully developing an in vitro-in vivo correlation for immediate release products
based on solubility and permeability. Table 1.4.1 presents these expectations, which were
subsequently adapted in guidance documents released by numerous regulatory agencies.
Table 1.4.1 In vitro-in vivo Correlation Expectation for Immediate Release Products Based on
Biopharmaceutics Class (Adapted from Amidon et al. (1995) 14)
Class
I

Solubility
High

Permeability

In vitro-In vivo Correlation Expectation

High

In vitro-in vivo correlation expected if dissolution rate is
slower than gastric emptying rate, otherwise limited or no
correlation

II

Low

High

In vitro-in vivo correlation expected if in vitro dissolution
rate is similar to in vivo dissolution rate, unless dose is
very high

III

High

Low

Absorption (permeability) is rate determining and limited
or else no in vitro-in vivo correlation with dissolution rate

IV

Low

Low

Limited or no in vitro-in vivo correlation is expected

A limited correlation means that the dissolution rate, while not the absolute rate controlling step, may be similar to the
absorption rate; thus, the extent of correlation will depend on the relative rates
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Chapter 2. Literature Survey
The major areas of interest and implication for this work include i) events that
require the assessment of bioequivalence, ii) the approaches used to assess
bioequivalence, iii) in vitro-in vivo correlation modeling, and iv) physiologically based
modeling. Therefore, this document will begin by reviewing these concepts using
pharmaceutical science literature. Additionally, it is a reality of the pharmaceutical
industry that drug product development activities are shaped by federal guidances and
regulations. Therefore, this section also covers regulatory policies pertinent to the
assessment of bioequivalence in the pharmaceutical industry.

2.1 The Assessment of Bioequivalence
2.1.1 Regulations, Guidances, and Examples
Title 21 of the Code of Federal Regulations (CFR) governs food and drugs within the
United States by the Food and Drug Administration. Sections 200 and 300 include
regulations pertaining to pharmaceuticals. The specific sections in the CFR which i)
identify the circumstances that require the assessment of bioequivalence, and ii) discuss
the methods for its evaluation, are identified in Table 2.1.1.1.
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Table 2.1.1.1. Relevant Sections of the Code of Federal Regulations Related to BA/BE
21CFR section
Type of provision/information
314.94(a)(9) Chemistry, manufacturing, and controls; permitted changes in inactive ingredients for parenteral,
otic, ophthalmic, and topical drug products
320.1
Definitions of bioavailability, pharmaceutical equivalents, pharmaceutical alternatives, and BE
320.21
Regulatory requirements related to submission of in vivo bioavailability and bioequivalence data
320.22
Criteria for waiver of evidence of in vivo bioavailability or bioequivalence data
320.23
Basis for measuring in vivo bioavailability or demonstrating bioequivalence
320.24
Types of evidence to measure bioavailability or establish bioequivalence
320.25
Guidelines for the conduct of an in vivo bioavailability study
320.26
Guidelines on the design of a single dose in vivo bioavailability or bioequivalence study
320.27
Guidelines on the design of a multiple-dose in vivo bioavailability study
320.28
Correlation of bioavailability with an acute pharmacological effect or clinical evidence
320.29
Analytical methods for an in vivo bioavailability or bioequivalence study
320.30
Inquiries regarding bioavailability and BE requirements and review of protocols by the FDA
320.38
Retention of bioavailability samples
320.63
Retention of bioequivalence samples
Adapted from the CFR and Midha et al. (2009) 16

Section 320.21 specifically references the role of bioequivalence studies with respect to
abbreviated new drug applications (ANDAs) and supplements to new drug applications
(NDAs). The regulations of this section may be summarized as in the following table.

Table 2.1.1.2. Summary of Requirements for Submission of Bioequivalence Data
cited in 21CFR320.21

Supplements to
NDAs

ANDAs

 Any sponsor submitting an abbreviated new drug application to FDA shall include in
the application either:
 Evidence demonstrating that the drug product that is the subject of the abbreviated
new drug application is bioequivalent to the reference listed drug

 Information to show that the drug product is bioequivalent to the reference listed
drug which would permit FDA to waive the submission of evidence demonstrating
in vivo bioequivalence [i.e. a biowaiver]
 Any person submitting a supplemental application to FDA shall include in the
supplemental application the evidence or information set forth in the section above if
the supplemental application proposes any of the following changes:

 A change in the manufacturing site or process, including a change in product
formulation or dosage strength, beyond the variations provided for in the approved
application
For full text of CFR title 21 section 320.21 see: [17]
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Events which may necessitate submission of bioequivalence data are identified in section
320.21 as “changes beyond those provided for in the approved drug application.” Such
changes can often occur over the lifecycle of a product. Section 314.70 provides further
detail regarding the nature of a proposed change by identifying three categories: minor,
moderate, and major. The classifications are based on the “potential to have an adverse
effect on the identity, strength, quality, purity, or potency of the drug product as these
factors may relate to the safety or effectiveness of the drug product.” Determining the
magnitude of this potential adverse effect is performed during the review process of the
application for change approval. However, it can be stated that the FDA typically errs on
the side of caution, often electing to require in vivo assessments of bioequivalence in the
absence of rigorously supported justification(s) for the waiver of such trials (i.e.,
biowaiver). Examples for minor, moderate and major changes are provided in section
314.70. A selection of notable instances are contained in Table 2.1.1.3.
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Table 2.1.1.3. Summary of the Severity of Changes to New Drug Applications
Cited in 21CFR314.70

Moderate
Major

Severity of change

Minor

Examples

Examples
 The deletion or reduction of an true colorant
 Replacement of manufacturing equipment with that of the same design and
operating principles
 Change in the size and/or shape of a nonsterile solid dosage form container
without a change in system
 Change in the container closure system
 An increase or decrease in biopharmacutical production scale during finishing
steps that involves different equipment
 Addition to a specification or changes in the methods or controls to provide
increased assurance that the drug substance or drug product will have the
characteristics of identity, strength, quality, purity, or potency that it purports or is
represented to possess
 Changes that may affect drug substance or drug product sterility assurance
 Changes in the synthesis or manufacture of the drug substance that may affect the
impurity profile and/or the physical, chemical, or biological properties of the drug
substance
 A change in the manufacturing site or a change in the manufacturing process,
including a change in product formulation or dosage strength, beyond the
variations provided for in the approved application.
For full text of CFR title 21 section 314.70 see: [18]

The CFR is considered to be federal law. Therefore, sponsors must interpret the
document as legally-binding regulations. The FDA, in an effort to complement the CFR,
periodically releases “Guidance for Industry” documents. Guidance documents represent
the Agency's current thinking on a particular subject. They do not create or confer any
rights for or on any person and do not operate to bind FDA or the public. The primary
guidance document concerning the regulatory imposition of studies for the assessment of
post-approval bioequivalence is entitled, Immediate Release Solid Oral Dosage Forms;
Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In vitro
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Dissolution Testing, and In vivo Bioequivalence Documentation (henceforth referred to as
the SUPAC guidance).

This SUPAC guidance provides the following support to industry:
i)

a framework of product lifecycle management categories within which
changes occur

ii)

examples of levels of change that can occur within each category

iii)

suggested chemistry, manufacturing, and controls (CMC) tests for each level
of
change

iv)

in vitro dissolution tests and/or in vivo bioequivalence tests for each level of

change
v)

documentation to support the change.

The four specifically described categories in which a change can occur are identified as i)
changes to the components and composition of the drug product ii) site changes iii) changes
in the batch size (scale-up/scale-down), and iv) changes to the manufacturing process. The
differences in these categories are described in Table 2.1.1.4.
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Table 2.1.1.4. Post Approval Change Categories as Defined in the SUPAC Guidance
Category of
SUPAC-defined Change
Components and composition
Site

Batch size
(scale-up/scale-down)

Manufacturing

Description
Focuses only on [batch-wise] changes in excipients and not on changes in
the amount of drug substance
Changes in location of the site of manufacture for both company-owned
and contract manufacturing facilities
Postapproval changes in the size of a batch from the pivotal/pilot scale
biobatch material to larger or smaller production batches call for
submission of additional information in the application.
Scale-down below 100,000 dosage units is not covered by the SUPAC
guidance
Changes that may affect both equipment used in the manufacturing
process and the process itself.
For full text of SUPAC Guidance see: [19]

The SUPAC guidance echoes the CFR by identifying up to three levels of change within
each category (now referred to as levels 1, 2 and 3). Some of the general examples used
in the SUPAC guidance broadly mirror those found in the CFR. However, the guidance
moves a step beyond the qualitative criteria used in the CFR (e.g.,likelihood of detectable
impact vs. potential to have an adverse effect, respectively) by citing quantitative examples
and invoking the concepts of therapeutic range, solubility, and permeability in definitions
and examples. In each category, the levels are uniquely defined, with a guiding principle
of maintaining pharmaceutical quality (i.e., consistently meeting the needs of the patient)
over varying degrees of change.
Level 1 changes are defined as component and composition changes that are unlikely
to have any detectable impact on quality and performance (e.g., nonfunctional colorants).
An example of level 1 changes includes changes to excipients that do not effect API
performance characteristics. Such changes are cited as percentage-wise (w/w) changes of
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total formulation, less than or equal to the following ranges and predicated on the sum of
all excipient changes being < 5%:
“filler”



±5

“starch disintegrant” (or other)



±3 (±1)

“binder”



±0.5

Ca or Mg stearate lubricant (or other)



±0.25 (±1)

talc glidants (or others)



±1 (±0.1)

“film coating”



±1

It is minimally suggested that such changes be formally filed with the FDA for prior
approval. Instead, the suggestion is to document level 1 changes as part of the sponsor’s
annual report.
Level 2 changes to excipients are broadly considered as those that “could have a
significant impact on formulation quality and performance.”

Suggestions for the

assessments of consistent performance, and the filing of the associated documentation, for
a level 2 change vary depending on three prefaced factors of the API in the drug product
whose excipients are undergoing some change, namely the therapeutic range (i.e., narrow
or non-narrow), solubility (i.e., low or high), and permeability (i.e., high or not high).
Identified examples of level 2 excipient changes can include the technical gradte of an
excipient. Additionally, examples of level 2 changes are once again identified as changes
in the relative percent, only now the when the degree of change is double than those
thatwhat could be considered a level 1 changes. Here, specific dissolution tests are
recommended for BCS class I, II (e.gi.e., Carbamazepine), and III with the suggestion for
in vivo bioequivalence documentation still being dnone if the situation meets the previous
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BCS-based dissolution test. If the dissolution tests are not metdo not meet the requirements
for level 2, then the recommendation is to refer to level 3 changes. Level 3 changes are
those that are “likely to have a significant impact on formulation quality and performance.”
Suggestions for the assessments of consistent performance, and the filing of the associated
documentation, for a level 3 change vary depending on the therapeutic range, solubility,
and permeability of the drug product’s API. Some cited examples
of level 3 changes are:


Any qualitative and quantitative excipient changes to a narrow therapeutic index drug
beyond the level 1 ranges



Level 1 and 2 changes that occur in BCS class 4 drugs (i.e. low permeability and low
solubility)



Changes in the excipient ranges of all drugs beyond those considered to be level 2

A generally defined dissolution test is recommended for all level 3 changes (i.e. multi-point
dissolution profile from the application/compendial medium at 15, 30, 45, 60 and 120
minutes or until asymptote). Additionally, a full bioequivalence study is recommended.
However, the bioequivalence study may be waived where an acceptable IVIVC has been
established. Based on this information, it can be expected that in vivo bioequivalence
assessment will be required by the FDA for the approval of excipient changes to an
immediate release carbamazepine product (due to carbamazepine’s narrow therapeutic
index and status as BCS Class 2) beyond those identified as level 1, unless a suitable IVIVC
exists.
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Changes to an approved manufacturing process are the other instance were
bioequivalence trials are recommended by the SUPAC guidance. Specifically, such trials
are recommended for level 3 manufacturing process changes. This level includes processes
change such as a change from wet granulation to direct compression of dry powder. Here,
the same recommendations for the performance of dissolution trials and bioequivalence
hold true, as as previously described in the case of level 3 excipient changes.
It should be noted that the descriptions for the specific level of change are not defined
in totality;the level is defined as part of the iterative review process.

2.1.2 Current practices for the Assessment of Bioequivalence
Current approaches for the demonstration of bioequivalence can be classified as
being performed either in vitro or in vivo. Section 320.24 in the CFR describes types of
evidence to measure bioavailability or establish bioequivalence. The following summary
of in vivo and in vitro approaches, in descending order of accuracy, sensitivity, and
reproducibility, are acceptable for determining the bioavailability or bioequivalence of a
drug product:
1. a) An in vivo test in humans in which the concentration of the active ingredient in
the plasma is measured as a function of time (i.e. a pharmacokinetic method)
b) An in vitro test that has been correlated with and is predictive of human in vivo
bioavailability data (i.e. an IVIVC)
2. An in vivo test in humans in which the concentration of the active ingredient in
the (urinary) excretions of subject are measured as a function of time.
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3. An in vivo test in humans in which an appropriate acute pharmacological effect of
the active moiety, and are measured as a function of time (i.e. a
pharmacodynamic method)
4. Well-controlled clinical trials of safety and effectiveness, for purposes of
demonstrating bioequivalence. This approach is one of the least accurate,
sensitive, and reproducible of the general approaches for measuring
bioavailability or demonstrating bioequivalence.
5. A compendial in vitro test acceptable to FDA (i.e. USP based dissolution test)

Interestingly an IVIVC is in fact the most preferred method for bioequivalence
determination after pharmacokinetic methods.

2.1.2.1 In vivo Assessment of Bioequivalence
A detailed protocol, including study objective(s), patient inclusion criteria, dosing
schedules, a study design, and statistical methods, must be identified before a human
in vivo trial is conducted.
The objective of bioequivalence trials, as found in the pharmaceutical literature, are
based, typically, on the 21CFR320.1 definition of bioequivalence and the FDA
guidance documents on bioavailability and bioequivalence studies. They generally
recapitulate the objective for bioequivalence studies stated in the SUPAC guidance:
“To compare the rate and extent of absorption of the drug product for
which the manufacture has been changed, as defined in this guidance,
to the drug product manufactured prior to the change.”
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The patient inclusion criteria for in vivo bioequivalence trials is typically shaped by
ethical constraints. It is untenable to expose a patient who is medically dependent on
a certain drug product to a potentially toxic/ineffective product for the sole purpose of
determining bioequivalence. As such, bioequivalence studies are typically conducted
in healthy patients. Also, dosing schedules can again be ethically constrained by the
side effect profiles of medications. Most bioequivalence trials therefore utilize a singledose format as evidenced in a 2009 retrospective study conducted by several FDA
officials regarding bioequivalence trials of generic drug products approved by the
agency from 1996 to 2007.20

2.1.2.2 Trial design
Prospective experimental designs are used to analyze the effect of independent
variables. In vivo bioequivalence trials typically follow the characteristics of a
randomized controlled trial (RCT). According to the Cochrane Collaboration, RCTs
are highly regarded because they are designed specifically to minimize bias. By
randomly assigning participants to groups, for example, the likelihood that the groups
will differ on important baseline characteristics that confound the assessment of an
intervention (whether the investigator knows them or not) is minimized. The majority
of regulatory documents recommend a two-treatment, two-period crossover study with
an equal number of subjects randomly assigned to each of the two dosing
sequences.21,22 These regulatory documents typically make provisions that alternative
methods can be selected if appropriate. To maintain efficiencies, however, the most
common design employed is the 2-by-2 crossover design. This design allows each
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subject to serve as their own control, providing an increase in statistical power. This is
important because the statistical power of a simple parallel trial would be extremely
limited when considering that most clinical trials rely on only 24 to 36 healthy
patients.20
The 2-by-2 crossover designs means that there are two product groups (i.e. the
reference product and the test product) and two treatment sequences (test product
administration “crossed over” to reference product administration and vice versa; see
Figure 2.1.2.2.1).

Figure. 2.1.2.2.1 Illustration of a 2-by-2 Crossover Study Design
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Given the absorption and elimination kinetics for carbamazepine, this type of study can
take over two weeks (in addition to the setup time for such a trial). 23 Other higherorder designs exist but are rarely used; such methods account for high within-subject
variability. However, as recent FDA draft guidance states, carbamazepine has low
within-subject variability. 24
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2.1.2.3 Trial Analysis
Variability in outcomes is a hallmark trait of higher order biologic systems. It is
unrealistic to expect ‘test’ and ‘reference’ responses to ever be exactly identical.
Therefore, in vivo methods utilize intervals to define acceptable degrees of difference.
When analyzing the results of a clinical trial for bioequivalence, a generally stated goal
is to determine whether it is reasonable for one to expect the difference between test
and reference responses to exceed reasonable limits, given the observed data. In
statistical terms, the expected value for a normal distribution of responses is the mean.
In frequentist (classical) statistics, the standard deviation of a normal distribution is the
basis for defining the certainty with which the mean of a sample from a population (i.e.
subjects in a clinical trial) is said to be known.

Based on this, FDA has adopted the

two one-sided test (TOST) procedure described by Schuirmann et al. 25-27 The level of
bioequivalence most commonly recommended is average bioequivalence, there are
however other less frequently employed levels of bioequivalence which require higher
order study designs.1
Schuirmann’s TOST procedure begins by defining the hypotheses to be tested,
Eq. 2.1.2.3.1

𝐻

= 𝜇 −𝜇

≤ 𝜃

𝑣𝑠

𝐻

=𝜇 −𝜇 > 𝜃

= 𝜇 −𝜇 ≥ 𝜃

𝑣𝑠

𝐻

=𝜇 −𝜇 < 𝜃

and
Eq. 2.1.2.3.2

𝐻

Hypothesis 2.1.2.3.1 is tested to verify that the average bioavailability of the T product
does not exceed a lower limit (𝜃 ). Hypothesis 2.1.2.3.2 is tested to verify that the
average bioavailability of the T product does not exceed an upper limit (𝜃 ). In both
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equations, the null hypothesis (H0#) represents bioinequivalence. This setup is the
reverse of the ordinary view of hypothesis testing. During conventional hypothesis
testing the null hypothesis is usually the hypothesis of interest, but the set up in the
equations is more applicable for bioequivalence assessment. Here, the type I error (α)
is declaring the drugs to be bioequivalent, when they are not. By setting up the
hypothesis as shown, the consumer’s risk is protected. The two hypothesis tests can
performed using one sided t-tests
Eq. 2.1.2.3.3

𝑇 =

𝑌𝑇−𝑌𝑅 −𝜃𝐿
𝜎𝑑 𝑛1 +𝑛1
1
2

> 𝑡(𝛼, 𝑛 + 𝑛 − 2)

and
Eq. 2.1.2.3.4

𝑇 =

𝑌𝑇−𝑌𝑅 −𝜃𝑈
𝜎𝑑 𝑛1 +𝑛1
1
2

> 𝑡(𝛼, 𝑛 + 𝑛 − 2)

where 𝑌 is the average response of the T product, 𝑌 is the average response of the R
product, 𝑛 is the number of observations in the T product, 𝑛 is the number of
observations in the R product, and 𝜎 is the pooled sample standard deviation of period
differences from both sequences (see Equations 2.1.2.3.3 and 2.1.2.3.4). It is considered
an unbiased estimator of the true standard deviation (𝜎 ) in the absence of carryover
effects.
𝜎 =

𝜎

(2.1.2.3.5)

where,

𝜎

=

∑

∑

(𝑑 − 𝑑̅∙ ) and 𝑑 = (𝑦

25

−𝑦

)

Thus, the TOST procedure confirms bioequivalence if, and only if, 𝐻

and 𝐻

are

both rejected at a predefined -level; otherwise stated, when both |𝑇 | and |𝑇 | are
greater than test statistic: 𝑡(𝛼, 𝑛 + 𝑛 − 2).

2.1.2.4 In vitro Demonstration of Bioequivalence
2.1.2.4.1 Dissolution-based Biowaivers
The waiver of in vivo bioequivalence studies is federally provided under certain
conditions by 21CFR320.22. This type of a waiver is referred to as a biowaiver. The
circumstances stated in the CFR provides, for certain drug products, that bioequivalence
may be demonstrated by evidence obtained in vitro in lieu of in vivo data is summarized in
the following Table 2.1.2.4.1.1.
Table 2.1.2.4.1.1. Highlights of Requiments of Bioavailability and Bioequivalence
Assessments as Cited in 21CFR320.22
Bioequivalence may be demonstrated by evidence obtained in vitro in lieu of in
vivo data under one of the following criteria:
1) The drug product is in the same dosage form, but in a different strength, and is
proportionally similar in its active and inactive ingredients to another drug product for
which the same manufacturer has obtained approval and the following criteria are met:
a) The bioavailability of the other drug product has been measured
b) Both drug products meet an appropriate in vitro test approved by FDA, and
c) The applicant submits evidence showing that both drug products are
proportionally similar in their active and inactive ingredients.
2) The drug product is, on the basis of scientific evidence submitted in the biowaiver
application, shown to meet an in vitro test that has been correlated with in vivo data.
3) The drug product is a reformulated product that is identical, except for a different
color, flavor, or preservative that could not affect the bioavailability of the
reformulated product, to another drug product for which the same manufacturer has
obtained approval and the following conditions are met:
a) The bioavailability of the other product has been measured, and
b) Both drug products meet an appropriate in vitro test approved by FDA.
For full text of title 21 section 320.22 of the CRF see: [28]
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The critical role an IVIVC can play for the approval of a biowaiver application (as
referenced in criterion 2 of the previous summary table) is another example of its value.
As before, there are FDA guidance documents to augment section 320.22 of the CFR. One
such document is entitled Waiver of In vivo Bioavailability and Bioequivalence Studies for
Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification
System Guidance. This guidance explains how biowaivers can be requested for an IR solid
oral dosage forms based on its BCS class. The guidance notes that, "when combined with
the dissolution of the drug product, the BCS takes into account three major factors that
govern the rate and extent of drug absorption from IR solid oral dosage forms: (1)
dissolution, (2) solubility, and (3) intestinal permeability." However, this guidance is
focused on BSC class I/III products and does not address BCS-based biowaivers for the
narrow therapeutic index drugs.

Therefore, it is of little help for drugs such as

carbamazepine (i.e. BSC class II and a narrow therapeutic index).
Immediate release BCS class II products are discussed (albeit briefly) in the FDA’s
1997 guidance entitled Dissolution Testing of Immediate Release Solid Oral Dosage
Forms with no preclusions concerning the breadth of the therapeutic index. This document
specifically mentions BCS class II products in two sections: i) Approaches for Setting
Dissolution Specifications for a New Chemical Entity and, ii) In vivo-In vitro Correlations.
For dissolution specification setting, the guidance notes that “a two-point dissolution
specification, one at 15 minutes to include a dissolution range (a dissolution window) and
the other at a later point (30, 45, or 60 minutes) to ensure 85% dissolution, is recommended
to characterize the quality of the [BCS class II] product.” For IVIVCs, the guidance only
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states that an IVIVC may be possible with BCS class II products as opposed to BCS classes
I and III.

2.1.2.4.2 F2 Analysis
It is noted in the 1997 Dissolution Testing of Immediate Release Solid Oral Dosage
Forms guidance single-point dissolution tests and specifications have been employed in
evaluating scale-up and post-approval changes. This test may be appropriate for assuring
consistent product quality and performance for certain minor changes. For more major
changes however it is recommended that an entire dissolution profile comparison for
similarity be performed under identical conditions for the product before and after the
change(s). Indeed, this guidance, the biowaiver guidance, and the SUPAC guidance all
state that dissolution profiles may be compared using a similarity factor (F2).
F2 is a logarithmic reciprocal square root transformation of the sum of squared error.
This represents a measurement of the similarity in the percent (%) dissolution between
the two curves. This metric will be calculated using the mean dissolution profile of the
two products (test and reference), using the same time points for both the profiles (e.g.,
15, 30, 45, 60 minutes).
2

f 2 = 50  log{[1+ (1/n)(t =1) (R t - Tt ) ]-0.5  100}
n

In this equation, n is the number of time points, Rt is the dissolution value of the reference
(prechange) batch at time t, and Tt is the dissolution value of the test (postchange) sample
at time t. Curves are identical if F2 is 100. FDA guidances state that generally, F2 values
greater than 50 (50-100) ensure sameness or equivalence of the two curves and, thus, of
the performance of the test (postchange) and reference (pre-change) products.
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2.1.2.5 IVIVC Development
2.1.2.5.1 Levels of IVIVCs
There exist three levels of IVIVC: A, B, and C. A level C IVIVC establishes a
relationship between an amount dissolved at a specific time and a summary
pharmacokinetic parameter (e.g. AUC, Cmax, Tmax).A level B IVIVC uses the principles
of statistical moment analysis. The mean in vitro dissolution time is compared to either
the mean residence time or to the mean in vivo dissolution time. A level A IVIVC focuses
on the “the relationship between in vitro dissolution and the in vivo input rate.” According to
regulatory documents, a level A IVIVC is the most informative. Guidance points out that
“whatever the method used to establish a level A IVIVC, the model should predict the entire
in vivo time course from the in vitro data”.

2.1.2.5.2 Existing Methods for IVIVC Development
There are numerous approaches to developing an IVIVC. They can be considered as either
a one-step or a two-step procedure. The direct differential equation based method described
by Buchwald is a defining example of a one-step procedure.29 This method, and others like
it, directly relate the time-profiles of in vitro dissolution rates and in vivo plasma
concentrations by using a one compartment pharmacokinetic models and a corresponding
system of differential equations.” Here, the rate of in vivo input is connected to the rate of in
vitro dissolution through a time scaling/shifting function that was simultaneously
parameterized with the rates of clearance using fitting algorithms (e.g. Nelder-Mead). These
types of methods can be advantageous because they can recover in vivo plasma profiles from

29

several formulations directly from the in vitro dissolution data in a “single [modeling] step”.
However, these methods can be subject to overfitting. This can be avoided by placing
constraints on the parameters of the pharmacokinetic model parameters and time scaling
factors that are guided by a priori information.
Two step methods are typically referred to as deconvolution-convolution based methods.
In the first stage, the in vivo absorption profile (fraction absorbed vs. time) is deconvoluted
from the plasma concentration profile. Systematic methods for the deconvolution of the in
vivo absorption profile have been notably described by Wagner & Nelson, and Loo &
Riegelman.30,31 Other methods, based on noncompartmental analysis, exist for deconvoluting
of the in vivo absorption profile exist (e.g. Wagner32; Wang & Nedelman33; Gibaldi &
Perrier34) however they often require many assumptions to handle the underlying
pharmacokinetic behavior. Nevertheless, once the in vivo absorption profile has been
deconvoluted, the second stage is focused on regressing the in vivo absorption profile to the
in vitro dissolution profile. This is typically accomplished by any host of regression models
wherein the in vitro dissolution profile is the independent variable and the in vivo input profile
is the dependent variable. The model most frequently desired to achieve a satisfactory
recovery of the plasma concentration profile is a linear model. However, sometimes nonlinear
models such as the Weibull or Hill models are necessary. The reliance upon what is
essentially a regression model is why some authors prefer to call IVIVCs in vitro-invivo
regressions (IVIVRs).35 A graphical representation of the two step IVIVC procedure and the
one step IVIVC procedure can be found in the following Figure 2.1.2.5.2.1.
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Figure 2.1.2.3.2.1. Illustration of Conventional Two and One Step methods for
the Generation of an IVIVC
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2.1.2.5.3 Regulatory Perspectives on IVIVC Development
While there are several guidance documents and sections in the CFR that make reference
to the utility of IVIVCs, few specifically address the area of IVIVC development
methodologies. The FDA guidance entitled Dissolution Testing of Immediate Release Solid
Oral Dosage Forms is one such guidance that briefly discusses this area. As its title implies,
IVIVC development is referred to in only in the larger context of dissolution test development.
With respect to IVIVCs, this guidance focuses on how the presence or absence of clinical
differences should be used to develop the dissolution test. It described how at least three
batches that differ in the in vivo as well as the in vitro performance should be used to develop
an IVIVC. The guidance notes how “If the batches show differences in in vivo performance,
then in vitro test conditions can be modified to correspond with the in vivo data to achieve an
in vitro-in vivo correlation [and likewise modified for equivalence if no in vivo difference is
found].” This document does not detail how to evaluate an IVIVC for predictability.
The guidance does state that, very often, the in vitro dissolution test is found to be more
sensitive and discriminating than the in vivo test. It goes on to note that this is not entirely
undesired. This is because, from a quality assurance point of view, a more discriminative
dissolution method could indicate possible changes in the quality of the product before in vivo
performance is affected. However, this scenario is primed to raise inappropriate cause for
concern when the link between the in vitro quality measurement and clinical significance is
poorly defined.
The guidance document which does specifically address IVIVC development and
evaluation is entitled Extended Release Oral Dosage Forms: Development, Evaluation, and
Application of In vitro/In vivo Correlations (henceforth referred to at the IVIVC guidance).
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While no guidance document is rigidly prescriptive, this one is geared towards extended
release products. Therefore, its recommendations must be carefully interpreted when
referenced in the context of immediate release products. Nevertheless, the document is the
most instructive piece of regulatory literature available on the topic of IVIVCs. The guidance
divides its discussion between general discussions on “developing the correlation” and
IVIVC-level specific recommendations. The first general comments state how, despite the
existence of commonly used approaches, the strategy used to develop an IVIVC is largely the
prerogative of the sponsor. This is stated with the understanding that any IVIVC must be
reviewed before it can considered fit for sponsor-proposed purposes that are regulatorily
approved. The following points summarize the key general recommendations of the
guidance:


The review of > 3 formulations with different release rates is considered optimal



In vivo comparison is to be made using a single crossover study



If one or more of the formulations (highest or lowest release rate formulations)
does not show the same relationship between in vitro dissolution and in vivo
performance compared with the other formulations, the correlation may still be
used within the range of release rates encompassed by the remaining formulations



Once a discriminating system is developed, dissolution test conditions should be
consistent across formulations during IVIVC development

With respect to the discussion of level A IVIVCs, the guidance specifically recommended
that the release rates for each formulation studied should differ “adequately” (e.g. by 10%).
Moreover, this difference should result in comparable in vivo profile differences (e.g. a 10%
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difference in the pharmacokinetic parameters of interest (𝐶

or 𝐴𝑈𝐶) between each

formulation).
Methodology for the evaluation of IVIVC predictability is an active area of investigation
and a variety of methods are possible and potentially acceptable.36 The agency’s stated IVIVC
evaluation approaches was developed according to the objective of a level A IVIVC, i.e. to
establish a predictive mathematical model describing the relationship between an in vitro
property and a relevant in vivo response. As such, the proposed evaluation approaches focus
on the estimation of predictive performance or, conversely, prediction error. The guidance
notes that the evaluation of prediction error should be guided by intended application of an
IVIVC and the therapeutic index of the drug.
Two distinct aspects of predictability are discussed by the IVIVC guidance: internal and
external predictability. Evaluation of internal predictability is based on the initial data used to
define the IVIVC model. Evaluation of external predictability is based on additional test data
sets. Both aspects are not recommended in all instances. However, in the case of narrow
therapeutic index drugs such as carbamazepine, the external predictability of the correlation
should be evaluated along with internal predictability. According to the guidance, internal
predictability is established when the average absolute percent prediction error (% PE) of 10%
or less for 𝐶

and 𝐴𝑈𝐶. In addition, the % PE for each formulation should not exceed 15%.

Likewise, the external predictability is established when the average absolute percent
prediction error (% PE) of 10% or less for 𝐶
IVIVC.

and AUC establishes the predictability of the

Non-compartmental reference methods for determining 𝐶

and 𝐴𝑈𝐶 are

identified in guidance documents and detailed by Shargel et al. The methods include the
trapezoidal approach for 𝐴𝑈𝐶 calculation, analytical integration of spline interpolations for
35

the plasma concentration profile, and the absorption-elimination rate derived max
concentration.37

2.1.3 Emerging Trends and Alternatives in the Assessment of in vivo
Bioequivalence
Equivalence testing is used to provide statistical statements about parameter estimates
by relating them to intervals of effect sizes considered practically important rather than
just to an effect size of zero. The tests are specific examples of applied inferential
statistics. As such, there are a host of different inferential techniques that can be used to
accomplish tests of equivalence. The options can largely be classified as either Bayesian
or classical (i.e. frequentist) techniques. A frequentist framework considers that, for a
given model parameter θ, there exists a fixed value, and the data represents a random
sample from a larger population. They are based on the expected results of hypothetically
repeated samples, generated by the same sampling process. Bayesian inference considers
observed data as fixed and model parameters random. Bayesian inference is described
probabilistically through the use of probability distributions for model parameters. Simply
stated, a Bayesian approach allows for a researcher to make statements such as: “the
probability that a parameter θ lies in the range 0.8-1.2 is 95%.” By contrast, the equivalent
frequentist statement is: “if the same experiment is repeated many times and intervals are
computed for each experiment, then 95% of those intervals will contain the true value of
the parameter.”
Alternatives to the classical TOST procedure for assessing bioequivalence includes the
Anderson and Hauck test. 38 This method uses a hypothesis test statistic 𝑇
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to directly

test 𝐻 rather than testing 𝐻

and 𝐻

independently. Ennis and Ennis proposed an

expansion of the Anderson and Hauck test that controlled type I error.39 In their work,
they recommended adjusting the non-centrality parameter using a positive constant c to
ensure that the Type I error remains at or below a nominal level. Additionally, there are
nonparametric alternatives to the classical parameters procedures discussed thus far. They
can be considered in a unified manner by treating them as variations of a rank
transformation procedure. Of nonparametric methods, the Wilcoxon rank-sum test
(WRS; otherwise known as the Wilcoxon-Mann-Whitney test) is arguably the most
appropriate method due to a 2x2 crossover trial being composed of a pair of
sequences.40,41 Several examples exist in the literature where this method was used
during bioequivalence assessment.42-47

A common critique of non-parametric

methods is that they are considered to be less efficient than their parametric
counterparts. For example, the rank correlation test has an efficiency rating 0.91, see
Table 5.6 from Triola.

That is to say, for all other things being equal, the

nonparametric rank correlation test requires 100 sample observations to achieve the
same results as 91 sample observations analyzed through parametric linear correlation.
This assumes the requirements for the parametric method are satisfied.
extrapolated to a clinical trial, this difference could be significant.

When

However,

satisfying the assumptions of a specific distribution, such as normality, are not
required for the use of nonparametric methods as they are with parametric methods.
The assessment of bioequivalence can be performed using several Bayesian
approaches. In the literature, procedures have been constructed by attempting to
answer one of two questions: Does the evidence offered by the data support a model

37

representing bioequivalence or biononequivalence? What percent of the posterior
distribution for the treatment effect (i.e. AUC mean) in a random effects model of 2x2
crossover lies outside of a relevant interval? The first question has been notably
addressed by Ghosh and Khattree, the second by Fluehler et al. 48,49 Ghosh and Khattree
described how hypothesis testing can be accomplished by calculating the Bayes’ factor
between two competing hypotheses. Their method is based on principles established
by Harrold Jefferys and Alan Turning for the Bayesian comparison of two models.50,51
The approach is especially useful when using uninformative prior distributions on
model parameters.
The approach by Fluehler, et al. focuses on integrating a specific region of the
posterior probability distribution for the treatment response, i.e. the treatment-wise
AUC responses. It is essentially a Bayesian interval hypothesis test. As such the results
can be easily interpreted in probabilistic terms and distributional assumptions can be
customized. Bayesian interval hypothesis testing estimates the probability of a model
parameter (𝜃) satisfying a given inequality, e.g. 𝑃(𝐻 ) = 𝑃(−𝛿 ≤ 𝜃 ≤ 𝛿) = 𝑃( 𝜃 ∈
[−𝛿, 𝛿]). Evaluation is accomplished by simulating, to convergence, a posterior
distribution of model parameters and testing the rate at which 𝜃 lies in the test interval:
𝑃(𝐻 ) = ∑ 1{

∈[

, ]}

where 1{

}

is an indicator function returning 1 when f is true

and 0 when false.
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2.2 Model Drug: Carbamazepine
2.2.1 Background

Figure 2.2.1.1. The chemical structure of carbamazepine
The model drug in this study is carbamazepine. Carbamazepine was discovered by
chemist Walter Schindler in Switzerland (1953). It was first marketed as a drug to treat
trigeminal neuralgia in 1962 and has been approved in the United States since 1974 under
the trade name Tegretol® (Ciba-Geigy, today owned by Novartis International AG).52-54
According to archived ANDA approval reports the first-time generic for Tegretol was
approved in August of 1986. The application was sponsored by Inwood Laborites Inc, Ltd.
Oral preparations consist of various solid dosage forms, including immediate release
formulations, controlled-release formulations, and an oral suspension. The marketed
formulations include tablets of 100, 200, or 400 mg, chewable tablets of 100 or 200 mg,
controlled-release tablets of 100, 200, or 400 mg, and a suspension of 100 mg/5 mL. tablet
preparations with extended release profiles have been developed to reduce peak-related
toxic effects and to decrease variations in plasma carbamazepine concentrations during the
dosage interval.55

In addition to the commercially available oral preparations, an

intravenous preparation has recently (October 2016) gained approval in the US under the
trade name Carnexiv™ (Lundbeck A/S, Copenhagen, Denmark).

Intravenous

formulations prior to this point were developed and used for research purposes only.
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Carbamazepine is an iminostilbene and a structural conjugate of the tricyclic
antidepressant drug imipramine (Figure 2.2.1.1). Its labeled indications include specific
forms of epilepsy and trigeminal neuralgia. It has been shown to be effective in the
treatment of simple partial, complex partial, and generalized tonic-clonic seizures, but it is
ineffective against generalized absence seizures.56-59

Carbamazepine and the

anticonvulsant drug phenytoin have been shown to be effective in treatment of partial
seizures and tonic-clonic seizures when they are used alone or as initial therapy, and both
carbamazepine and phenytoin are drugs of first choice in the treatment of such seizure
disorders.60-61 However, carbamazepine may be more effective in the treatment of complex
partial seizures when complete seizure control is used as an end point.62 Carbamazepine is
an effective anticonvulsant drug in experimental animals, and it has an anticonvulsant
profile that is similar to that of phenytoin.63-66 It is effective against maximal electroshock
seizures at nontoxic doses but is not active against subcutaneous metrazol-induced
seizures. Carbamazepine may also be effective in the short-term and long-term treatment
of manic-depressive illness, and it is the drug of choice for treatment of trigeminal
neuralgia.67,68 It is administered to adults in doses of 10 to 20 mg/kg/day to achieve total
plasma concentrations of 6.5 + 3 µg/mL.69,70 The lower range of plasma concentrations are
adequate to control seizures in patients with primary or secondarily generalized tonicclonic seizures alone, but the higher plasma concentrations are often required to treat
seizures in patients with partial seizures with or without tonic-clonic seizures.71
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2.2.2 Mechanism of Action
The mechanism of action for carbamazepine is unknown according to the package insert
for Tegretol®. However, several pharmacologic mechanisms of action for carbamazepine
have been independently agreed upon in the literature. They can be generally classified under
two categories, including i) activity on neuronal voltage gated sodium ion channels and ii)
synaptic activity on specific receptors and neurotransmitters, most notably those related to
the N-methyl-D-aspartate (NMDA) system.72

The former mechanism of action is

commonly held as the primary mechanism responsible for carbamazepine’s antiepileptic
properties. This viewpoint is a result of the established relationship between voltage gated
sodium ion channels, the propagation of action potentials, and the pathophysiology of
electrical signals in epileptic disorders.73
Early efforts aimed at explaining a basic physiologic description of carbamazepine’s
antiepileptic mechanism of action are found in the reports by Krupp (1969) and subsequently
Honda and Allen (1973).74,75

Using electrical stimulation, Krupp reported that

carbamazepine caused an reduction in amplitude and an increase in latency and duration of
signals in the peroneal and sciatic nerves of rabbits. Honda and Allen demonstrated that
carbamazepine reduced the spontaneous firing of action potentials recorded from peripheral
nerves immersed in isotonic sodium oxalate or phosphate solutions. Additionally, in
controlled electromyography studies performed by Heshkowitz, et al. carbamazepine was
demonstrated to limit sustained high frequency tetany of muscle bundles without affecting
the conduction of single action potentials.76 This was demonstrated at therapeutic free
carbamazepine serum concentrations of >1 µmol/L (4.2 µg/mL). Ultimately, a more
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pharmacologic description of carbamazepine’s activity on sodium channels was specified
through the performance of studies using voltage-clamp techniques.77,78 Notable studies are
listed in Table 2.2.2.1 along with the cell systems in which they were performed.

Table 2.2.2.1 Carbamazepine Method of Action: Voltage-Clamp
Studies
Cell System
peripheral nerve and muscle cells
neuroblastoma cells in culture
human NT2-N cells in culture
acutely dissociated hippocampal neurons
rat brain type IIA sodium channels stable expressed in CHO cells

Reference
79, 80
81, 82
83
83, 84, 85
86

Carbamazepine was shown in these studies to slow the rate of recovery from inactivation and
to shift the voltage dependency of steady-state inactivation to more negative voltages by
producing a frequency and voltage dependent blockade of the sodium ion channels. This
pharmacologic explanation of carbamazepine’s mechanism of action agreed with the initial
physiologic studies and additionally indicated that the blockade appeared to be selective for
the inactive form of the closed sodium ion channel.

2.2.3 Pharmacokinetics
Carbamazepine pharmacokinetics have been qualitatively described in FDA
documents to demonstrate low within subject variability.24 This section will go over the
absorption, distribution, metabolism, and excretion (ADME) properties of carbamazepine
which describe the absorption, distribution, metabolism and elimination characteristics
of the drug.
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2.2.3.1 Absorption
Oral absorption characteristics are defined by the rate and extent of absorption. The extent
of absorption is typically described in terms of bioavailability, F. The overall extent of oral
bioavailability Foral of a drug can be expressed by the following equation
Eq. 2.2.3.1

𝐹

= 𝑓 ∙𝐹 ∙𝐹

where the fraction of drug absorbed (fa) is the fraction of the dose entering the cellular space
of the enterocytes, Fg is the fraction of the drug entering the enterocytes that escapes firstpass gut wall metabolism (equivalent to 1 - EG, the intestinal extraction ratio) and FH is the
fraction of drug entering (or by-passing) the liver that escapes first-pass hepatic metabolism
and biliary secretion (equivalent to 1 - EH, the hepatic extraction ratio).
𝐹

has several subcategories but the most informative is the absolute bioavailability.

This type of oral bioavailability is calculated by dosing a drug by both an intravenous and
oral route. The area under the plasma concentration profile (AUC; area under the curve) is
then calculated for both routes of administration and the dose normalized oral-to-intravenous
ratio is defined as the absolute bioavailability.87
Marino et al. used stable labeled carbamazepine in an intravenous formulation and
commercially available tablets to calculate 𝐹. Its estimated value was 78% with a reported
coefficient of variation equal to 30.8%. This range was similar to the range of 75% to 85%
estimated through the recovery of radio labeled carbamazepine in urine and feces after
single-dose administration reported by Faigle and Feldmann.88 Data from different studies
suggest that the oral bioavailability of carbamazepine is similar whether given as
conventional tablets, solutions, suspensions, syrups, or newly developed chewable or
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sustained-release formulations.89-96 Notably, Levy et al. did demonstrate a slight food effect
was present in the case of carbamazepine wherein the bioavailability was increased when
taken with food (approximately 20% relative increase in 𝐹 on average which broadly varied
and was not statistically significant).97 This effect is generally believed to be the result of an
increase in the solubilization of the drug by the presence of food and the physiologic response
therein.
Interestingly, Levy et al. also examined the relative bioavailability of carbamazepine.
Here, carbamazepine tablets and bulk powder were supplied by the Ciba-Geigy Corporation.
Since the drug is poorly soluble in water, a propylene glycol solution at a concentration of
20 mg/ml was prepared for oral administration. Both formulations were given to six normal
drug-free volunteers (3 male, 3 female) in good health. Their mean age was 25.8 ± 3.8 yr and
mean weight was 69.3 ± 18.8 kg. All were Caucasian, and none had any significant medical
history. Physical examinations and clinical laboratory studies conducted prior to the study
and every 2 weeks during the study revealed no significant medical findings. The subjects
fasted overnight, took the drug with 100 ml of water, and fasted for 3 hours. Sixteen blood
samples were collected over a 72 hour period at 0,0.5, 1, 1.5, 2, 3,4,5,6,7, 8, 10, 12,24,48,
and 72 hours (see Figure 2.2.3.1). The relative bioavailability was calculated using the
following equation:
𝐵𝑖𝑜𝑎𝑣𝑎𝑖𝑙𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = (

(

)
)

×

,

×

,

× 100 .

The relative bioavailability of the tablet compared to the solution was 79 % (p < 0.05) and
ranged between 56% and 109 %. This value agrees with the absolute bioavailability of
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carbamazepine from intravenous dosing studies of Marino et al. Therefore, it is reasonable
to assume that the contribution of metabolism from the gut is minimal.

Figure 2.2.3.1 Relative Bioavailability Study by Levy et al.

Plot of average serum carbamazepine concentration vs time following the administration of 6
mg/kg propylene glycol solution (○) and Tegretol Tablet (●). Adapted from Levy (1997) 97

The fraction absorbed at a given time in Equation 2.2.3.1 can be determined using the
rate of absorption (ka). For a one compartment model, the rate value is typically calculated
using the method of residuals or using the Wagner-Nelson method. Shargel, et al. describe
these methods in detail. The method of residuals separates the initial exponential phase of a
biexponential plot of plasma concentration against time by extrapolation of the terminal
elimination rate constant.37 The Wagner-Nelson method estimates the loss of drug from the
gastrointestinal tract over time, whose slope is inversely proportional to ka. Its methodology
is based on calculating partial 𝐴𝑈𝐶𝑠.
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Carbamazepine, like many small molecules, has been demonstrated to be orally absorbed
by passive diffusion.98,99 This mode of absorption is characterized by the permeability of a
molecule though the apical and basolateral cell membranes of the intestinal epithelium.
Permeability can be estimated by a variety of means.100 The permeability of carbamazepine
has been estimated in Caco-II permeability assays to be 22.8 × 10 cm/s.

,
101 102

Additionally, studies performed using the Ussing chamber technique in rodents have
reported the apparent permeability of carbamazepine to be 15.2 + 5 × 10-6 cm/s. Such in
vitro permeability methods however often require calibration to effective permeability (𝑃

)

of humans in vivo. This value is derived from gut perfusion experiments such the Loc-i-Gut
technique. Lennernäs et al. performed such a study where ‘high permeability’ characteristics
(i.e. 2-4 × 10-4 cm/s as defined by Amidon at al. and the FDA) were verified with a Peff,CBZ
≈ 4*10-4 cm/s.

103

This value serves a primary drug-dependent parameter for the

physiologically based prediction of oral drug absorption described by Jamei et al.104
Olling et al. used the MoR to calculate ka, reporting the absorption half-lives of four
different carbamazepine products including the reference product, Tegretol®, from a relative
bioavailability study.105 A similar study including Tegretol® was perfomed by Meyer et al.
in 1992. The details of these studies will be discussed in greater detail later. However, it is
interesting to note that the absorption rates for the common drug product reported in the
studies were in good agreement: 0.23 vs 0.24 hr-1, respectively. This consistency is observed
despite different subjects being used in the two studies and a seven year difference between
when the trials were performed.
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2.2.3.2 Metabolism
Carbamazepine has been reported to undergo >97% hepatic metabolism via three
pathways: epoxidation and hydroxylation by CYP3A4, CYP3A5, and CYP2C8 and
glucuronidation by UGT2B7.106-110

Carbamazepine also strongly stimulates the

transcriptional upregulation of genes involved in its own metabolism through RNA
analysis.111,112 The only form of the drug that has been demonstrated to be therapeutically
active is its unmetabolized form, with little (< 3%) carbamazepine being excreted unchanged.
Mechanistic drug-drug interactions via CYP3A4 and CYP2B6 induction are well
documented and can complicate the use of carbamazepine in polytherapy.113,114
Cazali et al. performed studies to characterize the in vitro and in vivo inhibitory effect of
a new anticonvulsant, saquinavir, on the metabolism of carbamazepine. The performance of
their study required the performance of control studies on carbamazepine alone. Human
liver microsomes (HLMs) and cDNA-expressed CYP enzymes were used for the in vitro
experiments where nonspecific binding was controlled for during the calculations.
Pharmacokinetic data from epileptic children and healthy adults were used for the
carbamazepine

and

saquinavir

in

vivo

studies,

respectively.

Carbamazepine

biotransformation by human liver microsomes (Vmax=10.3 nmol min-1nmol-1 P450,
apparent Km=362 uM), cDNA expressed CYP3A4 (Vmax= 1.44 nmol min-1nmol-1P450,
apparent Km= 335.5 uM), and cDNA expressed CYP2C8 (Vmax=0.669 nmol min-1nmol1

P450, apparent Km=757uM) was reported by the authors. The findings from this study

were supported by the findings from similar studies that reported the intrinsic clearance
(𝐶𝑙

=𝑉

/𝐾 ) of carbamazepine in both HLMs and other cDNA-expressed CYP
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enzyme systems including CYP3A5 (Vmax=1.17 nmol min-1nmol-1P450, apparent
Km=119uM).115-117
Staines et al. in 2004 reported the results of studies aimed at identifying the uridine
diphosphate glucuronosyltransferase (UGT) isoform responsible for the N-glucuronidation
of carbamazepine. They developed a sensitive liquid chromatography/mass spectrometry
assay to quantify carbamazepine glucuronidation. There, the researchers reported that
carbamazepine is specifically glucuronidated by human UGT2B7.

The kinetics of

carbamazepine glucuronidation in human liver, kidney, and intestine microsomes were
reported in their study and shown to be consistent with those of recombinant UGT2B7, which
displayed a Km value of 214 uM and Vmax value of 0.79 pmol/mg/min. This was the first
example of primary amine glucuronidation by UGT2B7.
Oscarson et al. studied the global induction response of drug-metabolizing enzymes,
drug transporters, and nuclear receptors using liver sampled from epileptic patients treated
with carbamazepine and control subjects. They confirmed the induction of several genes
previously shown to be inducible in vitro, including multiple cytochrome P450 (CYP) genes
in the CYP1A, CYP2A, CYP2B, CYP2C, and CYP3A subfamilies, as well as glutathione
S-transferase A1, UGT 1As, the drug transporter ABCC2, and the nuclear receptors CAR
(constitutive androstane receptor) and PXR (pregnane X receptor). Additionally, the
research reported the relative increase in the expression of the CYP isoforms for treated
patients. These values were then used to inform induction factor calculations (i.e. max
induction value; Indmax). Almond et al. specifically reported the CYP3A4 Indmax and IndC50
for carbamazepine using RNA quantification in hepatocytes across serial carbamazepine
concentrations (21.9 fold and 58.7uM, respectively). The autoinduction characteristics of
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CYP2C8 and CYP3A4 deconvoluted by application of the mechanistic framework for the
prediction of drug-drug interactions laid were out by Almond et al.118 The approaches
predicted the extent and time-course of enzyme induction in vivo based on in vitro
experimentation using serial dosing, probe substrates, and knowledge of the percent
contributed toward total clearance by each enzymatic isoform.119,120

2.2.3.3 Distribution
Carbamazepine is a neutral and lipophilic compound that easily crosses the blood–
brain barrier and other biologic membranes of the body and rapidly distributes to various
organs and tissues. A study by Takayasu et al. simultaneously assayed carbamazepine and
its metabolites by gas chromatography-mass spectrometry (GC-MS) in body fluids and
organ tissues taken from victims in five autopsy cases.121

The concentrations of

carbamazepine were generally much higher in organ tissues than in blood and urine, and
were higher in the liver than in the lung in three cases. Practically speaking, however, the
concentration of interest for clinical purposes is the concentration in the plasma. The
volume of distribution (Vd) represents a volume that must be considered in estimating the
amount of drug in the body from the concentration of drug found in the sampling
compartment i.e. the plasma. A reliable means by which this value can be calculated is
through serial plasma collections following i.v. dosing. This was performed by Marino et
al.122 The researchers developed an intravenous, stable-labeled (SL) formulation in order
to characterize carbamazepine pharmacokinetics in patients. Ninety-two patients received
a 100 mg infusion of SL-carbamazepine as part of their morning dose. Blood samples were
collected up to 96 hours after drug administration. Plasma drug concentrations were
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measured with LC-MS and concentration-time data were analyzed.

The weight

normalized volume of distribution was 1.11 L/kg with a standard deviation of 0.26. Given
the study design, this value represented a Vd at steady state and was observed to be
consistent across the subpopulations of the study. The value reported is in agreement with
those reported by other researchers. 123-126 The combined interpretation of these works is
that the Vd of carbamazepine can vary from 0.8 to 2 L/kg in adults and older children.
The value of Vd can be shaped in large part by the binding of drug to plasma proteins.
The two most common plasma binding proteins are human serum albumin (HSA) and α1
acid-glycoprotein (AGP). The acidic nature of AGP means that most of the drugs that bind
to it are basic ones with pK values of 8 or higher, which implies that such drugs are
positively charged at physiologic pH. Indeed is it clear from binding studies, which have
included carbamazepine as a model drug, that HSA accounts mainly for the binding of
acidic and neutral drugs (i.e. carbamazepine) whereas AGP associates more readily with
basic drugs.127-135 Indeed the studies that have been performed in vitro using equilibrium
dialysis methods have shown that the unbound carbamazepine fraction for AGP is 25%, a
value that agrees with the in vivo free fraction reported by Marino et al.

2.2.3.4 Elimination
Carbamazepine is eliminated by biotransformation followed by urinary and biliary
excretion of the parent drug and the formed metabolites with less than 5% of the drug being
excreted unchanged.136 After administration of a single oral dose of 14C-labeled
carbamazepine, 72% of the radioactivity was excreted in the urine, and the remaining 28%
was recovered in feces.137
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2.2.4 Carbamazepine Historical Issues with Bioequivalence
All available generic carbamazepine products are designated as AB as defined in a
publication entitled Approved Drug Products With Therapeutic Equivalence Evaluations
(commonly known as the Orange Book). It contains therapeutic equivalence evaluations for
FDA approved multisource prescription drug products. Drug products are considered to be
therapeutic equivalents only if they are pharmaceutical equivalents for which bioequivalence
has been demonstrated, and they can be expected to have the same clinical effect and safety
profile when administered to patients under the conditions specified in the labeling. Drug
products are considered pharmaceutical equivalents if they contain the same active
ingredients, are of the same dosage form and route of administration, and are formulated to
contain the same amount of active ingredient and to meet the same or compendial or other
applicable standards (i.e., strength, quality, purity, and identity). Drug products that FDA
considers to be therapeutically equivalent to other pharmaceutically equivalent products
include those for which:
(1) there are no known or suspected bioequivalence problems; these are designated AA
(2) actual or potential bioequivalence problems have been resolved with adequate in vivo
and/or in vitro evidence supporting bioequivalence (designated as ‘AB’).
Despite the AB status of carbamazepine, the use of generic versus brand-name antiseizure
medications, such as carbamazepine, have attracted much attention and debate. This is a
results of studies such as that performed by Krauss et al.138 Using pharmacokinetic data
submitted to the FDA, the researchers found that while most generic antiseizure drugs
provide total drug delivery similar to the reference product, differences in peak
concentrations were more common. Additionally, these researchers identified how switches
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between generic products caused greater changes in plasma drug concentrations than generic
substitution of the reference product.
In 1992 Meyer et al. performed studies to assess the in vitro dissolution and in vivo
bioavailability of brand carbamazepine (Tegretol®; product 1) and three lots from a generic
manufacturer (Pharmaceutical Basics Inc.; products 2, 3 and 4) which were reported to have
clinical failures.139

This study is an important source of in vitro-in vivo data for

carbamazepine. The in vitro tests were performed using the compendial dissolution method
for carbamazepine: type II dissolution apparatus, 75 rpm paddle speed and 900 ml of water
containing 1% sodium laurel sulfate at 37○C. The in vivo study was performed in twentyfour, nonsmoking males. Their ages ranged from 21 to 35 years and their weights ranged
from 61 to 93 kg. All subjects had normal clinical chemistry laboratory values, including
reticulocyte counts and serum iron. The subjects did not ingest any drugs for twenty-one
days and avoided alcohol for forty-eight hours prior to any carbamazepine dose. The subjects
were randomly divided into four groups and each group received a single 200mg dose of
each of the four medications in a different sequence. There was a twenty-one day washout
period between doses. After an overnight fast, each of the subjects receive one of the
products with 180ml of room temperature water. No food was allowed until a standard meal
was served 4 hours after dosing. Ten milliliter blood samples were obtained just before doing
and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 25, 49, 73, 97, 121, and 169 hours after dosing. Acceptable
accuracy and precision was indicated by the quantitative analysis of triplicate fortified plasma
quality-control samples containing 0.43, 1.6, and 3.1 ug/ml of carbamazepine along with
each set of unknown plasma samples. The between day and within day coefficient of
variation for these assays was < 10% and < 4% respectively.
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Figure 2.2.4.1. Dissolution profiles of four 200mg carbamazepine tablet
products. (○) Product 1; (●) Product 2; (■) Product 3; (▲) Product 4 [Meyer et
al. (1992) 139]
The wide range of in vitro results are shown in Figure 2.2.4.1. Using the USP
specficication for carbamazpine (i.e. bewteen 45% and 75% dissolved at 15 minuites and
that not less than 75% of the drug be dissolved within 60min) it was shown that: i) products
2 and 4 fail the dissolution requirements; ii) product 1 meets the dissolution requirements;
iii) product 3 meets the dissolution requirements despite being faster than product 1.
The respective range of in vivo results are shown in Figure 2.2.4.2. An analysis of the
elimination rates between the study periods demonstrated no statistical difference. However,
there were some statistical differences among the clearance rates between the products.
Additionally, there were some statistical differences between some of the summary
pharmacokinetic metrics across the different products. These differences are reported in
Table (2.2.4.1.). In the discussion of the study the authors stated that the source(s) of
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difference in performance was unknown. However, they referenced how moisture storage
conditions have been demonstrated to result in dissolution and bioavailability changes (likely
due to dihydrate conversion) and this may been a contributing factor in their work.140
Additionally, the authors stated that the manufacturer had suggested the cause to be related
to a change in the source of the raw carbamazepine and/or changes in particle size of the
active ingredient.

Figure 2.2.4.2. Plasma profiles of four 200mg carbamazepine tablet
products. (○) Product 1; (●) Product 2; (■) Product 3; (▲) Product 4
[Meyer et al. (1992) 139]

Table. 2.2.4.1. Summary of Meyer et al. 1992 results
Parameter
Cmax (ug/ml)
Tmax (hr)
AUC (ug hr/ml)
kel (hr -1)
●

Product 1
1.89 (20)*
15.9 (51)†
134.8 (15)※
0.0183 (15)‡,‡‡

Product 2
1.15 (62)**
13.6 (74) †,††
80.9 (48)※※
0.0173 (19) ‡‡

Product 3
2.69 (18)***
8.3
(72) ††
154.2 (18) ※※※
0.0191 (16) ‡

Product 4
1.40 (39)**
19.6 (78) †
104.5 (30) ※※※※
0.0177 (16) ‡‡

Number in parenthesis is the coefficient of variation; %
Differences in the number of row-wise symbols denotes a statistically significant difference (p > 0.05)
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Another study that investigated biononequivalence issues specifically related to
differences in the side effect profile of immediate release carbamazepine products was
performed by Olling et al. This work was performed in response to several publications over
the years leading up to the work describing the occurrence of side effects after changing from
one carbamazepine product to another.141-145 In different countries experiments were started
to find some explanations for these reports. 146-148 The studies seemed to indicate that
between-product differences in the rate of absorption might be responsible for the occurrence
of switch-related side effects.
The Olling el at. study, like the previous Meyer et al. work (1992), represents an important
source of in vitro-in vivo data for carbamazepine. In this study, the subject sample was again
taken from a normal healthy volunteer population (i.e. the results of routine laboratory tests
on blood and urine of the volunteers were within normal ranges). Eighteen healthy, nonsmoking volunteers, ranging in age from 20 to 38 years, weighing 49 to 88 kg were enrolled.
Included in the study were three 200 mg carbamazepine products with large differences in
compendially measured dissolution rates (Figure 2.2.4.3.), as well as the innovator product
Pharmachemie, Lot no. 92 A 21 NF (product A), 200 mg Centrafarm, Lot no. 92 E 18A
(product B), Pharbita, Lot no. 920401 (product C) and Tegretol® Ciba Geigy 200 mg, Lot
no. 92 F 22 (product D). All of the products were licensed and were purchased from a
hospital pharmacy.
The study protocol used volunteers that were currently not receiving medication. The
volunteers were to abstain from alcohol use 24 hour prior to the first study day until the end
of the study. The administration of the drugs was accomplished in a four-way randomized
cross-over design with 2 week washout periods. Before administration the volunteers fasted
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overnight. After administration of the products the volunteers were instructed to sit in an
upright position for the first 4 hours. Standardized meals were given 4 and 10 hours postdose.
Blood samples were taken just before dosing and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20,
24, 28, 32 48, 56, 72, 80 and 96 hours postdose and analyzed using a suitable HPLC method
(i.e. linear over the range of 0.05–6 ug/mL plasma and the variability less than 10%).
The qualitative differences in the in vitro dissolution rates of the four products investigated
were in the same order as the in vivo absorption rates after administration of the products to
healthy volunteers.
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Figure 2.2.4.3. Dissolution (top) and plasma (bottom) profiles of four
carbamazepine 200 mg products in 1% lauryl sulphate (Paddle method):
product A (); product B (); product C (▲); product D (). Adapted from:
Olling (1992) 105

All of the summary pharmacokinetic metrics obtained from product A are statistically
significantly different (p < 0.05) from the reference product D. Product B did not show any
significant difference from product D. For product C all pharmacokinetic characteristics
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except the AUC values are significantly different (p < 0.05) from product D. The summary
pharmacokinetic metrics are contained in Table 2.2.4.2.

Table. 2.2.4.2. Summary of Olling et al. 1999 results
Parameter
Cmax (ug/ml)
AUC (ug
hr/ml)
t1/2,abs (hr)
t1/2,el (hr)

●

Product A
3.2 (31)
246 (25)
16 (63)
39 (18)

Product B
5.9 (27)
294 (29)
3.8 (184)
34 (18)

Product C
6.1 (26)
292 (24)
1.9 (263)
32 (16)

Product D
4.5 (18)
295 (20)
13 (62)
34 (15)

Number in parenthesis is the coefficient of variation; %

The extent of absorption (i.e. 𝐴𝑈𝐶) of products B and C were well within the range of
acceptance (0.8–1.20) for bioequivalence. With respect to the 𝐶

values, however, none

of the test products were bioequivalent with Tegretol as the 90% confidence intervals are out
of the 0.75–1.35 range. When Olling et al. examined the product-wise differences in they
observed the measured side effects followed the same pattern for the total adverse events as
for the of the Cmax values.
Carbamazepine was one of the medications investigated in a 2010 literature review
performed by Desmarais et al. focusing on the development of clinical deterioration and
decreased tolerability associated with switching from brand-name to generic psychotropic
medications. 149 The results of that work specific to carbamazepine are summarized in the
following Table.
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Table 2.2.4.3. Literature findings concerning Carbamazepine brand-generic
switches
Finding
Ref
Increased seizures after generic substitution
150,151-154
Decreased levels after generic substitution
150,152
Toxicity and increased levels after generic substitution
155,156
Adrenal decompensation after generic substitution in a patient on hydrocortisone 157
90% CI of AUC of generic not within 80–120% of original.
158
Shorter average time to Cmax with generic
159
More neurological side effects with generic
160
Shorter mean time to Δ of medication, more central nervous system side effects 161
with generic
Source for references [149]

While these studies were focused on clinical outcomes, a Spanish pharmacoeconomic study
suggested that if 9% of epilepsy patients treated with original carbamazepine were switched
to generic carbamazepine, annual per-patient cost would rise 38-fold due to the accidents,
deaths, emergency visits, and days off work associated with the anticipated increased
number of seizures.162
The AB status of Carbamazepine products requires that the in vitro and/or in vivo
bioequivalence criteria has been satisfied. How then could the studies of table 2.2.4.3 be
reconciled with this status? Consider how meeting compendial USP dissolution criteria is
often used to justify the waiver of in vivo studies. This is done on the basis that the acceptable
windows for the dissolution profiles are derived for classical in vivo trials for bioequivalence.
However, the in vitro tests are still limited by the same the shortcomings of in vivo methods
previously described. This may be a possible explanation for the cited findings, the
interpretation of which suggests a disconnect between the Orange Book recommendations
and best clinical practices.
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2.2.5 Material Characteristics and Physical Chemistry
For decades, carbamazepine has served as a model compound for groups engaged in the
study of crystal polymorphism. A portion of the seminal research article published by
Grzesiak et al. focused on definitively identifying each of the four anhydrous polymorphs of
carbamazepine.163 In that work they reexamined the reported data for the anhydrous
polymorphs of cabrmazepine in the literature.164-183. From that work, it was evident that
early on the nomenclature of polymorphs was inconsistent, leading to confusion and
misidentification of forms (see Table 2.2.5.1). Since then the most common approach to
classifying the carbamazepine polymorphic forms is as follows:





form I – triclinic cell
form II – which is trigonal
form III – P-monoclinic cell
form IV – C-centered monoclinic polymorph (see Figure 2.2.5.1)
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Table 2.2.5.1. Nomenclature of the four carbamazepine polymorphsa
Year

Reference

Triclinic

Trigonal

1968
1975
1981
1984
1984
1986
1986
1987
1987

164
165
166,167
168
169
170
171
172
173

I
C3
⸺
III
III
I
Α
I
⸺

⸺
C2
⸺
II
II
II,IV
⸺
⸺
α, Trigonal

1991
1991
1992

174
175
176

I
Γ
I

⸺
α
⸺

1996
1997
2000
2000
2000
2002
2003

177
178
179
180
181
182
163

I
Triclinic
⸺
I
I
⸺
I

⸺
⸺
α
⸺
⸺
⸺
II

Method of
Confirmation
III
⸺
Melting behavior
C1
⸺
PXRD, IR
Monoclinic
⸺
Crystal Structure
I
⸺
PXRD, DSC
I
⸺
PXRD, DSC
III
⸺
PXRD, DSC
β
⸺
PXRD, DSC
III
IIb
PXRD, DSC
β
⸺
Structure, PXRD,
DSC, IR
III
⸺
DSC, preparation
β
⸺
Preparation
III
⸺
IR, melting
behavior
III
⸺
PXRD
⸺
⸺
PXRD
β
⸺
PXRD, SEM
III
⸺
PXRD, DSC
III
IIb
PXRD, DSC, IR
⸺
IV, C-Monoclinic Structure
III
IV
XRD, DSC, IR

P-Monoclinic

C-Monoclinic

a

Each form was verified by the listed method as well as the method of preparation of each form.
Adapted from Grzesiak et al. (2003)
b
These forms are most similar to C-monoclinic CBZ, however, differences noted in the text exist.
PXRD – powder X-ray diffraction; IR – infrared spectroscopy; DSC – differential scanning calorimetry; SEM – scanning electron
microscopy

According to Grzesiak et al., the four forms are close in energy, the stability order at room
temperature is: III > I > IV > II. Thermochemical data from Upadhyay et al. indicate an
enantiotropic relationship between polymorphs III and I. As shown in Figure 2.2.5.1., free
energy curves of carbamazepine polymorphs intersect at 360.5K, below the melting of both
the forms. This confirms the enantiotropic relationship between them.
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Figure 2.2.5.1. Configurational phase diagram of carbamazepine polymorphs.
Adapted from Grzesiak et al. (2003) 163

Form III (P-monoclinic) shows the lowest free energy of all forms at and below room
temperature. Among the forms, Šehić et al. established that the anhydrous form III is the
most commonly encountered form.184 The form II (trigonal) is the least stable of all
anhydrous forms. Fast transformation of the trigonal form has made it very difficult to
determine its melting point, and therefore the thermodynamic relationship of this polymorph
to other anhydrous forms is still unclear.185
All four polymorphs of carbamazepine share a common hydrogen bonding pattern
resulting in a dimer with two amide–amide hydrogen bonds according to the Cambridge
Crystallographic Data Centre. Observed polymorphism results from the alternative
possibilities of packing these dimers into a stable crystal structure: forms I and II have similar
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packing of dimers, with offset π–π stacking of the aromatic rings as the main interaction
between neighboring dimers. In forms III and IV aromatic rings form both π–π stacking and
edge-to-face contacts in an interlocked packing arrangement (see Figure 2.2.5.1).186

Figure 2.2.5.1. Packing diagrams of carbamazepine polymorphs: (a) form I, (b)
form II, (c) form III, and (d) form IV (Cambridge Crystallographic Data
Centre).

While there is no officially released FDA specification for the reference polymorphic
form of carbamazepine, a publication by L. Yu et al. provides some regulatory insight. The
article was entitled Regulatory considerations of pharmaceutical solid polymorphism in
Abbreviated New Drug Applications (ANDAs), in it reviewed the impact of polymorphism
on drug product manufacturability, quality, and performance. Carbamazepine was a
particular example in this work. It was noted that “Approved ANDAs for carbamazepine
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utilize the corresponding drug substance β-form [form III], presumably due to the unique
solubility and processability characteristics associated with this form.” This will be an
important concept when comparing the performance of different generic carbamazepine in
later sections.
The dihydrate of carbamazepine has been studied in numerous publications.187-200 Like
anhydrous polymorphs, there can exist different configurations of hydrates (i.e.
stoichiometric or nonstoichiometric201,202). To assess the potential for different hydrate forms
of carbamazepine dehydrate, McMahon et al. characterized materials by thermal analysis
(TGA and DSC) and spectroscopic techniques, including 13C solid-state nuclear magnetic
resonance (13C SSNMR) and variable-temperature Fourier transform (FT) Raman
spectroscopy.203 The thermodynamic behavior of the dihydrate obtained form III was
different than the one produced from form I. However, water was readily lost from
dihydrates III and I in a similar manner, when maintained isothermally at 25 °C in the TGA.
Additionally, the powder X-ray diffraction patterns and spectroscopic data were almost
identical between all of the hydrate formations. Therefore, the observed differences were
hypothesized to be the result of trace anhydrous original polymorph existing in the dihydrate
phase. This was proposed to act as a seed, regenerating the original polymorph under
conditions where liberated hydrate water cannot readily escape from around the sample
during dehydration. Thus, they concluded that there is no evidence supporting the existence
of two different dihydrate forms. This supported the findings of Khoo and Harris et al that
carbamazepine exists as a channel hydrate.204,205
In addition to understanding the polymorphic forms and hydrate forms of carbamazepine,
another important feature of a drug is its ionizability and octanol-water partition-coefficient
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(logP). It is known from an examination of the chemical structure that carbamazepine does
not contain any ionizable groups. It can therefore be considered a neutral compound. This
is an important feature as it can inform the evaluation of dissolution methods. Additionally,
according to the scientific literature, it is generally agreed that the logP of carbamazepine is
approximately 2.2 suggesting high lipophilicity and permeability. Such knowledge supports
the findings of Lee et al., where it was reported how carbamazepine is poorly soluble and its
dissolution is independent of pH.206
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2.3 QbD initiatives – PBPK Modeling and Simulation
Quality by Design (QbD) is a systemic approach to development that begins with
predefined objectives and emphasizes product and process understanding and process
control, based on sound science and quality risk management to meet patient needs using
clinical information and safety targets in the Quality Target Product Profile (QTPP).207 In a
September 2017 speech Dr. Scott Gottleib, at the very start of his tenure as FDA
commissioner, stated how the FDA will continue taking new steps to modernize how
sponsors can evaluate clinical information, and how FDA reviews these data as part of the
regulatory process for efficient assurance of QbD. He stated how this enhanced review
process will involve a more widespread use of modeling and simulation, and high
performance computing clusters cross FDA review programs. These efforts take aim at one
of the main challenges of efficient QbD drug development: translating in vitro observations
to in vivo performance.
The role of predictive biopharmaceutic methods in QbD has been emphasized in recent
conferences and workshops sponsored or co-sponsored by the FDA.208,209 Areas of focus
include the following:


the mechanisms of in vitro release



physiology in relation to drug absorption, and



in silico models that mimic in vivo release characteristics

Leveraging such knowledge as a tool to facilitate the implementation of QbD is a key
concern. The domain of physiologically based pharmacokinetic modeling unifies these
concepts in a way that greatly facilities clinical trial simulation, allowing for quantitative
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predictions through the mechanistic integration of prior knowledge. The growing
commitment to increase the use of PBPK modeling and simulation on the part of industry
sponsors and regulatory agencies is obvious in a review of the current literature. Researchers
from the FDA’s Office of Clinical Pharmacology published an article in 2013 on the utility
of modeling and simulation in drug development and regulatory review.210 The researchers
looked at the 33 INDs/NDAs received between 2008 and 2012 containing PBPK modeling
approaches as part of that work. Figure 2.3.1 shows the distribution of submitted INDs and
NDAs containing physiologically based pharmacokinetic modeling and/or simulation over
that time period.
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Sponsor's PBPK (IND)
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Sponsor's PBPK (NDA)
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Reviewer's PBPK
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1
0
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2009

2010

2011

2012

Figure 2.3.1. The number of PBPK applications contained in IND/NDA
submissions or developed by US FDA reviewers from 2008 to 2012. (Adapted
from Huang et al. (2013) 211)

Here the increasing support in PBPK modeling is visible by the increasing trend in PBPK
utilization on the part of industry sponsors. Interestingly, the authors of this data stated that
the paralleling of this practice by the agency has been de novo (i.e., US FDA initiated). They
note that increased use physiologically based pharmacokinetics has been a help to the
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regulatory review process by aiding the characterization of pharmacokinetics in a variety of
complex clinical scenarios that would be unable to test using traditional methods in vivo. The
clinical applications covered by the PBPK models in Figure 2.3.1 are broken down by topic
in Figure 2.3.2.

3%

9%

17%
59%

6%
6%

Absorption
Pharmacogenetics (PG)
Pediatrics
Hepatic impairment
DDI + PG
Drug-Drug Interactions (DDI)

Figure 2.3.2. Areas of applications in the 33 PBPK submissions in IND/NDA
received by US FDA’s Office of Clinical Pharmacology from 2008 to 2012. (Adapted
from Huang et al. (2013) 211)

It is observable in this Figure that, at the time of the study, the majority of PBPK applications
were related to drug-drug interactions. The authors discussed two emblematic case studies
where major drug development questions were answered using PBPK modeling. The first
case was concerning the combined use of in vitro inhibition data and PBPK modeling and
simulation to provide for a more focused performance of clinical drug-drug interaction
studies.211 The second case used a similar extrapolation approach to test unstudied drug
interaction scenarios. The work ultimately allowed for labeling which read, “There is no
68

clinically relevant effect of moderate CYP3A inhibitors on the pharmacokinetics of [the
sponsor’s active ingredient].”212 The language was justified using in silico simulations thus
sparing a lengthy and costly clinical drug-drug interaction trial. Other questions that can be
addressed using PBPK modeling and simulations are summarized in Table 2.3.1.

Table 2.3.1 Summary of general regulatory questions addressed using PBPK modeling and
simulations
Main enzymatic pathways of drug;
Interacting drug/ substrate relationships

New Molecular Entity (NME) is…

a CYP inhibitor in vitro (I/Ki > 0.1)

Regulatory questions addressed related to PBPK modeling and
simulations
The magnitude of DDI with a CYP substrate in vivo?

a CYP substrate

An in vivo DDI study with a CYP inhibitor has been conducted when
NME was dosed orally. Can PBPK simulation predict the magnitude
of DDI when NME is given intravenously?

a CYP substrate and also renally excreted

Can PBPK simulations predict the magnitude of DDI in subjects with
varying degrees of renal impairment (mild, moderate, or severe)?

a CYP inhibitor in vitro (I/Ki > 0.1)
metabolized by multiple CYPs in the liver

Can PBPK simulations predict the magnitude of DDI with a CYP
substrate in vivo?
Can PBPK simulations predict the magnitude of DDI with CYP
inhibitors?
Can PBPK simulations predict PK in subjects with hepatic
impairments?

a substrate of a polymorphic CYP in vitro

Can PBPK simulations predict the PK in extensive, intermediate, or
poor metabolizers of this CYP?

a CYP substrate and an in vivo DDI study
Can PBPK simulations predict the magnitude of DDI using a
using a specific inhibitor dose has been done different inhibitor dose as recommended by the FDA?
a CYP substrate and an in vivo DDI study
has been conducted with a CYP inhibitor

Can PBPK simulations predict the magnitude of DDI with a CYP
inducer?

a TDI of a CYP

Its single-dose PK data are available:Can PBPK simulations predict
dose- and time-dependent PK after multiple dosing?Can PBPK
simulations predict TDI in vivo?

metabolized in the liver

In vivo data are available in hepatically impaired subjects taking
lower than recommended doses of NME. Can PBPK simulations
predict PK of NME in hepatic impairment patients taking
recommended doses?

metabolized by multiple CYPs

Can PBPK simulation be used to predict fractional metabolism based
on enzyme kinetic studies in vitro?

NME’s adult PK data are available
NME and its meta. both inhibitors of a CYP

Can PBPK simulations help determine the optimal doses for
pediatric studies?
Can PBPK simulation predict the DDI potential of the NME?

CYP, cytochrome P450; DDI, drug–drug interactions; FDA, US Food and Drug Administration; NME, new molecular entity; PBPK, physiologically
based pharmacokinetic; PK, pharmacokinetic; TDI, time-dependent inhibitor. (Table adapted from Zhao et al (2011)213)

69

2.4 PBPK Modeling and Simulation – Technical Components
2.4.1 Fundamental differences between PBPK modeling and classical PK
modeling
A spectrum of unique approaches exist for learning the clinical pharmacology of a drug,
via pharmacokinetic modeling,. The classical approach to pharmacokinetic model, also
known as a “top-down” model, is constructed using clinical data with model parameters and
covariance estimated statistically. Typically there is a central compartment representing
plasma that can be linked to one or more peripheral compartments via rate constants. When
defined in terms of rate constants, the model parameters do not generally have any
physiological meaning but can be used to provide more interpretable pharmacokinetic
descriptors such as systemic clearance and volume of distribution. Clearance in classical
pharmacokinetic modeling refers to the volume of plasma cleared of drug per unit time via
metabolic or excretion processes. The volume of distribution refers to the volume required to
occupy the total amount of drug in the body at the concentration observed in plasma. While
useful for the concise and standardized representation of both the preclinical and clinical
experimental results, classical methods have limitations. These approaches do not readily
incorporate population-level covariate information from either the drug or physiology a
priori. 214
Covariates are accounted for in classical population-level pharmacokinetic modeling
through an observational top down process known as nonlinear mixed effects (NLME)
modeling.215 An exhaustive explanation of NLME methods is beyond the scope of this
dissertation, therefore a brief summary of the main methods will be discussed. The “mixed
effects” in NLME is so called because in the modeling procedure some parameters are
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assigned to vary across individuals and are considered random effects while others are
constant and considered fixed effects. There are essentially three functional components of a
NLME model: i) the structural model, ii) the statistical error model, and iii) the covariate
model. The structural model describes the typical concentration time course within the
population.

The statistical model accounts for random variability (residual error) in

concentration within the population. The covariate model explains variability predicted by
subject characteristics (covariates).

Nonlinear mixed effects modeling software (e.g.

NONMEM, Phoenix NLME) brings dependent/independent data together with models and
applies an estimation method for parameterization for the structural, covariate, and statistical
residual models that describe the data.216
To illustrate an NLME method consider the following single-compartment intravenousbolus plasma concentration model:
𝐶 =

−𝐶𝑙 ∙ 𝑡
𝐷
exp
𝑉
𝑉

where 𝐶 is the mean plasma concentration at time j from a population, 𝐷 is the dose at t = 0,
𝑉 is the volume of distribution for the population, and 𝐶𝑙 is the clearance for the population.
If one was to assume that the 𝐶𝑙 changes randomly between the individuals from the study
population and Vd was fixed, the NLME modeling would begin by using the following
equation:
𝐶 =

−(𝐶𝑙 + 𝑛 ) ∙ 𝑡
𝐷
exp
𝑉
𝑉

where 𝑛 is the deviation of the ith subject’s clearance from the mean Cl for the population.
Accounting for the residual error of this model is accomplished by addition of the residual
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model which can be expressed additively, proportionally, exponentially, and through a
combination thereof in the following ways, respectively:
𝐶 =

−(𝐶𝑙 + 𝑛 ) ∙ 𝑡
𝐷
exp
𝑉
𝑉

+𝜀

𝐶 =

−(𝐶𝑙 + 𝑛 ) ∙ 𝑡
𝐷
exp
𝑉
𝑉

∙ (1 + 𝜀 )

𝐶 =

−(𝐶𝑙 + 𝑛 ) ∙ 𝑡
𝐷
exp
𝑉
𝑉

∙ exp(𝜀 )

𝐶 =

−(𝐶𝑙 + 𝑛 ) ∙ 𝑡
𝐷
exp
𝑉
𝑉

∙ 1+𝜀

,

+𝜀

,

A covariate model can be added to this equation to describe various clearance-patient
relationships (e.g. 𝐶𝑙 = 𝑓(𝑎𝑔𝑒, 𝑤𝑒𝑖𝑔ℎ𝑡, 𝑑𝑖𝑠𝑒𝑎𝑠𝑒 𝑠𝑡𝑎𝑡𝑢𝑠, 𝑒𝑡𝑐.)) in the following way:
𝐶 =

−(𝜃 + 𝜃 , 𝑥 , + 𝑛 , ) ∙ 𝑡
𝐷
exp
𝑉
𝑉

+𝜀

where 𝐶𝑙 is a linear function of kth clinical factor x specific to the ith subject with intercept 𝜃
and slope 𝜃 , . Here, 𝑛

,

now represents the deviation of subject i from the population mean

of 𝑥 , .
The approaches for estimating coefficients of covariates and pharmacokinetic models
have undergone several evolutions since the early NLME modeling efforts. Most share the
concept of parameter estimation based on minimizing an objective function value (OFV). The
OFV often uses maximum likelihood estimation and is expressed as minus twice the log of
the likelihood describing how closely the model predictions (given a set of parameter values)
match the data (maximum likelihood = lowest OFV = best fit).
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In population modeling, calculation of the likelihood comes with an analytical challenge.
When fitting population data, predicted concentrations for each subject depend on the
difference between each subject’s parameters (Pi) and the population parameters (Ppop) and
the difference between each pair of observed (Cobs) and predicted (cˆ) concentrations.
Therefore, a marginal likelihood needs to be calculated based on both the influence of the
fixed effect (Ppop) and the random effect (η). The challenge is that analytical solutions for
the marginal likelihood do not exist. Thus, several methods have been developed for
approximating the marginal likelihood while searching for the maximum likelihood. Initial
methods were generally identified as first-order (FO) methods. The first was developed by
Sheiner and Beal and was based on a “first order” Taylor expansion of the pharmacokinetic
model under the assumption that all 𝑛

,

= 0.217 Since then, Lindstrom and Bates developed

a similar method; however, their approximation included the conditional estimates of 𝑛

,

and

is referred to as the First Order Conditional Estimation (FOCE) method.218 The FOCE
method is, in general, the most common method used in NLME estimation for population
pharmacokinetic modeling. However, with the advent of multi-core computer processors,
high computational demand methods yielding more stable parameter estimates from sparser
data, such as the Quasi-Random Parametric Expectation Maximization method, are
becoming more efficient.219 The advantages of these methods is that they follow a Bayeian
framework, and, as such, can provide posterior estimates of the covariates and parameters
with associated variance estimates.

These variance estimates can be used in IVIVC

simulations as demonstrated by Bondi, Bigora et al. O’Hara et al., Soto et al., and others.220222
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Sound statistical practice suggests the addition of covariates should be based on some
statistical criteria, such as Akaike Information Criterion (AIC), Bayes Information Criterion
(BIC), p-values, log likelihood, etc.; significant covariates will lead to a reduction in the intersubject variability (ISV) and residual variability. The error model should be selected to
preserve homoscedasticity, which can be assessed based on a plot of the residuals versus the
predicted plasma concentrations for the case presented. For more information on NLME and
how it relates to population pharmacokinetic modeling, see the comprehensive three-part
tutorial by Mould and Upton.223-225
A fundamental limitation of NLME modeling for the classical estimation of population
level covariates and pharmacokinetic parameters is that they can only be derived after the
study has been performed, and critical parameters such as the elimination rate can only be
resolved to units of inverse time. Thus, the ability to predict the pharmacokinetics of a similar
drug, or extrapolate the pharmacokinetics to a different physiology a priori is significantly
restricted. Unlike this “top down” modeling, a physiologically-based pharmacokinetic
modeling is considered “bottom-up.” This is because it uses information from i) human
physiology/pathophysiology, and ii) detailed biological processes and interactions to
mechanistically describe drug absorption, disposition, and elimination. While this type of
pharmacokinetic modeling can be parameterized using the same computational methods as
with the classical method, the compartments of the physiologically-based structural model are
now based on different organs and tissues in the body. These compartments are then
connected by tissue flow rates that are a function of cardiac output. While these models can
still provide classical pharmacokinetic parameters (see previous paragraph), the means by
which this is achieved is more translatable. The very units of the parameters provide a clear
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way by which a dose in healthy volunteers can be extrapolated to one in a clinically relevant
population, so long as the relevant physiological properties of the target population are
available. Developing a pathophysiologic understanding at the level of quantitative systems
pharmacology is becoming more and more the prelude to the modern drug discovery process.
The principles used for physiologically based pharmacokinetic modeling are not new.
The use of differential equations parameterized using known physiological variables to
represent a quantitative mechanistic framework by which the absorption, distribution,
metabolism, and excretion (ADME) of drugs may be modeled can be traced back to as early
as 1937. At that time, Teorell used multi-compartmental models to integrate biological and
physiological components for the simulation of pharmacokinetic data.226 What has changed
since that time is computer technology, an improved understanding of human
physiology/pathophysiology, and an increased availability of highly representative in vitro
systems which can act as surrogates for in vivo reactions relevant to ADME through a process
known as in vitro in vivo extrapolation (IVIVE). The performance of such in vitro trials are
typically termed distribution-metabolism pharmacokinetic (DMPK) studies. Advancements
in the domain of DMPK studies have grown exponentially since sub-optimal DMPK
properties were recognized approximately 25 years ago as a major contributor to the failure
of potential new therapies in early clinical trials.227 Such advancements were paralleled by
database innovations and evolutions in computational technology. This provided a greater
ability to integrate these studies within physiologically based pharmacokinetic modeling
framework for the performance of computationally demanding simulations.
Proponents of physiologically-based pharmacokinetic modeling believe that learning the
clinical pharmacology of a drug, and developing a model to describe it, should not start with
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the first clinical study. Rather, it is suggested to use in vitro tests, quantitative structureactivity relationships (QSARs), and physiologically based models to specifically define the
details of what in vivo studies are absolutely necessary and in doing so work to eliminate
studies that are doomed to fail. Leading researchers within the FDA’s Office of Clinical
Pharmacology have published a perspective article on best practices when using
physiologically based pharmacokinetic modeling and simulation to address clinical
pharmacology regulatory questions. In the article, the discussion is based on the “predictlearn-confirm” paradigm for the physiologically-based population pharmacokinetic modeling
in an optimized drug development process (see Figure 2.4.1.1).228 These cycles are based on
screening lead compounds into candidate drugs by determining potency against the target,
physicochemical properties, and basic in vitro data such as metabolic stability and cytochrome
P450 inhibition assessment. Subsequent in vitro studies can be aimed at establishing, and if
necessary optimizing, in vivo efficacy so that pivotal in vivo trials can be performed with better
quality compounds and subsequent clinical questions can be answered with greater certainty
and efficiency.
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Figure 2.4.1.1 “Predict-Learn-Confirm” Paradigm for Physiologically Based Population
Pharmacokinetic Modeling

Predict

 Model construction
o Start from discovery and first in
human predictions

Learn

 Model Refinement
o Further experimental data
o Estimation of parameters based on clinical data
o Sensitivity analysis of uncertain parameters

Confirm

 Model’s recovery of clinical data

Apply

 Model application to a specific
question

Adapted from Suri et al (2015)228
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2.4.2 Functional Components of a PBPK Model
As stated in the previous section, physiologically based pharmacokinetic models use
differential equations parameterized using known physiological data to represent a
quantitative mechanistic model structure by which the ADME of drugs may be modeled. The
availability of networked, open source data libraries has greatly facilitated the performance of
physiologically based pharmacokinetic simulations. The data that feed into a physiologically
based pharmacokinetic model can be classified as either drug-dependent or drug-independent.
Drug-independent data can also be called the system components of the model. These
components are defined by population level estimates of the basal physiology and
pathophysiology of the in vivo study subjects. Some examples of these components include
tissue flow rates, organ volumes, and gut segment transit times. Huang et al. discussed how
these drug-independent components are shaped by intrinsic and extrinsic patient factors.
Some examples of intrinsic patient factors included age, allometric correlations, race, organ
dysfunction, disease, pregnancy, gender, and genetics. In the context of PBPK modeling,
researchers have databases at their disposal that describe the drug independent parameters of
populations with the following conditions: health-impaired elderly,229 pediatric,230
pregnancy,231 obesity,232 comorbid diseases such as cirrhosis233,234 and chronic kidney failure,
235

and smoking. 236 These data, often collected from rigorously conducted federal health

interview studies (e.g., NHANES, NHIS, EHIS, etc.) have allowed the covariance between
age, gender, height, weight and other anthropomorphic values to be modeled by researchers.
Data libraries based on meta-analysis of these reports are maintained by many PBPK software
providers (so called ‘population libraries’). 237 These libraries provide the means by which
the required drug independent parameters can be generated using correlated Monte Carlo
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sampling techniques to effectively generate in silico patients. These databases have been
integrated into modeling efforts to account for changes in hepatic blood flow, CYP
abundance, liver volume, hematocrit, and liver/renal function as a function of disease or age,
for the prediction of human pharmacokinetics in atypical subpopulations.238,233,234 This
practice occupies the growing domain of clinical trial simulation research.239 The specifics
of such methodologies in the context of this work will be introduced in subsequent sections.
While understanding the physiologic factors that influence key ADME mechanisms for a
particular compound is important, the ultimate success of a prediction also requires welldefined and well-measured drug dependent parameters. The drug-dependent parameters of a
physiologically based pharmacokinetic model can be broken down into pharmacologic and
physical categories. The pharmacologic drug dependent parameters define values such a
permeability, intrinsic clearance of drug on a per enzyme basis, protein binding, etc. For
carbamazepine, some of the important drug-dependent ADME properties and methods for
their determination have been discussed in section 2.2.
After conversion to relevant units, in vitro values can directly be used as inputs for
physiologically based mechanisms, in conjunction with extrinsic factors (e.g., blood-binding
data), to parameterize specific pathways such as clearance. Here, assumptions of the pathway
define how the data is used. In the case of clearance from liver blood flow, for example,
Poulin et al. showed how well-stirred models can be used to predict clearance based on a
combination of in vitro drug dependent data and a priori knowledge of human physiology.240
This work was based on the publication of Proctor et al. In this foundational work, a model
was developed for how whole organ intrinsic drug clearance may be predicted from
recombinantly expressed CYPs (𝑟ℎ𝐶𝑌𝑃) based on the works of Houston et al and Iwatsubo
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et al. 241-243 The specific case of predicting liver clearance can be accomplished using the
following equation:
Eq. 2.4.2.1
𝐶𝐿𝑢
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(

)

= ∑

×

,

∑
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∗

…

× 𝑀𝑃𝑃𝐺𝐿 × 𝐿𝑖𝑣𝑒𝑟 𝑤𝑒𝑖𝑔ℎ𝑡
where, ISEF (intersystem extrapolation factor) is a dimensionless number used as a direct
scaler to convert data obtained with a 𝑟ℎ𝐶𝑌𝑃 system, 𝑉

, , (

)

is the Michalis-Menten

rate constant representing the maximum velocity of the in vitro metabolism assay incubation
for the 𝑝
𝐾

, ,

with

clearance pathway of the 𝑒

enzyme isoform, 𝐸𝑛𝑧

, ,

is the percent abundance,

is the Michalis-Menten rate constant representing the concentration that corresponds
0.5 ∙ 𝑉

, , (

, 𝑓𝑢

)

is the fraction unbound in the metabolism assay

incubation, and 𝑀𝑃𝑃𝐺𝐿 is the microsomal protein per gram of liver. The ISEF is calculated
by the following equation,
Eq. 2.4.2.2
where 𝐶𝐿
𝐶𝐿𝑢

, ,

(𝐻𝐿𝑀)

(

𝐼𝑆𝐸𝐹 , =
is

, ,

(

)

)×

(

the intrinsic clearance in human

)

liver microsomes,

(𝑟ℎ𝐶𝑌𝑃) is the intrinsic clearance of the recombinant enzyme system, and

𝐶𝑌𝑃 , 𝑎𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒(𝐻𝐿𝑀) refers to the abundance of the 𝑒

CYP in the liver sample(s)

used to determine the 𝐼𝑆𝐸𝐹. Proctor et al. described how the application of ISEFs in IVIVE
exist along three levels, reflecting a balance between confidence in extrapolation and highthroughput compatibility. 242
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Figure 2.4.2.1. The incorportation of ISEFs into in vitro-in vivo extrapolation.
HTS – high throughput system. Adapted from Proctor (2012) 242

Poulin et al. used the ISEF framework of Proctor et al. to model hepatic metabolic
clearance of highly bound drugs.244 The researchers evaluated the performance of this IVIVE
methodology and others using a data set of 25 compounds which including acidic, basic, and
neutral model drugs. The ability to predict in vivo clearance from in vitro data is shown in
Figure 2.4.2.2. Comparison between predicted and observed human clearance in this Figure
returned a high correlation R2 = 0.95.
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Figure 2.4.2.2. The solid line indicates the best fit (unity). Dashed lines on either side of
unity include a factor of two and three. Cross (red), circles (green), and squares (blue)
indicate bases, neutrals, and acids, respectively. CL - clearance (mL/(min kg)). Adapted
from Poulin et al (2012) 244

Similar to that of Proctor et al., Jamei et al. showed how a IVIVE methodology could be
used for predicting the effective permeability of the gastrointestinal tract. 245 Jamei et al. then
demonstrated how this prediction could be combined with an understanding of gastric transit
times, gastrointestinal physiology/pathophysiology, and assumptions of gastrointestinal fluid
dynamics to achieve a mechanistic prediction of population-level of oral drug absorption.
There is an extensive range of drug-specific and physiologic parameters which can be
defined during drug development and used for the mechanistic prediction of pharmacokinetic
model parameters. Although, not all parameters are needed in all circumstances depending on
both the simulation mode and the models chosen. For example, the tissue:plasma partition
coefficient required by a physiologically based pharmacokinetic models to describe the
accumulation of drug within a specific organ would require data that is not needed for the one
compartment distribution model. A list of some of the typical names, values (and units),
source of the parameter values, and assumptions being made are provided in Table 2.4.2.1.
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Table 2.4.2.1. Sample Input Parameters of Drug for Physiologically Based
Pharmacokinetic Modeling
Sample parameter
Compound type
Molecular weight
LogP

Sample assumptions and references
Summary of clinical pharmacology studies in NDA submission
Summary of clinical pharmacology studies in NDA submission
Measured value. Summary of clinical pharmacology studies in NDA submission

pKa
Solubility (mg/ml)

NA (neutral compound)
Measured at pH 7.4. Summary of clinical pharmacology studies in NDA submission

Particle size radius (mm) Monodispersed. Summary of clinical pharmacology studies in NDA submission
B/P ratio 1
Measured value from in vitro experiments. Summary of clinical pharmacology studies in
NDA submission
fp
Measured value from in vitro experiments. Summary of clinical pharmacology studies in
NDA submission
fu,gut
Assumed and tested plausible using sensitivity analysis
Fa
Ka (l/h)

Predicted using Caco-2 Papp data246; assumed first-order absorption kinetics
Estimated from single-oral-dose study in young adults using compartmental analysis;
summary of clinical pharmacology studies in NDA submission

Qgut (l/h)
Papp

Predicted using the software’s built-in method
Measured value using Caco-2 cell lines; summary of clinical pharmacology studies in
NDA submission
Measured value in vitro; not an inhibitor of P-gp; not a substrate and inhibitor of other
transporters; summary of clinical pharmacology studies in NDA submission

In vitro transporter
P-glycoprotein (P-gp)
Jmax (pmol/min)
Km (mM)
In vitro CYP inhibition:
IC50 (mM)

Measured value in vitro ; not an inhibitor of major CYP other than CYP2D6 (see below); not a
CYP inducer; summary of clinical pharmacology studies in NDA submission

Ki on CYP2D6 (mM)

Measured value from in vitro experiment using human liver microsomes; summary of clinical
pharmacology studies in NDA submission

Predicted Vss (l/kg)

CYP3A4 CLint
(ml/min/pmol)

Predicted using the software’s built-in method247 ; observed mean value from the i.v. study in
young adults = 3.5 l/kg
From i.v. study in young adults; summary of clinical pharmacology studies in NDA submission
From i.v. study in young adults; summary of clinical pharmacology studies in NDA
submission248
Retrospectively calculated using CLi.v. and well-stirred hepatic clearance model , assuming 80%
of total hepatic metabolism; summary of clinical pharmacology studies in NDA submission

CYP1A2 CLint
(ml/min/pmol)

Retrospectively calculated using CLi.v. and well-stirred hepatic clearance model, assuming 20%
of total hepatic metabolism; summary of clinical pharmacology studies in NDA submission

CLi.v. (l/h)
CLR (l/h)

B/P ratio, blood-to-plasma ratio; CLint, intrinsic clearance; CLi.v., clearance after intravenous administration; CLR, renal
clearance; Fa, fraction absorbed; fp, fraction unbound in plasma; fu,gut, apparent unbound fraction in enterocytes; IC50,
inhibitor concentration that causes 50% inhibition of enzyme/transporter activities; i.v., intravenous; Jmax, maximum rate of
transporter-mediated efflux or uptake; Ka, first-order absorption rate constant; Ki, reversible inhibition constant; Km,
Michaelis constant; LogP, logarithm of the octanol–water partition coefficient; NA, not applicable; NDA, new drug
application; Papp, apparent passive permeability; pKa, logarithmic acid dissociation constant; Qgut, hypothetical blood flow
term that is used to complex interplay among passive intestinal permeability, active transport, enterocyte drug binding, blood
flows to enterocytes, and gut metabolism; Vss, volume of distribution at steady state.
Adapted from Zhaoet al (2012) 214

83

The work of Zhao et al. visually summarizes the structure of data-types and equations
within a PBPK modeling framework. 249 In that regulatory review article, members of the
FDA’s Office of Clinical Pharmacology used the frameworks Huang et al. and others to
describe the drug-dependent and drug-independent components of physiologically based
pharmacokinetic modeling applications. Sections a. and b. of Figure 2.4.2.3. represent the
work’s summative adaptation of the previous two efforts.250

a.









b.
Extrinsic Factors:
Drug-drug interactions
Environment
Medical practice
Regulatory requirements
EtOH
smoking/diet
Etc.









Intrinsic Factors:
Age
Race
Organ dysfunction
Disease
Pregnancy
Gender
Genetics
Etc.

System Components
(drug-independent):
perfusion rates, volumes, transit times, etc.
Effects on human
physiology directly
included in model

Renal Elimination

ADME, PK, PD, and
MOA

Central Compart.
QHA

QHV

Liver Metabolism

Liver
QPV

Portal Vein
Gut
Metabolism

Drug-dependent
Components:

+

Qvilli

Enterocytes

Villi Capillary

Lumen Fluid of GI

PO Dose







Metabolism
Active transport
Passive diffusion
Protein binding
Drug–drug
interactions
 Receptor binding
 Etc.

The advanced dissolution, absorption and
metabolism model (ADAM model)

PBPK Model

Predict, learn, confirm

Figure 2.4.2.3. a and b. Relationship between the proposed physiologically based
pharmacokinetic model and extrinsic/intrinsic factors that impact drug exposure (a) Intrinsic and
extrinsic patient factors to be accounted for during simulations. (b) Components of the PBPK
model. Illustration modified from Huang et al (2008) 250
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2.4.3 IVIVC-based Clinical Trial Simulation
Clinical trial simulations represent an approach to answer deterministic questions by
accounting for the inherent stochastic variability of biology via random sampling algorithms.
This iterative approach generates a trial population in silico with inter-individual differences
via Monte Carlo sampling from user-defined distributions. The name for such sampling was
coined by Stanislaw Ulam and John von Neumann in 1945 for the gambling capital in Europe
(Ulam’s uncle apparently liked to gamble and this was his inspiration) while in Los Alamos,
New Mexico working on the Manhattan Project (development of the atomic bomb)
(Metropolis 1987). If the model were 𝑌 = 𝑥 + 𝜀 where 𝜀 is a random draw from some
probability density function (PDF) then the process considered is deterministic if when
performed repeatedly the outcome converges to a reproducible outcome.
The use of Monte Carlo simulation can also be performed during classical NLME
modeling of population pharmacokinetics. Bondi used NLME to define the coefficients of
relevant patient covariates in an IVIVC model.251 He then resampled from their posterior
levels of uncertainty to assess the performance of different delayed release products. A key
advantage of physiologically based pharmacokinetic models is the ability to include sources
of physiological and biochemical variability in the system parameters and to simulate the
expected pharmacokinetics in a population of individuals rather than for an average subject.
A virtual population can be generated from values and formulae describing demographic,
anatomical, and physiological variables using a correlated Monte Carlo approach.39 Equations
describing distributions of system parameters for the physiologically based pharmacokinetic
model are derived from distributions of data based on real populations and patients. This
allows prediction of variability before clinical studies in contrast to a NLME approach
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(population pharmacokinetic analysis), which requires prior clinical data to characterize
variability. Being able to assess variability in a population is particularly important when
considering the risk, as it is usually a few individuals with certain characteristics that are of
more concern than the average individual.
In the case of physiologically simulated hepatic clearance, individualized liver weights
are generated by first randomly sampling from a user defined distribution of ages and genders.
Next, a sample is drawn from marginal age-vs.-gender-vs.-height-vs.-weight probability
distribution. This distribution is defined by the results of rigorously conducted federal health
interview studies (e.g. NHANES, NHIS, EHIS, etc.). Body surface area (BSA) is then
calculated from this information using the following equation:
Eq. 2.4.3.1

𝐵𝑆𝐴 (𝑚 ) =

.

×

.

.

With BSA determined, liver volumes can be individualized based on the work of Johnson et
al.252 In this work, equations were developed based on simple regression against BSA and
multiple regression of liver volume with weight, height, BSA, age, gender, race,
methodology, and year of publication as covariates. The equation to describe liver volume
was selected according to the AIC, precision and bias and following visual inspection of
residual errors and observed vs. predicted plots:
Eq. 2.4.3.2

𝐿𝑖𝑣𝑒𝑟 𝑣𝑜𝑙𝑢𝑚𝑒 = 0.722 ∗ 𝐵𝑆𝐴

.

These coefficients represent the best, meta-level fit of the dataset in the Johnson et al study.
The simulation process would be able to create individualized estimates of these values based
on the reported levels of uncertainty from that study. The fit of this liver volume vs. BSA
model for the data is shown in Figure 2.4.3.1. Each individualized liver volume is then
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multiplied by a sample from a probability density function describing liver densities. This
parameter sampling process can then be repeated until Equation 2.4.2.1 and its components
are fully parameterized for a single in silico patient.

Figure 2.4.3.1. The model fit for liver volume vs body surface area described by
Johnson et al. Adapted from Johnson et al (2005) 254
253

The number of in silico patients is usually defined by the objective of the simulation study
and the variability in the parameters. Greater variably requires more patients to reach a
stable estimation of the pharmacokinetic metric of interest.
By its nature, a physiologically based pharmacokinetic model is based on the first
principles of human physiology. This allows the developers of such models to uniquely
leverage the findings of high throughput in vitro DMPK studies that now are the foundation
of preclinical drug development efforts. More and more sponsors have been able to
successfully account for population variability when considering the risk associated with
drug-drug interactions through the performance of simulations over these models. It is the
hope of this work to illustrate how the utility of a physiologically based pharmacokinetic
modeling and simulation can and should be extended beyond the preclinical and clinical
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phase of drug development, existing as a post-approval tool that iteratively refines itself to
facilitate the lifecycle management process.

Chapter 3: Development of an IVIVC Framework for
Immediate Release Carbamazepine Using a “Top Down”
Approach
3.1 Introduction
A strong link between the surrogates of in vivo performance and clinical response is
essential for the efficient assurance of quality. At the center of many definitions for
pharmaceutical quality is the concept of consistently meeting the needs of the patient. The
CFR states that one of the most preferred methods for the assurance of consistent
performance is the use of in vitro dissolution tests that have been correlated with in vivo
performance. There are three in vitro-in vivo correlation (IVIVC) levels according to a
FDA guidance documents: A, B, and C. The levels differ by the amount of detail output
by the correlative model. For example, a Level C IVIVC draws a relationship between
an amount dissolved at a given time and summary pharmacokinetic parameters such as
the area under the curve (AUC), maximum plasma concentration, or the time of the
maximum plasma concentration. This level does not reflect the complete shape of the
plasma concentration-time profile. Similarly, a level B IVIVC does not uniquely
reflect the actual in vivo plasma level curve. It uses the principles of statistical moment
analysis to regress an amount dissolved at a particular time against a pharmacokinetic
metric such as the mean residence time. A level A IVIVC predicts the entire in vivo
time course from the in vitro data. This level of IVIVC has been identified as the most
informative by the FDA and other health authorities. In this chapter, all future
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references to an IVIVC made without ‘level’ specification should be considered as
level A IVIVCs .
The model drug product for this work is an immediate release Carbamazepine
tablet. Carbamazepine is considered as a first line therapy drug for the treatment of
partial and tonic-clonic seizures. One of the reasons for carbamazepine’s efficacy is
its high permeability, allowing it to readily diffuse across the blood brain barrier. This
is the product of carbamazepine’s lipophilic structure, a characteristic that also
translates into poor aqueous solubility. The high permeability of carbamazepine, along
with its low solubility in aqueous systems, position it within the second class (II) of the
FDA’s biopharmaceutical classification system (BCS) based on the work of Amidon
et al. In that work, the likelihood of an IVIVC for class II compounds was favorable.
This expectation of Amidon et al. was a result of dissolution of such compounds often
being the rate-limiting step for the absorption.
Given the complexity of pharmaceutical drug products, health agencies do not
define a unified method for how an IVIVC should be developed. Regulators do
acknowledge that in order to maximize the utility of an IVIVC, certain bespoke
modeling decisions must be made. Despite the reality of such individuality, certain
core IVIVC components do exist that are common between applications. Specifically,
all level A IVIVCs can be considered as hierarchical in nature with the overarching
framework being a pharmacokinetic model.

Pharmacokinetic modeling seeks to take

a complex phenomena, such as the rise and fall of a drug substance’s plasma
concentration, and describe it as a function of parameters within a mathematical model.
Models can be classified into many different categories. Using the nomenclature of
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DiStefano and Landaw, pharmacokinetic models can generally be broken down into
two types: models of data and models of systems.254 In a pharmacokinetic model of
data, the model parameters are derived from, and fitted to, available clinical data. 255 In
the pharmacokinetic literature, this approach has grown to be referred to as ‘top down’
pharmacokinetic modeling.

This type of pharmacokinetic modeling will be the

approach used to the develop the IVIVC in this chapter.
In addition to the pharmacokinetic model, an IVIVC cannot exist without a model
that transforms in vitro drug release data into an in vivo input for the defined pharmacokinetic
model. Generally, the approaches for deriving this model are classified as either one- or twostep procedures. A two-step procedure was used in this work. The typical two-step
procedure is based on a deconvolution-convolution process. The classical approach to this
method is to derive an absorption profile that, when input to the pharmacokinetic model,
recovers the observed plasma concentration for each drug product used in the development
of the IVIVC. For a typical one compartment open model, this input profile may be derived
using either the standard Wagner Nelson method or the method of residuals. Once the
respective in vivo input profiles are determined, they are pooled and regressed against the in
vitro release rates. Thus, subsequent in vitro-in vivo transformations can be performed using
this model. This chapter will take a parallel approach to such a methodology. It will be
based on constructing a model that relates the parameters that define the rate and extent of
absorption within a pharmacokinetic model to those that define the rate and extent of in vitro
dissolution model.
This chapter is focused on the first specific aim of this work: the development of
an IVIVC for an immediate release carbamazepine product using a classical
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pharmacokinetic model. It begins by describing the methodology behind how a level
A IVIVC for immediate release Carbamazepine was developed. The chapter identifies
the in vitro-in vivo data that were ultimately used during modeling activities. It then
goes on to describe the types of models that were used to represent the data and how
the accuracy of the models was assessed. The chapter concludes by presenting and
discussing the performance of the IVIVC.

3.2 Methods and Materials
3.2.1 In vitro-In vivo Data
The data for this study was collected from 1992 and 1998 publications by Meyer et
al. and one previous work by Olling et al. Data was digitized using an open source
tracing software. All of the studies were 4-by-4 crossover studies. Table 3.2.1.1
describes the type of demographics, protocol details, type of in vitro experiments, and
the levels of in vitro and in vivo results. In this work, the 1992 Meyer et al and Olling
et al. data was used to train the IVIVC model. The 1998 Meyer et al. data was used to
test the model.
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Table 3.2.1.1 Details of in vivo studies for IVIVC model development
Author
[Reference]

Subjects

Meyer ‘92

Olling ‘99

Meyer ‘98

24 healthy, nonsmoking males;
21-35 y.o.; weighing 61-93kg

18 healthy; nonsmoking
volunteers, 20-38 y.o.;
weighing 49-88 kg

20 healthy, nonsmoking subjects;
16 males and 4 females; 22-36
y.o.; weighing 50-98 kg

Medication / Alcohol
Abstinence: 21 / 2 days

Protocol

Level of in
vivo results
In vitro
experiments

Medication / Alcohol
Abstinence: “no active
therapies” / 1 day

Products: Tegretol® and 3 lots
from a marketed generic
Products: Tegretol® and 3
marketed generics
Study Design:
Study Design:
 Randomized 4X4
 Randomized 4X4
 single, overnight fasted,
200mg dose with 180 ml of  double, overnight fasted,
room temp water
200mg dose with 150 ml
of room temperature
 21d washout between
water
treatments
 14 day washout between
 Standard meal 4 hrs after
treatments
dose

Medication / Alcohol Abstinence:
21 / 2 days
Products: Tegretol® and 3
marketed generics
Study Design:
 Randomized 4X4
 single, overnight fasted,
200mg dose with 180 ml of
room temp water
 21d washout between
treatments
 Standard meal 4 hrs after
dose

Entire plasma concentration profile with variance
estimates on AUC, Cmax, Tmax, elimination rate
Meyer 92’= over 168 hours

Olling = over 100 hours

Meyer 98’= over 168 hours

USP Method: type II apparatus; 75 rpm;
900ml of water containing 1% sodium lauryl sulfate (SLS)

Level of in
vitro results Meyer 92’= over 90 minutes

Entire Dissolution Profile
Olling = over 120 minutes

Meyer 98’= over 90 minutes

All of the plasma data was collected using HPLC and the calibration was demonstrated to
be linear over the following ranges: 0.05 – 4.03 ug/ml, 0.05 – 4.0 ug/ml, and 0.05 – 6.0
ug/ml for the Meyer et al 1992, Meyer et al 1998, and Olling et al. studies, respectively.
The digitized in vitro-in vivo data is shown in figure 3.2.1.1.
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Figure 3.2.1.1. In Vitro In Vivo Data
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3.2.2 Modeling Overview
The modeling activities of this chapter proceeded in three phases: i) “top down”
pharmacokinetic modeling, ii) dissolution modeling, and iii) in vitro-in vivo
modeling. The pharmacokinetic modeling allowed each plasma concentration profile
to be expressed as a function of the elimination rate (ke), the volume of distribution
(Vd), the bioavailability/fraction of drug absorbed (F), and the rate of drug absorption
(ka). The dissolution modeling provided a means to reduce a product’s entire
dissolution profile into several key dissolution model parameters to represent the rate
and extent of dissolution. Finally, two generalized linear models were used to relate
the dissolution model parameters for each product to their respective absorption terms
for the ultimate recovery of the plasma concentration profiles.

3.2.2.1 Pharmacokinetic Model
With the data from the reference studies digitized, the next step was modeling the
plasma concentration profile from the ‘top down’. This was accomplished with a
standard single-compartment model for oral absorption (see eq. 3.2.2.1). Here, 𝑘 is
the first order elimination rate constant, 𝑘 is the first order absorption rate constant, 𝐹
is bioavailability, and 𝑉 is the volume of distribution.
Eq. 3.2.2.1.1)

∙

= (𝐹 ∙ 𝑘 ∙ 𝐷𝑜𝑠𝑒 ∙ 𝑒
integrated form: 𝐶 =

∙
∙(

)/𝑉 − 𝑘 ∙ 𝐶
∙
)

∙ [𝑒

∙

−𝑒

∙

]

This model was used for both the 1992 and 1998 Meyer et al. studies. However, a
slightly amended pharmacokinetic model was used for the Olling et al. data given that
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this study used two 200 mg doses administered simultaneously. The two doses were
accounted for in the differential equation describing the rate of drug change in the
plasma in the following way:
Eq. 3.2.2.1.2)

= 2(𝐹 ∙ 𝑘 ∙ 𝐷𝑜𝑠𝑒 ∙ 𝑒

∙

)/𝑉 − 𝑘 ∙ 𝐶

The parameterization of equations 3.2.2.1 and 3.2.2.2. commenced by assessing
whether the elimination followed a first order process. This was confirmed via the
presence of linearity in the log-transformed terminal phase of the plasma concentration
profile. Once confirmed, the slope of this linear region is the (statistically) unbiased
estimation of 𝑘 . The value of 𝑘 was determined following the calculation of 𝑘 using
the method of residuals.256 𝑉 was defined using an aggregate of i.v. dosing trials from
literature using the following equation:
Eq. 3.2.2.1.3)

𝑉 = 𝐷𝑜𝑠𝑒/(𝑘 [𝐴𝑈𝐶] )

where [𝐴𝑈𝐶] is the area under the curve from time zero to infinity. The value for this
parameter has be previously defined by Marino et al. and others to be approximately
70 L (see literature survey on Carbamazepine; section 2.2 ). The bioavailability of a
product, 𝐹, was calculated using the Nelder-Mead least squares fitting algorithm within
WINNONLIN (Certara – Princeton, NJ). The AUCs calculated in this study were
determined using the following equation:
Eq. 3.2.2.1.4)

𝐴𝑈𝐶 =

∙
∙
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Models were compared on the basis of Akaike Information Criterion (AIC) and
goodness of fit was determined by calculating the root mean squared error (RMSE),
and 𝑅

:

Eq. 3.2.2.1.5)

𝑅𝑀𝑆𝐸 =

Eq. 3.2.2.1.6)

𝑅

∑

= 1−

(1 − 𝑅 )

where n is the number of dissolution data points and p is the number of parameters in
the dissolution model. In addition to these diagnostic statistics, slope and bias terms
were evaluated for significance by assessing the residuals for homoscedasticity around
0 and by testing the null hypothesis of a slope equal to 1 for an ‘actual vs. residual’
plot. The unbiased pharmacokinetic parameters of the model were observed for
deviations when they were again calculated using the plasma concentration profiles
that were regenerated via the IVIVC modeling.

3.2.2.2 Dissolution Model
Various models were investigated for the modeling of the in vitro dissolution data.
Those explored included the Makoid-Banakar, Weibull, first order, Hill, Higuchi, and
Hixson–Crowell (see Costa et al. for a review of the explored dissolution models). 257
Makoid-Banakar:
Eq. 3.2.2.2.1)

/

𝐶 =𝐹
where,
𝐶 =𝐹

∙
,

𝐶 =𝐶

∙ (1 − 𝑒

∙

∙𝑒

for 𝑡 > 𝑇𝑚𝑎𝑥

Weibull:
/

Eq. 3.2.2.2.2)
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,

for t <= 𝑇𝑚𝑎𝑥

First Order:
Eq. 3.2.2.2.3)

)+𝐾 𝑡

ln(𝐶 ) = ln(𝐶

Hill:
Eq. 3.2.2.2.4)

𝐶 = (𝐶

∗ 𝑡 )/(𝑀𝐷𝑇 + 𝑡 )

Higuchi:
Eq. 3.2.2.2.5)

𝐶 = 𝐾 √𝑡

Hixson–Crowell:
Eq. 3.2.2.2.6)

𝑊

/

−𝑊

/

=𝐾𝑡

Where 𝐶 is the amount drug dissolved at time t, 𝐶
infinity, 𝑇

is the amount released at time

is the time at which the dissolution profile plateaus, 𝑏 is the Makoid-

Banakar dissolution profile slope factor, 𝑀𝐷𝑇 is the mean dissolution time, 𝐾 is the
first order proportionality constant, 𝛾 is the Hill slope factor, 𝐾 is the Higuchi
dissolution constant, 𝑊

is the initial mass of the drug in the dosage form, 𝑊 is the

remaining amount of drug in the dosage for at time t, and 𝐾 is a constant incorporating
the surface–volume relation. Models were fit using the Levenberg-Marquardt
algorithm (nlinfit.m) within MATLAB® (v.R2018b, MathWorks, Natick, MA). The
dissolution models were compared on the basis of Akaike Information Criterion (AIC)
and evaluated for goodness of fit using the RMSE, 𝑅

, and the slope and bias

terms from the ‘actual vs. residual’ plot. The nonsignificance was used to assess the
suitability of the dissolution models. The assessment of the slope and bias terms for
the residuals-vs-observed plot was based on the inclusion of 0 in the confidence
intervals.
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3.2.2.3 In vitro-In vivo Model
A generalized linear modeling (GLM) approach was used to express the rate and
extent of absorption for each product from section 3.1 as a function of their respective
in vitro dissolution model parameters. As such, two generalized linear models were
generated that respectively correlated 𝑘𝑎 and 𝐹 with dissolution model parameters.
This provided a means to regenerate the entire plasma concentration profile from the
dissolution data. The procedure used to generate the GLMs was based on stepwise
regression and is illustrated in the following figure 3.2.4.1.
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The first step in the IVIVC modeling process illustrated by figure 3.2.4.1 was to
model the dissolution profiles using the array of dissolution models identified in
section 3.2.2.2. Only the dissolution model parameters from models that provided
suitable fits of the dissolution profiles were carried forward as potential independent
variables for the in vitro-in vivo GLM. The model was then built using a stepwise
approach within the JMP software (SAS Institute, Cary NC). Here, the forward
addition of variables was based on a maximum p-value threshold that a parameter
needed have in order to be entered into the model as part of the forward addition step.
The backward removal of a variable was based on a minimum p-value that an effect
must have to be removed from the model during a backward step. The critical pvalues for the forward and backward removal of parameters were 0.25 and 0.1
respectively. The calculation of p-values for each parameter was based on an F-test.
This test required determining the F-ratio for each parameter, which was calculated
by dividing the sum of squared error captured by the parameter by the mean sum of
squares error after addition/removal of the parameter to the model. The hierarchical
procedure that decomposed a dissolution profile into the necessary dissolution model
parameters, translated those parameters into 𝑘𝑎 and 𝐹, and then combined the
absorption parameters using a first order absorption model will henceforth be referred
to as the IVIVC.

3.2.3 IVIVC Model Evaluation
The evaluation of the IVIVC model for this project was based on regulatory
recommendations found in existing regulatory guidance literature.13 These guidance
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documents focus on the ability to predict two summary pharmacokinetic metrics: 𝐴𝑈𝐶
and 𝐶

.13 As such prediction error (𝑃𝐸) for these metrics were calculated using

equation 3.2.3.1.
Eq. 3.2.3.1)

%𝑃𝐸 =

|

|

The acceptability of the 𝑃𝐸 for 𝐴𝑈𝐶 and 𝐶

∙ 100

was based on FDA recommendations

which varied depended on whether an internal or external approach to the evaluation
of predictability was being perfromed. Internal predictability is based on the initial
data used to parameterize the IVIVC model, while the evaluation of external
predictability is based on additional test data. The FDA recommends that the on
evaluation of the IVIVC under one or both of these approaches constitutes an evaluation
of predictability.

The guidance documents support internal predictability when

average absolute prediction error (𝑃𝐸) for 𝐶

and 𝐴𝑈𝐶 is less than or equal to 10%

and the percent error for each individual formulation is less than or equal to 15%. 13
The criteria for satisfactory external predictability is similarly evaluated using
regulatory recommendations that the prediction errors for 𝐶𝑚𝑎𝑥 and 𝐴𝑈𝐶 were less
than or equal to 10%. The time at which the maximum concentration was achieved
(𝑇𝑚𝑎𝑥) was also used for the assessment of predictability. This metric was included
in the IVIVC assessment process because Olling et al. showed that, in addition to the
degree of exposure (summarized by the 𝐴𝑈𝐶 and 𝐶𝑚𝑎𝑥 metrics), 𝑇𝑚𝑎𝑥 was correlated
with adverse events (i.e. dizziness). Here, the same predictability criteria was used for
this summary pharmacokinetic metric.
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While internal predictability was based on the ability to predict the 1992 Meyer et
al. and Olling et al. summary pharmacokinetic metrics, external predictability was
assessed using separate in vivo-in vitro data from the 1998 Meyer et al. study. In
addition to the 𝑃𝐸 calculation, the 𝑅𝑀𝑆𝐸 was used for the evaluation of the 𝐼𝑉𝐼𝑉𝐶.
Also, a plot of the predicted vs the observed was generated to assess predictability.
Using this plot, additional suitability tests confirmed that i) the confidence interval for
the slope term contained 1, and ii) the intercept term was non-significant.

3.3 Results
3.3.1 In vitro Dissolution Profiles
The respective fits of the dissolution models used to fit the in vitro dissolution data
are shown in figure 3.3.1.1. Several models fit the dissolution data well. The MakoidBanakar model performed especially well with an 𝑅

of 0.99 and the lowest

𝑅𝑀𝑆𝐸 and AIC. However, a visual inspection of the fits demonstrated that the HixsonCrowell and Higuchi models did not fit the data well. This was demonstrated in table
3.3.1.1 by the large AIC and RMSE values as well as the lowest 𝑅

values. In

this table, the RMSE for the Hixson-Crowell and Higuchi models were more than triple
that of the next closest comparator. Additionally, neither of the 95% confidence
intervals for the slope nor the bias terms included 0 for these two models. The results
of the statistical analysis indicated that neither the Higuchi model nor the Hixson
Crowell model was suitable for the representation of the in vitro dissolution data.
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Table 3.3.1.1. Dissolution model fits
𝑹𝟐𝒂𝒅𝒋𝒖𝒔𝒕𝒆𝒅

𝑹𝑴𝑺𝑬∗

𝑨𝑰𝑪

𝑪𝑰𝟗𝟓% (𝑩𝒊𝒂𝒔)∗

𝑪𝑰𝟗𝟓% (𝑺𝒍𝒐𝒑𝒆)∗

First Order

0.98

4.48

658.1

(-2.86, 0.66)

(-0.007, 0.04)

Higuchi

0.78

15.9

941.3

(-19.3,-8.19)*

(0.14, 0.30)*

Hill

0.99

1.27

374.7

(-0.59, 0.41)

(-0.006, 0.008)

Hixson-Crowell

0.65

20.1

994.3

(-28.5, -15.7)*

(0.26, 0.44)*

Makoid-Banakar

0.99

1.21

365.5

(-0.54, 0.41)

(-0.005, 0.008)

Weibull

0.99

2.26

528.7

(-1.42, 0.68)

(-0.007, 0.021)
*

Figure. 3.3.1.1 Dissolution profile fitting

% Dissolved

(markers represent observed data; lines represent model fits)

Time (hr)
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percentage dissolved

3.3.2 In vivo Plasma Profiles
The observed plasma concentration profiles of the Olling et al. and the Meyer et al.
studies and their respective fits using the single compartmental model for oral
absorption are shown in Figure 3.3.2.1. The markers in this figure represent the
observed data digitized from the original publications. The solid lines represent the fit
of the pharmacokinetic model. The profiles followed a classical single peak plasma
concentration profile in all the cases. A basic visual predictive check of these models
figure demonstrated suitable fits. The fitting accuracy was also supported by high
R2adjusted in every case ( > 0.95), with the ratio of the RMSE to the summary
pharmacokinetic metrics being on the order of, or below, the analytical sensitivity of
methods originally used to quantify the plasma concentrations.
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Figure 3.3.2.1 Plasma Data and Model Fit
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Table 3.3.2.1 Diagnostic Metrics for Pharmacokinetic Model Fits
Study
Product ID
𝑹𝟐𝒂𝒅𝒋𝒖𝒔𝒕𝒆𝒅

Meyer et al. 1992

Meyer et al. 1998

Olling et al.

1

2

3

4

1

2

3

4

1

2

3

4

0.98

0.99

0.99

0.99

0.99

0.98

0.99

0.99

0.96

0.97

0.98

0.95

𝑹𝑴𝑺𝑬∗

0.06

0.05

0.12

0.06

0.06

0.13

0.05

0.06

0.18

0.28

0.21

0.28

𝑨𝑰𝑪

-33.7

-41.9

-14.6

-35.1

-24.4

-4.15

-30.9

-26.3

-5.68

11.3

-0.64

10.4

𝑪𝑰𝟗𝟓% (𝑩𝒊𝒂𝒔)∗

(-0.08,
0.06)

(-0.06,
0.04)

(-0.15,
0.11)

(-0.07,
0.05)

(-0.11,
0.08)

(-0.26,
0.18)

(-0.09,
0.08)

(-0.11,
0.09)

(-0.30,
0.13)

(-0.44,
0.21)

(-0.31,
0.19)

(-0.50,
0.21)

𝑪𝑰𝟗𝟓% (𝑺𝒍𝒐𝒑𝒆)

(-0.05,
0.07)

(-0.06,
0.09)

(-0.06,
0.09)

(-0.06,
0.09)

(-0.06,
0.07)

(-0.10,
0.15)

(-0.04,
0.05)

(-0.05,
0.06)

(-0.05,
0.13)

(-0.05,
0.11)

(-0.05,
0.08)

(-0.06,
0.15)

* units: μg/ml
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All of the pharmacokinetic studies used in this chapter collected data until at least
169 hours post dose. This provided each of the original researchers the ability to
capture the terminal phase of the plasma concentration profile. This was important as
the log transformed slope of this region is the elimination rate which was in turn is used
to calculate the absorption rate and bioavailability.
The 1992 Meyer et al. data in figure 3.3.2.1 shows how the entire mean plasma
concentration profile, including the terminal phase, was provided in the original
publication (reported interval: 0 to 169 hrs). With this interval the elimination rate
could be solved without any reference to the results section of the original document.
This scenario was also the case for the Olling et al. data. However, the 1998 Meter et
al. study only included plasma concentration data up to 50 hours post-dose in their
figure despite collecting data until 169 hours. Fortunately, the researchers of the 1998
Meyer et al. study reported the mean elimination rates for each product in their study
using the Stella II software which utilizes classical methods for the determination of
rate constants (i.e., slope of the log transformed terminal phase). These reported
elimination rates were then used as the starting point for subsequent modeling efforts
aimed at deriving the absorption rate and bioavailability for each product.
The ranges of 𝑘𝑎 and 𝐹 values for the Olling et al. and 1992 Meyer et al. studies,
calculated using the method of residuals and Nelder Mead least squares fitting
algorithm, were [0.23 – 1.08] and [0.44 – 1.00], respectively. The ranges of 𝑘𝑎 and 𝐹
values from the 1998 Meyer et al. used to evaluate the in vitro-in vivo model were [0.90.27] and [0.77-0.90], respectively. The 𝑘𝑎 term scaled well with measurements of
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𝑇𝑚𝑎𝑥, while the 𝐹 term scaled well with measurements of 𝐶𝑚𝑎𝑥 and 𝐴𝑈𝐶 (see tables
3.3.2.2 and 3.3.2.3).
Table 3.3.2.2. Pharmacokinetic Model Parameters
Study

Meyer et al. 1992

Meyer et al. 1998

Olling et al. 1999

Product ID
1

2

3

4

1

2

3

4

1

2

3

4

)

0.26
0.40
0.50
0.23
0.27
0.58
0.90
0.47
0.25
0.64
1.08
0.30
(0.0190) (0.0349) (0.0507) (0.0247) (0.0249) (0.0799) (0.0459) (0.0265) (0.0236) (0.059) (0.110) (0.0339)

𝑭 (%)

0.76
0.44
1.00
0.57
0.77
0.88
0.84
0.90
0.64
1.00
1.00
0.86
(0.0234) (0.0137) (0.0324) (0.0239) (0.0295) (0.0453) (0.0116) (0.019) (0.023) (0.030) (0.019) (0.0340)

𝒌𝒂 (𝒉𝒓

𝒌𝒆 (𝒉𝒓

𝟏

𝟏

)

0.015 0.014 0.017 0.014 0.012 0.014 0.013 0.015 0.0103 0.015 0.015 0.012
(0.0009) (0.0010) (0.0014) (0.0011) (0.0018) (0.0029) (0.0009) (0.0013) (0.0011) (0.0012) (0.0008) (0.0013)
The values in parenthesis represent the standard error of the parameter.

Table 3.3.2.3. Summary Pharmacokinetic Metrics
Study

Meyer et al. 1992

Meyer et al. 1998

Olling et al.

Product ID
1

2

3

4

1

2

3

4

1

2

3

4

𝑪𝒎𝒂𝒙 (𝝁𝒈/𝒎𝒍)

1.89

1.15

2.69

1.40

1.95

2.32

2.30

2.34

3.17

5.37

5.43

4.60

𝑨𝑼𝑪 (𝝁𝒈
∗ 𝒉𝒓/𝒎𝒍)

143

86.0

162

111

157

163

159

162

246

361.4 367.2

295

𝑻𝒎𝒂𝒙 (𝒉𝒓)

11.7

9.04

7.19

12.8

11.3

6.59

4.85

7.67

13.3

6.27

11.0

4.10

The results shown in Figure 3.3.2.1 and Table 3.3.2.1 provide a basis from which
it can be stated that the first-order pharmacokinetic models in equations 3.2.2.1.1 and
3.2.2.1.2 adequately described the data. Thus it was concluded that if the in vitro
dissolution model parameters can be accurately transformed into the in vivo absorption
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terms via the GLM-based IVIVC model, then the entire observed plasma concentration
can be recreated in the fulfillment of a level A IVIVC.

3.3.3 In vitro-In vivo Model
The final step in this chapter was to model the rate and extent of in vivo
pharmacokinetic input as a function of the rate and extent of in vitro drug release.
The method selected for this objective was generalized linear modeling.
The first step was to examine these model parameters for correlations. Paired
univariate regressions were performed for this step and the 𝑅 values are shown in
table 3.3.4.1. The most important regions of this table are a) the column representing
the correlations with the bioavailability term and, b) the last row representing
correlations with the first order absorption term.

Table 3.3.4.1. Correlation Table of Dissolution Model Parameters with ka and F
First
Order

Cinf 0.62
K1 0.82

0.23

Tscale 0.92

0.40

0.86

Gamma 0.55

0.52

0.25

0.25

Cinf 0.59

0.00

0.67

0.64

0.22

MDT 0.82

0.79

0.63

0.81

0.26

0.40

Cinf 0.83

0.92

0.49

0.71

0.46

0.18

0.92

b 0.89

0.57

0.82

0.96

0.16

0.52

0.92

0.82

Tmax 0.94

0.81

0.71

0.84

0.54

0.47

0.94

0.93

0.89

Cinf 0.58

0.37

0.47

0.73

0.28

0.30

0.73

0.62

0.82

0.56

Weibull Gamma 0.20

0.17

0.14

0.01

0.70

0.05

0.04

0.10

0.15

0.16

0.35

MDT 0.33

0.01

0.28

0.38

0.34

0.24

0.25

0.16

0.40

0.16

0.64

0.08

0.61

0.05

0.88

0.60

0.43

0.61

0.32

0.22

0.49

0.51

0.01

0.02

0.07

F

Cinf

K1

Tscale

b

Cinf

MDT

Cinf

Gamma

Tmax

Cinf

Gamma

MDT

Hill

Makoid
Banakar

ka

First Order

Hill
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Makoid Banakar

Weibull

It is observed in table 3.3.4.1. that some of the dissolution model parameters were
more highly correlated than others with 𝐹 and 𝑘 , respectively. Dissolution parameters
were added to the respective GLMs for the prediction 𝐹 and 𝑘 according to the
previously specified criteria and without any other supervision. The modeling process
for prediction of both 𝑘𝑎 and 𝐹 ultimately resulted in the inclusion of three terms. The
included terms (𝐹

,𝑇

, and 𝑏) were all from the Makoid Banakar model. The

performance of the model derived for the prediction of 𝑘𝑎 and 𝐹 is illustrated in Figures
3.3.4.1 and 3.3.4.2. The F-statistics in tables 3.3.4.2.a and 3.3.4.3.a demonstrated that
the parameterized models significantly predicted 𝑘𝑎 and 𝐹. The type III sum of squares
test in tables 3.3.4.2.b and 3.3.4.3.b showed that when each parameter is added last, the
resulting reduction in the sum of squares error was significant in all of the cases. Tables
3.3.4.2.c and 3.3.4.3.c show the final parameter estimates and the associated standard
error of the two models.
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Figure 3.3.4.1. Model for the Prediction of 𝒌𝒂

Table 3.3.4.2.a Sum of Squares Analysis for the Prediction of k
Source
Model
Error
C. Total

DF
3
4
7

Sum of Squares
0.16088118
0.00070632
0.16158750

Mean Square
0.053627
0.000177

F Ratio
303.7001

Prob > F
<.0001

Table 3.3.4.2.b Tests for Type III SS Error for the Prediction of k
Source
F

(

Sum of Squares
0.02345937
0.04285786
0.12314352

)

T
b

F Ratio
132.8548
242.7121
697.3848

Prob > F
0.0003
<.0001
<.0001

Table 3.3.4.2.c Parameter Estimates for the Prediction of 𝒌𝒂
Term
Intercept
𝐹

(

)

𝑇
𝑏

Estimate
0.4644768517
-0.004057305
0.0714231734
0.0543586598

Std Error
0.0292334485
0.0003520052
0.0045845158
0.0020584129
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Prob>|t|
<.0001
0.0003
<.0001
<.0001

Figure 3.3.4.2. Model for the Prediction of
𝑭

Table 3.3.4.3.a Sum of Squares Analysis for the Prediction of F
Source
Model

DF
3

Sum of Squares
0.32119351

Mean Square
0.107065

Error

4

0.00020649

0.000052

C. Total

7

0.3214

F Ratio
2074.0135

Prob > F
<.0001

Table 3.3.4.3.b Tests for Type III SS Error for the Prediction of F
Source

Sum of Squares
0.03080006
0.01400927
0.01963117

b
F

(

)

T

F Ratio
596.6473
271.3824
380.2877

Prob > F
<.0001
<.0001
<.0001

Table 3.3.4.3.c Parameter Estimates for the Prediction of 𝑭
Term
Intercept
𝑏
𝐹

(

)

𝑇

Estimate
0.261519
0.103141
0.001417
0.003271

Std Error
0.009931
0.004223
8.6E-05
0.000168
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Prob>|t|
< 0.0001
< 0.0001
< 0.0001
< 0.0001

The final error statistics for 𝐴𝑈𝐶 and 𝐶𝑚𝑎𝑥 are reported in table 3.3.4.4. The
mean internal percent error for 𝐴𝑈𝐶 was observed to be 35% lower than the external
data, while the mean percent error for 𝐶𝑚𝑎𝑥 in the external data was 34% lower as
compared to the internal data. However, the observed differences in the means were
not statistically significant in any of the cases. The model was also within the % PE
criteria defined by the FDA for both internal and external 𝐴𝑈𝐶 and 𝐶𝑚𝑎𝑥
predictions. Ultimately, the predicted vs. observed values for the 𝐴𝑈𝐶 and 𝐶𝑚𝑎𝑥
values were well correlated with low residuals (see table 3.3.4.4.).

Table 3.3.4.4. Parameter Estimates for the Prediction of AUC, Cmax and Tmax
Study

Internal
Data Set

Meyer et al. 1992

Product ID
1
2
3
4
1

Olling et al.

2
3
4

External
Data Set

1
Meyer et al. 1998

2
3
4

PE: AUC

PE: Cmax

PE: Tmax

4.20
2.79
7.41
5.41
1.22
6.09
4.36
1.69
3.18
6.13
7.55
5.56

1.06
2.61
4.09
7.14
2.19
1.02
4.26
2.39
5.13
0.43
0.43
2.14

6.2
4.8
7.8
6.6
4.2
5.9
8.9
2.3
2.9
4.8
5.2
6.7
PE = percent error

Table 3.3.4.5 Summary Statistics for the Prediction of AUC and Cmax
Summary PK Metric
AUC

(ug/ml/hr)
Cmax
(ug/ml)
Tmax
(hrs)

Summary Statistics
Predicted vs. Observed: R2
Predicted vs. Observed: RMSE
Predicted vs. Observed: R2
Predicted vs. Observed: RMSE
Predicted vs. Observed: R2
Predicted vs. Observed: RMSE
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Values

0.99
5.97
0.99
0.099
0.99
0.21

3.4 Discussion and Conclusion
The specific aim of this chapter was to generate an IVIVC framework that could
accurately predict mean in vivo exposure. Under an ideal scenario, this would be
performed using a prospective clinical trial. Here, plasma concentration profiles would
be generated within a consistent study population by deliberately altering features of
the drug product in a risk-based fashion to achieve an appropriate range of in vitro-in
vivo performance. While the performance of a prospective clinical trial could not be
performed for this work due to logistic reasons, actions were taken to overcome this
limitation using the wealth of publically available paired in vitro-in vivo data (i.e.
dissolution data and its corresponding plasma concentration data) collected on
carbamazepine from a variety of drug product manufacturers. The internal data used
to calibrate the IVIVC described in this chapter was generated using eight products.
Each product came from a unique lot that spanned across five different drug product
manufacturers. The data used to evaluate the external predictability of the IVIVC was
generated using four drug products, including three drug products from unique
manufacturers and one new lot of the reference product. In the end, the accuracy of the
generated model met regulatory, as well as in-house, criteria for internal and external
predictability. The ability to accurately generate an IVIVC using such a diverse drug
product data set supports the generalizability of IVIVC for future applications despite
the practical study limitations. The reliability of this IVIVC will be assumed for the
activities of subsequent chapters.
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Chapter 4: “Bottom-Up” Convolution of IVIVC with
Population-level PK Variance
4.1 Introduction
The previous chapter was built upon the concept that the rate and extent of per oral
carbamazepine absorption from a tablet was primarily a function of its dissolution
behavior.

Chapter 4 is focused on mechanistically modeling pharmacokinetic

pathways thus allowing the observed inter-subject variability to be recovered by
simulations. The specific aim is to account for population level pharmacokinetic
variance within the previously developed pharmacokinetic model of the IVIVC in a
physiologically-based manner (see section 2.4 for a discussion on physiologicallybased pharmacokinetic modeling).
The IVIVC developed in the previous chapter predicted a mean plasma
concentration profile. While this was informative, the statistical assessment of
bioequivalence ultimately requires that intersubject variability be considered. Chapter
4 demonstrates how this requirement was fulfilled by first embedding and refining
physiologically-based clearance pathways within the previously developed IVIVC, and
then performing simulations wherein the covariation of physiological parameters was
propagated across a population in a rational manner. The first step used the extrapolated
results of in vitro studies using models of physiologic systems to predict systemic in vivo
performance.258 The in vitro-in vivo extrapolation of population-based performance is
considered a “bottom-up” approach to pharmacokinetic modelling. This is because it
predicts in vivo pharmacokinetic outcomes using mechanistic information that has been
independently determined a priori. This approach models the concentration profile of a
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compound using i) first principles of human physiology, ii) the results of rigorously
performed federal health interview surveys, and iii) meta-analyses focused on the
abundance of metabolizing pathways. The integration in vitro assays, in vivo data, and
in silico modeling was performed to support the movement towards a more efficient
means of estimating the pharmacokinetic conditions expressed in therapeutic populations
during actual clinical practice.

4.2 Methods and a priori Data
4.2.1 Modeling Overview
A five-step strategy was used in this chapter to model the systemic exposure of
carbamazepine. The first step was to refine the physiologically-based clearance pathways
for carbamazepine. This required the definition of an intravenous physiologically-based
pharmacokinetic model wherein intravenous dosing data was ultimately used to confirm
intrinsic clearance parameters. The use of intravenous dosing for the evaluation and
refinement of clearance pathways eliminates sources of bias related to absorption. The
second step was to model intrinsic clearance using data collected from in vitro systems. Here,
intrinsic clearance was defined as the rate of drug removal absent any constrains from
limiting effects (e.g. perfusion rate of the liver). The third step was to extrapolate the in vitro
intrinsic clearance to whole organ clearance. This was performed using the established
relationship between height and weight as a function of age and gender for the calculation of
body surface area (BSA). The relationship between BSA and liver volume was combined
with an understanding of liver density to derive a value for the mass of microsomal protein.
Using the microsomal weight of the tissue and blood flow to the tissue, the last step for
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extrapolating whole organ clearance was to scale in vitro clearance by applying the percent
abundance of the specific metabolizing enzymes within the liver as reported by
pharmacogenomic meta-analyses.

The fourth step for mechanistically modeling the

systemic exposure of carbamazepine was to confirm the accuracy of the extrapolation
process using intravenous data. The fifth step was to recover the observed variability in the
summary pharmacokinetic parameters 𝐴𝑈𝐶, 𝐶

and 𝑇

. This was performed updating

a priori distributions placed overtop pharmacokinetic model parameters. The combination
of these steps facilitated the testing of more relevant clinical scenarios via the use of
correlated Monte Carlo resampling.

4.2.2 PBPK Modeling Software
Physiologically-based pharmacokinetic modeling was performed using SimCYP
Version 17 (Certara Ltd. Inc., Princeton NJ). The Simcyp® population-based simulator is a
platform and database that has been used for mechanistic modelling and simulation of
physiologic processes involved with the oral absorption, distribution, metabolism,
metabolically-based drug–drug interaction, and excretion of drugs in healthy and disease
populations (e.g. populations categorized by age, disease, race). Optimization algorithms
within the platform, specifically the Nelder-Mead algorithm, were used to recover in vivo
data via targeted parameter estimation.

4.2.3 Intravenous Model
The works of Rowland and Jones served as the foundation for the physiologically-based
pharmacokinetic modeling of this chapter.

259-262
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The modeling assumptions were as

follows: i) intercompartmental transport occurs via the blood, ii) drug concentrations in
efferent blood, and blood within tissues, are equal, iii) there is instantaneous equilibrium of
drug between tissue and blood within the tissue (i.e. perfusion rate limited clearance
kinetics), and (d) only unbound drug is eliminated. A structural representation of the model
is provided in Figure 4.2.3.1.

Figure. 4.2.3.1 Structural form of the physiologically based pharmacokinetic model

Q – blood flow rate; HV- hepatic vein; HA – hepatic artery; PV – portal vein

Two sites of elimination will be considered in the model: the gut and liver. The
differential equations that have been selected to define the physiologically-based
pharmacokinetic model within SimCYP® following intravenous dosing are listed in Table
4.2.3.1. From the first equation in this Table (4.2.3.1), is it clear that the concentration of
drug in the liver, 𝐶 , is an important factor for describing the change in drug concentration
in the central compartment. As described by Equation 4.2.3.3, the amount of drug in the

117

liver, 𝐴 , is in part a function of the drug in the portal vein, 𝐴 . In Equation 4.2.3.2 it is
seen how fraction of drug in the villous blood from that escapes gut metabolism, 𝐹 ,
shapes 𝐴 . The fraction of drug that escapes gut metabolism term is described by Yang
et al.263,279 Not only will this term differentially account for metabolic clearance from
gut enzymes, but it will also account for permeability based clearance of drug into the
gut lumen (𝐶𝑙

). The impact of the fraction of drug metabolized in enterocytes (1

- 𝐹 ) is minimal for the intravenous model.
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Table 4.2.3.1. Foundational Equations for Intravenous
Physiologically Based Pharmacokinetic Model
Eq .4.2.3.(see below)
1)
2)

⁄𝑑𝑡 =
𝑑𝐴
𝑖. 𝑣. 𝑖𝑛𝑓𝑢𝑠𝑖𝑜𝑛 𝑟𝑎𝑡𝑒 + (𝑄

∗ 𝐶 ) − (𝑄

𝑑𝐴 ⁄𝑑𝑡 = [ 𝑄

,

− ∑𝑄

∗

]+∑𝐹

)∗𝐶

/[ : ]

,

) − (𝑄

𝑄

,

∗𝐶

.

.

∗ 𝐶

)

− (𝑄

∗𝐶 )

where,
𝐹 =
𝑄

∙

= (𝐶𝑙

𝐶𝑙

3)
4)

∙𝑄

=𝑆×𝑃

𝑑𝐴 ⁄𝑑𝑡 =
(𝑄 ∗ 𝐶
) + (𝑄
𝐶𝑙 = (𝑄 × 𝑓𝑢 × 𝐶𝐿

,

(

)

)/(𝐶𝑙

,

;
+𝑄

,

);

,

∗𝐶 )−
,

(

𝑄

∗ 𝑓𝑢

) )/(𝑄

⁄[ : ]

+ 𝑓𝑢 × 𝐶𝐿

−
,

𝐶𝐿 ∗ 𝑓𝑢
(

⁄[ : ]

) );

where,

Terms and Subscripts

T=[liver, intestinal segment ‘n’], fu = ‘fuB’;
T=liver;
T= intestinal segment ‘n’;
Q = blood flow (L/hr)
C = concentration
(mg/L)
CL = whole tissue
clearance (L/hr)
A = amount (mg)
CLT,int(unbound) =
unbound intrinsic
clearance in tissue

cent = central
compartment
T = tissue
G = gut tissue
L = liver tissue
villi = villous
vasculature
HV = hepatic vein

[𝑩: 𝑷] = blood:plasma
partition ratio
Kp = tissue to plasma partition
coefficient
fu=fraction unbound in plasma
fuB=fraction unbound in blood,
=fu ⨉ Cp,total/CB,total
fugut = fraction unbound in gut
Peff = effective permeability

FG = fraction of drug
that escapes gut
metabolism
S = available surface
area
v. = venous
u= unbound
th
n = n region in the
GI tract

fugut = 1; assumes insufficient time for plasma protein binding equilibrium or erythrocyte uptake before the drug is removed from the
basolateral side of the enterocyte263
For references used to identify the center and spread of anthropomorphic inputs (i.e. drug-independent, physiological factors) of the
ADAM model see Jamei et al.
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The tissue to plasma partition coefficient (𝐾𝑝) in Equations 4.2.3.1 and 4.2.3.3 was
calculated using the set of equations derived by Rodgers et al. based on the ionization for a
given molecule of interest.264 The derived equation for a neutral compound (such as
carbamazepine) is:
Eq. 4.2.3.5)

𝐾 =𝐾

× 𝑓𝑢

where
𝐾

=𝑓

+𝑓

+ (𝑃 ∙ 𝑓

+ (0.3𝑃 + 0.7)𝑓 )

+ (𝐾𝑎 [𝑃𝑅] )

The three major assumptions in Equation 4.2.3.5 are: i) Non-saturating conditions exist for all
binding processes ii) Drug transport is a passive process, and iii) Each tissue has a well-stirred
distribution model limited by blood perfusion. Equation 4.2.3.5 required the determination of
a compound’s affinity constant (𝐾𝑎 ) for tissue binding protein where [𝑃𝑅]

is the

concentration of protein in tissue T. The binding protein for carbamazepine is albumin ([𝑃𝑅]
has been consistently reported for carbamazepine using in vitro techniques that include
equilibrium dialysis, ultrafiltration, surface plasmon resonance, and various chromatographic
methods

265 268).

The plasma-to-liver and plasma-to-gut ratio for albumin has been

experimentally determined to be 11.6 and 6.33, respectively. 264,269-272 Lastly, Equation
4.5.3.5 was parametrized with the octanol to water partition coefficient for unionised species
(𝑃), and the fractional volume of tissue components (𝑓, where 𝐸𝑊 refers to extracellular
water, 𝐼𝑊 refers to intracellular water, 𝑁𝐿 refers to neutral lipids and 𝑁𝑃 refers to neutral
phospholipids; see Rodgers and Rowland [2007] and Poulin and Theil [2002] for
experimentally determined reference values273,274).
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The interstitial fluid-to-plasma

concentration ratio will be considered as a whole organ-to-plasma ratio, an assumption that
aligns with the well-stirred model of the liver and gut segment. The values and references for
the drug specific parameters are reported in Table 4.3.1.1.

4.2.4 Parameterization, Extrapolation, and Refinement of in vivo Intrinsic
Clearance
The intrinsic clearance of a tissue 𝑇 (𝐶𝑙

,

, where the intrinsic clearance of the gut

or liver 𝑇 equals 𝐺 or 𝐿, respectively), represents its ability to deplete the concentration
of a compound absent rate limiting factors such as blood flow or tissue partitioning.
The major clearance pathways for carbamzepine include metabolism cytochrome P450
(CYP) and the Uridine 5'-diphospho-glucuronosyltransferase (UGT). The specific
isozymes of these pathways (discussed in section 2.2.3) have been identified as
CYP3A5, CYP3A4, CYP2B6, and UGT2B7.
The methodologies used for predicting organ clearance from in vitro systems (e.g.,
hepatocytes and microsomes) have been described in detail by Houston and others, and
have been validated extensively. 275-278

Briefly, the in vitro data in this work was

collected using substrate depletion assays. The key inclusion criteria for in vitro
clearance studies was as follows:
1) The use of validated in vitro systems, which included but was not limited to
harvested liver cells and recombinant enzymes systems
2) The reporting of unbound in vitro intrinsic clearances by accounting for free
fraction of drug in the in vitro incubation, fu
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3) The normalization of clearance parameters on a ‘per milligram of metabolizing
enzyme’ basis (or per cell basis if hepatocytes are being used) as defined by the
incubation media
The general procedure employed by the studies was to incubate various concentrations
of carbamazepine with a fixed concentration of commercially sourced, recombinantly
expressed, monoclonal isozymes.

The carbamazepine was quantified for each

incubation design point using a suitable analytical method (in most cases liquid
chromatography coupled mass spectroscopy). The slope for the concentration vs time
was normalized for nonspecific binding and then recorded as the clearance of
carbamazepine.

The process was then repeated at a subsequent carbamazepine

concentration.

Once the process was performed at all of the carbamazepine

concentrations

for

each

of the

isozymes

the

‘clearance-vs-carbamazepine

concentration’ profiles were modeled according to typical Michaelis–Menten kinetics.
This type of kinetic behavior is defined by the following
equation:
Eq. 4.2.4.1)
Here, 𝑉

𝑟𝑎𝑡𝑒 𝑜𝑓 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 =

∙[
[

]
]

.

represents the maximum rate achieved by the system at the saturating

substrate concentration. This plateau was observed/reported in all of the studies. The
Michaelis-Menten constant 𝐾 is the substrate concentration at which the reaction rate
is half of 𝑉

. In the context of pharmacokinetic modeling, the intrinsic clearance of

an API that follows Michaelis-Menten is defined in the following manner:
Eq. 4.2.4.2)

𝐶𝑙

=

.
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The unbound intrinsic clearance (i.e. 𝐶𝐿

,

) ) in the liver and gut was defined by

(

Equations 4.2.4.1 and 4.2.4.2. These equations follow works reported by Rowland et al.
(2010,2011) and Almond et al. (2009,2016).262,279-281 Here, a standardized scaling
procedure was used to determine the intrinsic clearance of whole organs/tissues (i.e. 𝐶𝐿
and 𝐶𝐿 ) from in vitro intrinsic clearances (see Houston et al. for reviews282-286).

Table 4.2.4.1. Foundational Equations for Unbound Intrinsic Clearance in the
Physiologically Based Pharmacokinetic Model
Eq. 4.2.4.(see below)
𝐶𝐿𝑢
1)

Terms

(

)

=∑

∑

, , (

∑

)

, ,

where,
𝑉 , ,
𝐶𝐿𝑢

2)

,

,

(

)

= ∑

,

= 𝐼𝑆𝐸𝐹 , × 𝑉
, , (

∑
, ,

where,
𝑉 , ,

,

∗

⁄[ : ]

)

, , (

)

× 𝐸𝑛𝑧

, ,

∗

⁄[ : ]

= 𝐼𝑆𝐸𝐹 , × 𝑉

, , (

)

× 𝐸𝑛𝑧

, ,

L= Liver; G= Gut; p = clearance pathway (e.g. CYP, UGT); e = isoform (e.g. CYP2C9, CYP3A4);
fuinc = in vitro fraction unbound in the incubation

The clearance parameters derived from recombinant in vitro systems were scaled to humanderived in vitro systems using the respective inter-system extrapolation factor (ISEF). These
values are reported by the suppliers of recombinant metabolizing enzyme systems and are
based on methods described by Proctor et al.287,288 This allowed whole organ clearances to
be calculated using the abundance of the 𝑒

isoform (𝐸𝑛𝑧

, ,

) and the amount of

microsomal protein per gram of human liver (MPPGL) or length of intestinal segment (𝑠)
(MPPIL) multiplied by the liver mass or intestinal segment length.289-293
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Table 4.2.4.2. Foundational Equations for Unbound Intrinsic Clearance in the
Physiologically Based Pharmacokinetic Model
Eq. 4.2.4.(see below)
𝑑𝐸 ⁄𝑑𝑡 = (𝑟𝑎𝑡𝑒 𝑜𝑓 𝑠𝑦𝑛𝑡ℎ. ) × (𝑖𝑛𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟) − (𝑟𝑎𝑡𝑒 𝑜𝑓 𝑑𝑒𝑔. )
3)

4)

Terms

=𝐸 ×𝑘

× 1+

×[
[

]
]

−𝑘

×𝐸

𝐸 = 𝑏𝑎𝑠𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑒𝑛𝑧. 𝑖𝑛 𝑡𝑖𝑠𝑠𝑢𝑒
= (𝑀𝑃𝑃𝐺𝐿 𝑜𝑟 𝑀𝑃𝑃𝐼 ) × (𝑙𝑖𝑣𝑒𝑟 𝑤𝑡. 𝑜𝑟 𝑖𝑛𝑡𝑒𝑠𝑡. 𝑙𝑒𝑛𝑔𝑡ℎ) × (𝑒𝑛𝑧. 𝑎𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒)
[𝑰𝒏𝒅] = free inducer conc.; 𝜸= Hill eqn. term; 𝑬𝒎𝒂𝒙 = max induction, fraction of
vehicle/control; 𝑬𝑪𝟓𝟎 = concentration that supports half-Emax

The time dependent amount of enzyme in the metabolizing tissue, 𝐸𝑛𝑧

, ,

in Equations

4.2.4.1 and 4.2.4.2, will be calculated using Equations 4.2.4.3 and 4.2.4.4. Equation 4.2.4.3
includes the induction terms: 𝐸

and 𝐸𝐶 . The maximum fold-wise induction to the

synthesis rate of enzyme generation is 𝐸

, while the concentration of inducer that results

in half max induction is 𝐸𝐶 . These terms account for the auto-inductive effects of
carbamazepine and any other concomitantly administered inducers. These values were
informed by quantitative transcriptomics studies reported by Almond et al. in the relevant
clearance pathways (see Chapter 2). Verification of these values were based on the in silico
confirmation that a mean three-fold autoinduction would be complete within a 1-2 week
period as reported in the package insert for Tegretol.294
The liver weight in Equation 4.2.4.4. was calculated by multiplying liver density (1.051
g/L(295)) by individualized liver volumes. Liver volumes and total intestinal lengths were
individualized using the correlated Monte Carlo methods described in section 2.4.3.296 As
previously detailed, the statistical sampling method randomly drew from prior distributions
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of covarying anthropomorphic values for height and weight. The algorthim began by defining
upfront the baseline patient demographics from which subsequent samples would be drawn.
The demographics specifically included the age range and percent of female subjects within
the trial. Samples were drawn from height and weight crosstabs based on the synthetic
patient’s age and gender. BSA was calculated from these values using the previously
discussed Du Bois Equation and individualized liver volumes were simulated using the metaanalysis of Johnson et al. which correlated BSA with liver volume.297,298 Liver weight was
then calculated using the liver density reported by Heinemann et al.299 Similarly, total
intestinal lengths (where each segment, i.e. duodenum, jejunum, or ileum, is a proportion of
the total length) were generated using the correlation between BSA and total intestinal length
as reported by Valentin.300,301
It is important to note that the results of rigorously conducted federal health interview
studies (i.e. NHANES, NHIS, EHIS, etc.) have allowed the covariance structures between
age, gender, height, weight and other anthropomorphic values to be modeled by researchers.
Data libraries based on meta-analysis of such reports are provided with the SimCYP®
software and regularly updated by a consortium of industry, academic, regulatory, and
SimCYP® scientists to describe healthy and diseased populations (so called “population
libraries”). The information in these libraries, coupled with the physiologically based
pharmacokinetic models, were used to account for the physiologic characteristics that shape
drug exposure. This enabled the representative simulation of inter-individual drug exposure
variability.302 The remaining drug specific data necessary to perform the PBPK modeling of
carbamazepine, as per Equations 4.2.3.1 - 4.2.4.4, is provided in Table 4.3.1.1. (see results
section).
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4.2.5 Intravenous Dosing Studies
Data on plasma concentration profiles and pharmacokinetic parameters following
intravenous dosing was collected from the 2012 intravenous dosing study by Marino et
al.122 The details of this study are covered in chapter 2 section 2.2.3. Briefly, the study
used liquid chromatography-coupled mass spectroscopy to quantify the elimination of a
single 100mg intravenous dose of radio-labeled carbamazepine.

4.2.6 Refine and confirm clearance parameters using intravenous dosing
studies
Evaluation of the intravenous physiologically based pharmacokinetic model accuracy
was performed relative to the mean responses observed in the Marino et al. study.303 The
summary pharmacokinetic metric used for this activity was apparent systemic plasma
clearance (𝐶𝐿

).304 Each 𝐶𝐿

was calculated by 𝐶𝐿

= 𝑘 ∙ 𝑉 , where 𝑘 is terminal

rate constant of each simulated profile and 𝑉 = 𝐷𝑜𝑠𝑒/(𝑘 [𝐴𝑈𝐶] ). Here, a mean response
was collected from simulations run using the age range and the proportion of females
reported in the Marino et al. study as the starting point for the previously described correlated
Monte Carlo algorithm. These basis values were 18-61 years (similar to those reported in
the per orally dosed in vitro-in vivo studies by Meyer et al. and Olling et al.) and 51%,
respectively. The 𝐶𝐿

generated from the simulations were compared to those observed

in the study on the basis of the percent error. Ultimately, a test for zero slope of residuals vs.
observed plot was used as the test for model fit of the intravenous data and to justify
successful physiologically-based modeling of the clearance pathways.
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After verifying the accuracy of the clearance model, it was then inserted into the
pharmacokinetic model for per oral absorption. The accuracy assessment was again
undertaken. This time the evaluation was performed using the mean results from the per
orally dosed Meyer et al. and Olling et al. studies to confirm Equations 4.2.4.1 and 4.2.4.2
that had been appropriated, parameterized and integrated within a physiologically based
pharmacokinetic model now based on a per oral route of administration (see Equations
4.2.6.1 and 4.2.6.2).

Table 4.2.6.1. Equations for Physiologically Based Pharmacokinetic Model
Based on a Per Oral Route of Administration
Eq 4.2.6.(see below)
1)

𝑑𝐴

2)

𝑑𝐴 ⁄𝑑𝑡 =
[ 𝑄 − ∑𝑄
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∙

= (𝐶𝑙

,

∙𝑄

=𝑆×𝑃

(

,

)

)/(𝐶𝑙

;
+𝑄

,

);

,

Once the per oral model was demonstrated to be appropriately centered on the mean
responses from small, strategically selected in vivo trials, the goal of recovering
intersubject response variance was pursued.
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4.2.7 Perform Simulation to Recover Observed Levels of Pharmacokinetic
Variance
Having the ability to simulate inter-subject variance within an IVIVC via Monte
Carlo resampling algorithms is important. Such capabilities allow stochastic variability
to be accounted for during the prediction of plasma concentration profiles thus
providing a means by which traditional variance-based biostatistical assessments can
be performed. However, it is critical that variance estimates concerning the respective
system/drug dependent components of the physiologically based pharmacokinetic
model be informed by data-driven means. The plasma concentration-vs-time profile
following oral administration of carbamazepine is largely a function of three
components: the rate of elimination (i.e. apparent systemic plasma clearance, 𝐶𝐿

), the

rate of absorption (i.e. first order absorption rate constant, 𝑘 ), and the extent of
absorption (i.e. bioavailability, 𝐹). The accurate incorporation of inter-subject variance
began with running simulations until convergence. This was defined as the mean and
standard deviation of the distributions of pharmacokinetic metrics being < 1% upon the
addition of an additional in silico trial. For the pharmacokinetic parameters of interest,
reported vs. simulated comparisons of variance were performed using Levene’s test. 305
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The Levene test is defined as:
𝐻 :𝜎 =𝜎 =⋯= 𝜎
𝐻 :𝜎 ≠𝜎

for at least one pair (𝑖, 𝑗)

Test
divided
Statistic:

Given a group of responses 𝑌 with sample of size 𝑁
into 𝑘 subgroups, where 𝑁 is the sample size of the
𝑖

subgroup, the Levene test statistic is defined as:

∙

𝑊=

∑
∑

( . .. )
∑
( . .. )

where 𝑍 has the following definition:
𝑍 = 𝑌 − 𝑌.
where 𝑌 . is the mean of the 𝑖

subgroup.

𝑍̅ . are the group means of the 𝑍 and 𝑍̅.. is the overall mean of the
𝑍 .

Critical
Region:

The Levene test rejects the null hypothesis if:
𝑊>𝐹
where 𝐹

,

,

,

,

is the upper critical value of the 𝐹

distribution with 𝑘 − 1 and 𝑁 − 𝑘 degrees of freedom at a
significance level of α = 0.05.

129

The approach used to recover the coefficient of variation in clearance reported for
each product in the Meyer et al and Olling et al. studies followed the work of Ke et al.306
Specifically, the process began by modifying the Simcyp® default value for the liver volume
coefficient of variation, 𝐶𝑉

. The modification was based on the distribution of

values for liver weight as a percentage of body weight (simulated using the patient
demographics reported by Meyer et al and Olling et al. and the liver weight individualization
routine described in chapter 4 section 4.2.4). The range of liver weight as a percentage of
body weight reported by Johnson et al. served as the target during the 𝐶𝑉
optimization process. In a similar manner, the 𝐶𝑉 for microsomal protein per gram of liver
(MPPGL) as a function of age was modified to recover the range reported by Barter et al. in
the age range studied by Meyer et al and Olling et al.293 Lastly, default values for the 𝐶𝑉 of
the isozyme abundance were modified equally on a percent of default-basis for the recovery
of the 𝐶𝑉 in clearance reported for each product in the Meyer et al and Olling et al. studies.
Neither 𝐶𝑉 nor 𝐹 was directly reported by Meyer et al or Olling et al. Therefore, after
𝐹 was calculated in-house using digitization software and noncompartmental analysis (see
chapter 3). The objective following the determination of 𝐹 was i) the determination 𝐶𝑉 for
each product and, ii) the derivation of a pair-wise model relating 𝐹 and 𝐶𝑉 . This
relationship would provide the ability to build upon the IVIVC’s dissolution-based prediction
of 𝐹 by assigning a 𝐶𝑉 for a given 𝐹 value. The basis for this model was observed clinical
data, specifically the 𝐶𝑉′𝑠 for 𝐴𝑈𝐶 and 𝐶

reported by Meyer et al. or Olling et al. for

each product. This was because sensitivity analysis demonstrated a strong correlation
between these summary pharmacokinetic metrics and 𝐹 which was independent of 𝑘𝑎 in the
ranges observed in the studies (R2 for 𝐴𝑈𝐶 or 𝐶
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vs 𝐹 was > 0.95 in both cases and < 0.20

when 𝑘 was the regressor for 𝐴𝑈𝐶 or 𝐶

). Therefore, 𝐶𝑉 was assigned for a known

value of 𝐹 and the relationship was modeled according to the following procedure.

1. Determine 𝐹

for each product in the Meyer et al and Olling et al studies

a. Performed by digitizing the plasma concentration profiles and
performing noncompartmental analysis with a priori information on the
volume of distribution to derive the critical pharmacokinetic parameters
including 𝐹 for the recovery of the observed plasma concertation profile
and thereby 𝐴𝑈𝐶 and 𝐶

(see chapter 3)

2. Run simulations where each individual product’s 𝐹 value is sampled from a
normal distribution centered on its respective 𝐹

where the spread is

defined by an iteratively varied 𝐶𝑉
a. Simulations were defined by the number of trials and the number of in
silico patients within each trial
b. The number of in silico patients was representative of that used in the
Meyer et al. and Olling et al. studies (n=25)
c. The number or trials was dictated by the convergence upon stable pooled
mean of 𝐶𝑉

and 𝐶𝑉

, respectively.

3. For each simulation performed at a defined 𝐶𝑉 the distribution of outputs (i.e.
plasma concentration profiles) were recorded and the 𝐶𝑉
recorded.
4. The 𝐶𝑉

and 𝐶𝑉

was plotted as a function of 𝐶𝑉
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and 𝐶𝑉

was

5. A 𝐶𝑉 was individually assigned, based on this relationship, to each product’s
𝐹

on the basis of recovering the reported product’s respective 𝐶𝑉

and

𝐶𝑉
a. Recovery is based on the Levene test for equal variance

The last correlation to be modeled was between 𝑘 and the 𝐶𝑉 for 𝑘 , 𝐶𝑉 . Sensitivity
analysis shows that 𝑇

following a one-time dose is almost exclusively a function of ka

when clearance pathways are held constant. Meyer et al. and Olling et al. calculated 𝑇
as the time at which 𝐶
the respective 𝐶𝑉 for 𝑇

occurs. They reported mean 𝑇
, 𝐶𝑉

values for each product and

. Thus, the 𝑘 vs 𝐶𝑉 relationship was established using

a similar procedure for the refinement of the 𝐹 vs 𝐶𝑉 , this time 𝐶𝑉
𝐶𝑉

and 𝐶𝑉

took the place of

and 𝑘 / 𝐶𝑉 took the place of 𝐹/ 𝐶𝑉 .

4.3 Results and Discussion
4.3.1 Recovery of Systemic Clearance: Mean and Variance
The Simcyp® platform was able to successfully integrate:
i) data generated using in vitro enzyme and cellular systems (as part of typical
preclinical drug discovery activities), with
ii) the relevant physicochemical attributes of carbamazepine (i.e. LogP value) and,
iii) demographic, physiological and genetic information of patients
for the prediction in vivo pharmacokinetic parameters and profiles.
An intrinsic functionality of the Simcyp® platform is the inclusion of population
variability that, with proper consideration of the covariation of parameters, allows for the
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performance of virtual clinical trials and capturing of inter-individual differences in drug
exposure where they occur. Using robust data the software provided a framework to
model the covariation of physiological parameters and propagation of the respective
variability across an in silico population in a rational manner using correlated Monte
Carlo sampling to preserve the observed gender-age-weight-height-BSA-liver volume
relationship (see chapter 2 section 2.4). Thus, the fidelity of virtual individuals to real
people was maximized by preventing the impossible combination of physiologic
parameters. For further reading on the history, development, computer science, and
application examples of the software see Jamei et al. 307
Devising a physiologically based clearance model within the Simcyp® platform that
would accurately simulate plasma concentration profiles following intravenous dosing was
the first step pursuant to the goal of this chapter (i.e. the incorporation of physiologically
based clearance pathways within the previously developed IVIVC for the mechanistic
recovery of intersubject variance using correlated Monte Carlo simulations). The results of
the literature search of drug specific data necessary to perform the physiologically based
pharmacokinetic modeling of carbamazepine, as per Equations. 4.2.4.1 - 4.2.6.2, is provided
in Table 4.3.1.1.
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Table 4.3.1.1. Drug Specific Parameters of Carbamazepine in Physiologically Based Pharmacokinetic
Model
PK Property
3A4
(Enzyme Kinetics)
3A5
(Enzyme Kinetics)

2C8
(Enzyme Kinetics)

In vitro System
HLM &
Recombinant CYP
(Baculovirus-InsectCell-expressed)

Recombinant CYP
(Baculovirus-InsectCell-expressed)

Parameter

Valuea

Vmax
Km

1.2
120

Vmax
Km

Vmax
Km

1.17
119

0.67
760

Comments and References

Formation of Epoxide
(Major metabolite)
ISEF ≈ 1

Formation of Hydroxylated
Metabolites
ISEF ≈ 1

Cazali et al.308
Huang et al.309
Henshall at al. 310
Pearce et al. 311
Egnell et al.312
Kerr et al. 313
Korzekwa et al.314
Pearce et al.315
Cazali et al.Error!
Bookmark not defined.

Kerr et al. Error!
Bookmark not defined.

Pearce et al.Error!
Bookmark not defined.

Vmax
Km

Also measured Vmax/Km in HLM,
HIM and HKM. Allowed calculation
0.79
Staines et al 316
of UGT tissue scalars for Liver,
200
Intestine and Kidney (no need for
ISEF)

UGT
(Enzyme Kinetics)

UGT2B7 V79 cells

Free fraction of
CBZ in hepatocytes

HLM

0.98

unbound percent in
plasma

plasma samples

Hooper et al.317
Association constant (KA) = 5.3 × 103 Bonneton at al.318
25%
M−1
Tong et al.319

Volume of
Distribution in
Central
Compartment

In vivo studies using
IV dosing (L/kg)

V

0.8

blood to plasma
partition ratio

Whole blood
samples

BP

1.07

fup

Bookmark not defined.

Rawlings et al.320 Eichelbaum et al.321
Graves et al.322 Meyer et al.
Olling et al.
Christiansen et al.323

2.42 Octanol in water partition coefficient Novartis324

Log P
Fraction unbound in ultrafiltration
incubations
following incubation

Fraction unbound in
liver

Egnell et al. Error!

fuinc

1

)∗

= fu

0.76
Assumed to
Fraction unbound in equilibrate with free
concentration in
gut
blood

fu
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(see above) and…
Egnell et al.Error!
Bookmark not defined.

Austin et al.325

PLR: plasma-to-liver ratio of binding
proteins; equal to 11.6 according to a
unified algorithm by Peyret et al.326 forPoulin et al.327
predicting partition coefficients in
PBPK modeling studies

∗
(

Reference inclusion criteria: a)
unbound intrinsic clearances be
reported, or b) fuinc be reported (see
Pearce et al.). The majority reported
unbound Clint.

1

Albumin is the binding protein for
CBZ, it is made by hepatocytes, is
contained mainly in the central
compartment

Tong et al.Error!
Bookmark not defined.

Terms:

HLM: human liver microsomes; Vmax: Michaelis-Menten maximum rate of metabolite formation (pmol/min/mg of
rCYP);
Km: Michaelis-Menten constant (µM of substrate concentration); V: L kg-1

After including the data from Table 4.3.1.1 into Equations 4.2.4.1 - 4.2.6.2, predictions
were made using the 100mg i.v. dosing strategy of Marino et al. Figure 4.3.1.1.b
demonstrates good agreement between the mean plasma concentration profile observed from
the intravenous data in the Marino study and the profile generated from the simulations. The
Marino data used a clinical population. This means that the population was already induced.
The full profile of the data from Figure 4.3.1.1.b (data not shown) demonstrated that mean
autoinduction ceased at 235.2 hours during chronic administration. The accurate recovery
of a the 100 mg intravenous dose under autoinduced conditions was apparent by a visual
predictive check of Figure 4.3.1.1.b. These results confirmed the accuracy of the 𝐸
𝐸𝐶

and

of 2.1 and 211 uM used in this study.
The R2 for a plot of the observed vs simulated was 0.98 and the 95% confidence interval

for the slope and bias terms for the data contained in Figure 4.3.1.1.b contained 1 and 0
respectively (see Figure 4.3.1.1.c). Additionally, the percent error for the simulated 𝐶𝑙
was 2.3% when compared to the reported value (see Figure 4.3.1.1.a). This demonstrated the
initial suitability of the physiologically based model parameters for clearance. The results
from the modeling effort is graphically reported in Figure 4.3.1.1.c.

135

Figure 4.3.1.1.a Observed vs. Simulated Clearances
95% CI for Marino et al.
Mean Marino et al.
Mean Sim Clearance
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Figure 4.3.1.1.c Observed vs. Simulated
Observed Concentration (mg/L)

Concentration (mg/L)

Figure 4.3.1.1.b Recovered Marino et al. (2012) Data
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The next step was to insert the physiologically based clearance model into the model for
per oral carbamazepine administration used by the IVIVC of the previous chapter. This
activity had two requirements i) the accurate mean elimination rate prediction for each of the
formulations reported by the formative per oral studies, and ii) an accurate recovery of the
variance reported in these studies.

Figure 4.3.1.2. Observed and Simulated 𝒌𝒆 Values
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The Figure 4.3.1.2 visually demonstrates how the simulated elimination rates aligned
well with those observed. The variance in the outcomes were refined by decreasing the
default 𝐶𝑉 for 𝑀𝑀𝑃𝐺𝐿, liver volume, and reported isozyme abundances (i.e. 3A4, 3A5,
2C8, and UGT 2B7) by 75% . The final distributions for the liver weights are represented in
Figure 4.3.1.3. as a percentage of body weight.
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Figure 4.3.1.3. Distribution of Liver Weights

Liver weight as a percentage of body weight (%)
Solid red lines represent the range of liver weight as a percentage of body weight values for the age
interval investigated as reported by Johnson et al.254, the dashed line represented the reported median

Figure 4.3.1.4. Distribution of Individualized MPPGL values

MPPGL (mg/g)
Red lines represent the range of expected MPPGL values for the age interval investigated
as reported by Barter et al.293

Table 4.3.1.2. presents the data used to construct Figure 4.3.1.2. The ranges spanned by
the 95% confidence intervals were all observed to overlap. This signified that the differences
between the mean 𝑘 reported for each product in the studies and those 𝑘 generated by the
respective simulations were statistically insignificant. Futhermore, the Levene test for equal
variance was used to test for the equality of variances. Here, the n of the test statistic was
defined by the average number of patients in the Olling and Meyer studies (N=24). It was
observed that none of the variances were statistically significant (p > 0.05 for all of the cases).
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Table 4.3.1.2. Observed and Predicted Values for 𝑘𝑒
Observed
Product

ke

CV

ke

CV

1

0.0178

0.19

0.017

0.17

2

0.018

0.21

0.018

0.18

3

0.0178

0.21

0.017

0.17

4

0.0181

0.22

0.017

0.17

1

0.01725

0.15

0.017

0.17

2

0.01818

0.19

0.018

0.17

3

0.01721

0.16

0.017

0.17

4

0.0163

0.16

0.016

0.17

1

0.0155

0.18

0.015

0.16

2

0.017

0.18

0.016

0.16

3

0.016

0.16

0.015

0.17

4

0.0153

0.15

0.015

0.16

Olling

Meyer 1992

Meyer 1998

Study

Simulated

It should be noted that the Olling et al. study did not directly report elimination rates.
However, the study did report elimination half lives allowing 𝑘 to be calculated using the
equation: 𝑘 = ln(2) /𝑡

/

. Additionally, the 1998 Meyer et al. data was held back to be

used for evaluating external predictability after the refinement process. Despite this, the
model developed using the 1992 Meyer et al study and the Olling et al. could still accurately
predict the center and spread of the clearances from the 1992 Meyer et al. study.
Once the clearances parameters, and their respective 𝐶𝑉 converged on values that
satisfied the desired accuracy criteria, the final step was to refine the model that would
accurately provide a 𝐶𝑉 and 𝐶𝑉 based on the predicted mean of 𝐹 and 𝑘 . As a review,
this was achieved by:
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i) varying the 𝐶𝑉 for 𝐹 and 𝑘 in a full factorial scheme from 0% to 150% for each
of the four products reported by Meyer and Olling (total = 8)
ii) recording the post-simulation 𝐶𝑉

, 𝐶𝑉

, and 𝐶𝑉

iii) identify the 𝐶𝑉 that returned the observed 𝐶𝑉

and 𝐶𝑉

iv) identify the 𝐶𝑉 to each 𝑘 that returned the observed 𝐶𝑉
v) constructing models that captured the respective 𝑘 -vs.-𝐶𝑉

and 𝐹-vs.-𝐶𝑉

relationships
It is worth noting that one feature of the plasma profile simulation process was to preserve
the analytical features of each study. Specifically, the process used the same plasma
concentration time points as those reported in the studies. The analytical error reported for
each respective study was also accounted for within the simulations. This was accomplished
by randomly adding the noise to the profile which was on the order of the observed analytical
precision reported in the quality control sections for each study.
The importance of using simulation time points that were consistent with those reported
in the respective studies was to maximize the fidelity of the simulation. Without this the 𝐶𝑉
for the pharmacokinetic parameters would be conflated with the analytical error. This is
particularly important when considering the recovery of the 𝐶𝑉 for 𝐶

and 𝑇

. To

illustrate this, consider Figure 4.3.1.5. which was taken from the original 1992 Meyer et al.
study.

Figure 4.3.1.5. Plasma Concentration Profiles from 1992 Meyer et al.
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Figure 4.3.1.5. Mean carbamazepine plasma concentration. (○) Product 1; (●)
Product 2; (■) Product 3; (▲) Product 3; Adapted from Meyer et al 139

The square generated by the intersection between the red lines in Figure 4.3.1.5 indicates the
region of 𝐶

, and by extension 𝑇

this study directly defined 𝐶

, that occurs in product 4. Given that the authors of

as the largest concentration determined during drug-plasma

quantification, noise in the analytical procedure method directly propagates to the reported
variance in the 𝐶

metric. Furthermore, it can be seen in the peak plasma concentration

profile for product 4 is relatively broad. While this type of performance makes capturing the
true 𝐶

less of an issue, it can result in estimations of 𝑇

which are sensitive to the

sampling interval. Therefore, it was important that the simulations in this chapter accounted
for the procedural contributions to variance that were present in the 𝐶𝑉𝑠 for 𝑇
𝐶

and

reported by the formative studies.
The resulting models are reported in Figure 4.3.1.6. a. and b. The accuracy with which

the variance in 𝐴𝑈𝐶, Tmax, and 𝐶

was predicted is demonstrated in Table 4.3.1.3. The
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ability to predict the mean 𝐴𝑈𝐶, Tmax, and 𝐶

was unchanged from the previous chapter

since the center of the 𝑘 and 𝐹 were not altered.

Figure 4.3.1.6.a CVka vs ka
300
250

CVka

200
150

Series1
Expon. (Series1)

100

39.614e2.3158x

y=
R² = 0.9649

50
0
0

0.2

0.4

0.6

0.8

1

ka (1/hr)

Figure 4.3.1.6.b
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The primary indicator for 𝑘𝑎 variance was the variance in 𝑇
strong correlation between 𝑘𝑎 and 𝑇

. This was due to the

across the range of bioavailabilities and clearance

rates observed in this work (R2 > 0.95, individual simulation studies not shown). From
Figure 4.3.1.6.a it was observed that as 𝑘𝑎 decreased, 𝐶𝑉

decreased. Thus, it followed

that quicker releasing carbamazepine products had earlier 𝑇

values and were of higher

variability. This increased variability at faster release rates could have been driven by a
host of factors, including those related to the scenario of higher concentrations being
reached in the gut by faster dissolving products. These higher concentrations could have
lead to transient deviations from the sink conditions typically associated with drugs of
higher permeability as is the case with carbamazepine. Thus the higher variability in
𝑇

could have been driven by intersubject differences in permeability and gastrointestinal

tract transit transiently defining the rate of absorption in such cases. However, when the
drug was released as slower rates, the saturated concentrations required to cause a
temporary loss of sink conditions would not have been achieved. Thus, the rate of systemic
absorption would follow classical BCS class II behavior, i.e. dissolution existing as the
rate-limiting step in absorption. Given that the products were all marketed drug products, it
is conceivable that they were manufactured under consistent conditions resulting in
minimal within batch differences in performance. Thus, the decreased variability of in vivo
performance for products with a slower release was expected.
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The observed trend in Figure 4.3.1.6.b was that as 𝐹 increased the 𝐶𝑉 bioavailability
decreased.

To explain this relationship, consider how, similar to the 𝑇𝑚𝑎𝑥-vs.-𝑘𝑎

relationship, a strong correlation existed between 𝐹 and 𝐴𝑈𝐶, 𝐹 and 𝐶𝑚𝑎𝑥 (R2 > 0.95,
individual simulation studies not shown). Thus, variability in 𝐴𝑈𝐶 and 𝐶𝑚𝑎𝑥 could be used
as surrogates of 𝐶𝑉 . Thus, it was observed that as 𝐹 increased, the 𝐶𝑉 required to recover
the observed variabilities in 𝐴𝑈𝐶 and 𝐶𝑚𝑎𝑥, decreased. This was likely due to the
logarithmically increasing relationship of 𝐹 as a function of 𝑘𝑎. This is to say that as 𝑘𝑎
increases, 𝐹 increases and approaches 1. Thus, significant variation in large 𝑘𝑎 values result
in only minimal changes to 𝐹. By extension, if an immediate release drug that is highly
permeable quickly enters into solution (as was the case for drug with a high 𝑘𝑎) the
probability of it not being thoroughly absorbed over its residence time in the gastro intestinal
tract is minimal.

Since, carbamazepine undergoes little gut metabolism intersubject

differences in permeability and GI transit do not substantially impact 𝐴𝑈𝐶. It is only at slow
dissolution rates (i.e. low values for 𝑘𝑎) where the drug has difficulty escaping the dosage
form and thus variability in transit times and other physiologic factors begin to more
substantially vary the value of 𝐹.

Table 4.3.1.3. Observed vs Simulated CVs for Summary
Pharmacokinetic Metrics
Observed CV
Study Product

AUC

Cmax

Simulated CV
Tmax
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AUC

Cmax

Tmax

Olling

1
2
3
4

0.24
0.31
0.28
0.20

0.31
0.29
0.27
0.16

0.41
1.05
1.13
0.47

0.21
0.28
0.26
0.21

0.21
0.25
0.24
0.21

0.53
0.72
1.18
0.53

Meyer
1992

1
2
3
4

0.15
0.47
0.2
0.29

0.20
0.62
0.18
0.39

0.51
0.74
0.72
0.78

0.22
0.47
0.21
0.26

0.22
0.63
0.21
0.35

0.53
0.53
0.57
0.53

Meyer
1998

1
2
3
4

0.18
0.19
0.19
0.17

0.16
0.15
0.21
0.15

0.45
0.43
0.42
0.31

0.21
0.21
0.21
0.21

0.20
0.19
0.21
0.19

0.53
0.61
0.58
0.50

On average, the typical behavior of quicker dissolving drug products being absorbed at
faster rates and to a consistently larger extent of absorption was observed. While slower
releasing products were possibly less sensitive to physiologic differences, the risk of
incomplete absorption became higher. Ultimately, the 𝐶𝑉 reported by Meyer (1992) and
Olling differed insignificantly (p > 0.05) from the 𝐶𝑉 for 𝐴𝑈𝐶, 𝐶𝑚𝑎𝑥 ,and 𝑇𝑚𝑎𝑥 that
were respectively simulated. The products and reported 𝐶𝑉 for 𝐴𝑈𝐶, 𝐶𝑚𝑎𝑥 ,and 𝑇𝑚𝑎𝑥
from the 1998 Meyer study were used as a test for external predictability. Here the
differences were again insignificant (p > 0.05)

4.4 Conclusion
This work leveraged the results of in vitro DMPK studies that are commonly performed
during preclinical development to mechanistically identify metabolism pathways. The
product of these activities augmented the results of conventional clinical pharmacokinetic
studies performed in vivo. The combined product allowed for the systematic development
of a physiologically based IVIVC. While several researchers have attempted to construct
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IVIVCs for Carbamazepine, this work is unique in that it i) achieved an acceptable level A
prediction ii) while accounting for mechanistic metabolism pathways and iii) recovering the
observed population level variance. This work also accounted for the analytical error
reported by the conventional clinical pharmacokinetic studies in the clinical trial simulation
process. Here, the analytical error reported in the referenced clinical trials was added to the
in silico clinical trials to maximiz the fidelity of the simulation. Following the successful
development of this level of IVIVC it will be used as a tool to support the establishment and
assurance of bioequivalence in a more clinically relevant manner by the mechanistic
description of inter-subject variability.

Chapter 5: Assuring Consistent Performance:
F2 vs. Physiologically Based IVIVC – Associated Differences in
Bioequivalence Errors and Design Spaces

5.1 Introduction
Chapter five represents the zenith of this project. The quality attribute of interest
discussed throughout this document has been consistent drug product performance wherein
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dissolution tests are used as a means of assessment. In this final chapter, a comparison was
made between two methods for defining specifications of the dissolution performance. The
methods were based on the use of the conventional F2 statistic and the outputs of a
physiologically based IVIVC nested within a clinical trial simulation (PB-IVIVC-CTS)
platform. As such, three core assessments were performed. First, the difference between the
respective dissolution specifications was assessed. Second, the difference between the
resulting product/process parameters design spaces was assessed. Finally, a post hoc
assessment of F2-based dissolution profiles using the PB-IVIVC-CTS platform for type I (α)
and type II (β) errors in bioequivalence was performed pursuant to the central hypothesis of
this work:
For an immediate release carbamazepine product,
when a physiologically based IVIVC is coupled with a clinical trial
simulation platform and used to assure the bioequivalence of an
immediate release carbamazepine tablet, fewer errors for
bioequivalence will be observed when compared to an approach that
relies on the F2 criteria.
Many of the current tenants of pharmaceutical quality were inspired by the work of
Joseph Juran. He was a luminaire of quantity management theory during the transitional
period between the 20th and 21st centuries. Juran’s definition of product quality (and indeed
many other’s) can be distilled into two principles: first the presence of attributes within a
product which confer user satisfaction following exposure/interaction, and second the
reliability of such critical attributes. The FDA rarely defines pharmaceutical quality
explicitly. At most, the FDA references a product’s quality in the context of its “suitability
for an intended use”. However, a survey of FDA guidances related to pharmaceutical quality
provides further resolution of this definition. Here, the “intended use” of a drug product is
defined by the approved “label claims”. The context of these claims are based, to a great
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extent, on the clinical studies submitted by the product manufacturer and verified by FDA
review. Thus, the first aspect of a more integrated and resolved definition for pharmaceutical
quality includes the product’s ability to meet the dosing, safety, and efficacy criteria
identified in the labeling; and, by extension, used in the investigational batches used during
clinical development.

Furthermore, the statutory requirement of drug products and

substances to comply with the Federal Food, Drug and Cosmetic Act allows Juran’s second
concept of quality, consistency, to be considered within an operational definition of
pharmaceutical quality. This act states that a drug not made in accordance with current good
manufacturing processes (cGMP) is deemed "adulterated." CGMP regulations assure that
drugs meet the safety, identity, and strength requirements of the Federal Food, Drug, and
Cosmetic Act as well as the quality and purity characteristics that the product purports to
possess.328 As part of cGMP, firms must perform validation procedures to demonstrate that
their manufacturing processes can consistently produce a product that meets established
quality attributes.
In an op-ed article, Dr. Janet Woodcock (director of the FDA’s Center for Drug
Evaluation and Review) stated how conventional validation procedures are often empirical
in nature. Assessing the suitability of this practice is an aim of this work.8 Dr. Woodcock
additionally discussed how the Act viewed from the context of overall quality regulation, is
a statutory CGMP requirement that can be viewed as a legal representation of the frequent
statement that quality must be built-in.8 This concept is the basis for the pharmaceutical
industry’s adaptation of another of Juran’s concepts, i.e. quality by design.
The concept of quality by design, along with the utilization of design spaces and
the probabilistic assessment of risk (of propagating excessively wide or unnecessarily
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narrow specifications) are key aspects of this project. The term quality by design (QbD)
was first coined by Juran in his 1991 publication entitled Juran on Quality by Design and
has since been invoked by a variety of fields. According to Juran, achieving quality by design
during industrial manufacturing is the result of three central activities (i.e. Juran’s Trilogy)
which make up Juran’s philosophy for quality management. These activities include quality
planning, quality control, and quality improvement.

Paralleling the previous axiom

articulated by Dr. Woodcock, the FDA contextualizes Juran’s concept of quality by design
within the field of pharmaceutical manufacturing by stating that QbD is the process of
building quality into the product. The FDA expands on the importance of achieving quality
by design by emphasizing the recognition on the part of sponsors that quality “cannot be
tested into products”. While this position may seem counter intuitive, its reasoning is related
to the implication that such strategies (i.e. those based on “testing of quality into a product”)
represent a reactive, rather than proactive, position towards the assurance of quality and that
reliance upon which is a result of limited product/process understanding. This type of a
strategy is not in pursuit of maximizing efficiency. Thus, it is considered to increase the risk
of unnecessary waste, increased hold times, and higher cost. For these and other reasons, the
more holistic perspective on quality assurance is encouraged by the FDA.

The

administration specifically stresses the objectives for quality measurements be risk-based and
predefined. In this way, the assessment of critical product/process parameters provides a
path towards improved product understanding and more appropriate process controls.
The process of modeling the quality attributes of a drug product or substance as a
function of its critical product/process parameters is known as design space development.
The ICH Q8 definition of design space used by the FDA is “the multidimensional
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combination and interaction of input variables (e.g., material attributes) and process
parameters that have been demonstrated to provide assurance of quality.” Working within an
FDA approved design space is not considered as a change. Thus, the utilization of design
spaces can confer greater regulatory flexibility and confer improvements to efficiency.
Movement out of the design space, however, is considered to be a change and normally
initiates a regulatory post approval change process. The post approval change process can
be extremely costly to a sponsor and to patients. Therefore, the criteria used to define the
limits of a CQA is of great importance.
As introduced at the beginning of this chapter, dissolution performance was the CQA of
interest and two competing methodologies were used to define the upper and lower
acceptability limits of dissolution. Specifically, the methods used were the F2 criteria
and the previously developed IVIVC. Upper and lower limits on dissolution were made
with respect to the dissolution performance of the reference labeled product (RLP). The
focus on dissolution performance was motivated by the considerable regulatory significance
placed on this measurement of quality. This high degree of importance is a result of
dissolution being considered the rate limiting step for the absorption of BCS class II
substances like carbamazepine. While the F2 metric was used for the sole purpose of
defining an empirical region of dissolution profile similarity, the IVIVC usage illustrated in
this chapter was twofold. First the IVIVC was used to propagate a distribution of clinical
responses that, based on the range of F2 defined dissolution performance. Additionally, the
IVIVC was used to directly derive specifications on dissolution.
The final step of this work was to illustrate the implications of selecting one CQA
refinement methodology over the other in terms of the i) resulting dissolution specifications
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and design spaces, and ii) the associated risk to bioequivalence with either method. Design
space development began with the development of a knowledge space. Here the term
knowledge space means the intervals over which critical product/process attributes have been
systematically investigated and the dependent performance of the critical quality attribute is
known (also referred to as the calibrated range). A design space exists within a knowledge
space. The critical product attributes which defined the design and knowledge spaces used
in this work were: binder concentration, disintegrant concentration, and porosity. These three
factors were considered high risk and are known to significantly affect the dissolution of a
solid oral dosage form which could ultimately impact clinical performance.
In statistics, risk is a measure of the association between a binary occurrence and set of
continuous and/or binary predictors. The concept of risk is directly related to probability.
The probability of event 𝑎 occurring out of 𝑎 and 𝑏 possible events is defined as 𝑎/(𝑎 + 𝑏).
This is the same calculation for the (absolute) risk of event 𝑎 occurring. Monte Carlo-based
modeling techniques, such as that employed by the clinical trial simulation platform in this
work, have been widely used for the purpose of probabilistic risk assessment. This is due to
their ability to propagate the a priori variability associated with model parameters through
the model resulting in a distribution of outputs. In the context of a physiologically-based
IVIVC, such methods provide the ability to propagate the variability of physiologic systems
over an array of product performance inputs and generate a posterior probability distribution
of clinical effects. In this way, the risk of errors in bioequivalence can be compared between
the two identified CQA specification methodologies using a predefined objective of what
constitutes a clinically significant difference. This required estimating a probability density
function for the distribution of clinical responses resulting from an F2 defined range of
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dissolution profiles, and comparing the function with a PDF that represents an estimated
distribution of all possible bioequivalent responses.

5.2 Methods and Materials
5.2.1 Summary PK Metrics of Interest
Cmax and AUC at time 170 (AUC∞) were initially selected as the summary
pharmacokinetic metrics of interest. This was because of their widely accepted use as
markers for the extent of drug exposure. The importance of these characteristic was
demonstrated by works of Tothfalusi et al. and Olling et al. who reported how a
predictor of toxic events was the magnitude of drug absorption.

Olling et al.

additionally showed that the differences in absorption rate evidenced by deviations in
𝑇

were also used. Lastly, after considering that carbamazepine is administered in a

chronic fashion, the concentration at steady state (𝐶 ) was assessed along with the
minimum and maximum (𝐶

,

, and 𝐶

,

) concentration at steady state. The

concentrations at steady state was defined in this work as the average concentration
over the last 5 days of a 30 day dosing period.

5.2.2 F2-based Dissolution Limits and the resulting PDF of Clinical
Responses
Identifying dissolution model parameter limits using the F2 statistic and
transforming the resulting range of in vitro performance into a distribution of clinical
responses was accomplished according to Figure 5.2.2.1.

Figure 5.2.2.1. Work-flow for Generating a Distribution of Clinical Responses
from F2-based Dissolution Limits
153F2 Equation

Create dissolution parameter

Makoid Banakar
Dissolution Model

Defining the range of F2 defined dissolution began by nesting the Makoid Banakar
dissolution model within the F2 Equation.
n

Eq. 5.2.2.1

2

f 2 = 50  log{[1+ (1/n)(t =1) (R t - Tt ) ]-0.5  100}
where
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Eq. 5.2.2.2

𝑇 =𝐹

∙

∙𝑒

∙

,

for t <= 𝑇𝑚𝑎𝑥

and where for 𝑡 > 𝑇𝑚𝑎𝑥, 𝑇 = 𝐹
This allowed limits to be defined for the dissolution model parameters to achieve an F2
> 50 dissolution profile given the performance of a reference drug product. The
reference labeled drug product for carbamazepine is Tegretol.

Its dissolution

performance served as a benchmark for the comparisons performed in this study and
was based on the 1992 Meyer et al. study (see Figure 5.2.2.2). The dissolution test in
that study used the compendial dissolution test for carbamazepine (see Chapter 3

Figure 5.2.2.2. Dissolution profiles of four 200mg
carbamazepine Tablet products. (○) Tegretol [adapted from
Meyer et al.(1992)139]
section 3.2.1).
Using the referenced performance of Tegretol, the F2 metric was calculated for any
set of dissolution parameters.

Dissolution profiles are identical if F2 is 100. FDA

guidance states that generally, F2 values greater than 50 (50-100) ensure sameness or
equivalence of the two curves and, thus, of the performance of the test (e.g. postchange)
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and reference (e.g. prechange) products. The range of acceptable dissolution profiles
was thus defined as those with an F2 value > 50. This allowed any dissolution profile
of a simulated test product to be identified as either equivalent or nonequivalent.
The combination of dissolution parameters that resulted in an F2 > 50 provided an
asymmetric shape and volume. To process the infinite number of dissolution parameter
combinations using an IVIVC within the Simcyp® platform, a sampling strategy was
developed. The sampling routine was performed in two steps and was based on the
assumption that all possible F2 > 50 dissolution parameter combinations were equally
likely. From this assumption, the first step was guided by the principle that points on
the surface of the shape were of particular importance. This is because those points
represent dissolution profiles that were maximally different from the profile of the
reference product and when processed using the IVIVC would define the tails of the
distribution of clinical responses. Therefore, the surface of the shape (which describes
all of the possible combinations of 𝑏, 𝐹𝑚𝑎𝑥, and 𝑇𝑚𝑎𝑥 that resulted in an 𝐹2 > 50)
was sampled until the volume occupied by the samples was within 5% of the maximum
possible volume. The volume of the shape was defined using the alphaShape.m and
volume.m functions in MATLAB. To determine the maximum volume, ranges of [60
: 100%], [13 : 24000 sec], and [0.18 : 2.5] were respectively assigned to 𝐹𝑚𝑎𝑥, 𝑇𝑚𝑎𝑥,
and 𝑏. Sampling commenced and proceeded by increments of 50 samples until the
change in the volume occupied by the 𝐹2 > 50 region was < 1.0%. The surface of
the resulting shape was then sampled by rank ordering the respective F2 values (from
smallest to largest, i.e. 50 to 100). Beginning with the first 10 samples (i.e. single series
of 𝐹𝑚𝑎𝑥, 𝑇𝑚𝑎𝑥, and 𝑏) whose F2 value closest to 50, subsequent samples were added

156

until the volume of the subsamples converged to the max volume according to the
previous criteria (i.e. 5%).
The second step of the sampling algorithm was to sample the interior of the shape.
This was performed as per the assumed ability of dissolution parameters to exist
anywhere within the specification limits.

The number of samples randomly drawn

from the interior was set equal to the number needed to represent the surface.
With the surface and interior samples drawn, each set of dissolution model
parameters was processed using the IVIVC and transformed into a rate and extent of
absorption. Using the outputs the IVIVC, the clinical trial simulation platform was
then used to generate distributions plasma concentration profiles. These distributions
were then pooled into a single probably density distribution and saved for the
subsequent assessment bioequivalence errors.

5.2.3 Deriving an encompassing PDF of Bioequivalent Observations
Before bioequivalence errors associated with the use of the F2 statistic could be
assessed two activities needed to performed. First, the criteria for a clinically significant
difference first needed to be defined. Next, an encompassing PDF of bioequivalent
observations needed to be derived based on this criteria.

5.2.3.1 Defining the Criteria for a Clinically Significant Difference
It is extremely unlikely for a test and reference product to perform identically.
Therefore, the determination of bioequivalence requires that a threshold be defined for
what constitutes a clinically significant difference for metrics of interest. There are a
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variety of ways to assess the significance of an observed difference in test-vs-reference
responses for 𝐴𝑈𝐶, 𝐶

,𝑇

,𝐶

,

,𝐶

,

, and 𝐶 . The approach taken in this

work was to base the threshold on the width of the therapeutic window for
carbamazepine as reported by Shargel et al. and supported by others.
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Here, the

authors stated how the effective concentration for carbamazepine was 9 + 3 ng/ml
wherein concentrations below 6 ng/ml and above 12 ng/ml would be subtheraputic and
toxic, respectively. To translate this into a threshold for bioequivalence, the range was
normalized by the target concentration. This was performed according to reports which
discuss how while a target concentration can vary between subjects, the normalized
therapeutic window remains relatively constant.

The resulting window was

𝑇𝑒𝑔𝑟𝑒𝑡𝑜𝑙 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒 ± 33%. Additionally, the within subject variation has been
reported to be approximately 10%.329 While this value is considered low by the FDA,
it was nevertheless accounted for within the acceptance window by subtracting it from
the normalized therapeutic index to ensure consistent clinical performance despite a
patient’s inherent variability. Thus, the threshold for considering a difference to be
clinically significant in mean responses of 𝐴𝑈𝐶, 𝐶

,𝑇

,𝐶

,

,𝐶

,

, and 𝐶

was > + 23%. This window for the accepted difference in the median is illustrated in
Figure 5.2.3.1.1.

Figure 5.2.3.1.1. Introduction of the interval for bioequivalence
Region representing
95% of the observations
0.77*E(ref)
1.23*E(ref)

X-axis: value of 𝐴𝑈𝐶, 𝐶𝑚𝑎𝑥, 𝑇𝑚𝑎𝑥,
𝐶𝑠𝑠, 𝐶
,𝐶
Y-axis: frequency of responses
(i.e. probability)
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E(ref)
E(test)
E(test)
Based on therapeutic index carbamazepine
9 + 3 ug/ml and within subject variability of 10%
(E(X): expected value for the X-product’s responses)

5.2.3.2 Deriving the Encompassing PDF of Bioequivalent Observations
Figure 5.2.3.1.1. makes reference to a region representing 95% of the observations.
When placed in the context of frequentist statistics this interval is the functional
equivalent of the prediction interval for a single observation. In the context of Bayesian
statistics, this interval is the credible interval for a single observation. Deriving the
probability density function along this interval was accomplished according to the
procedure illustrated in Figure 5.2.3.2.1. This process ultimately allowed the primary
research question of this work to be assessed.
For carbamazepine, (and indeed many other drug substances) there is a dynamic
relationship between the mean drug exposure and the observed variability in drug
exposure given this metric of central tendency. With this understanding, the procedure
for deriving the probability density function of bioequivalent observations was guided
by three underlying principles. First, the pharmacokinetic parameters concerning
absorption, i.e. 𝐹 and 𝑘 , are largely dependent upon the dissolution performance of
the final drug product. Additionally, the coefficient of variation for these parameters
are a function of their central tendency.

Finally, the elimination kinetics of

carbamazepine are not zero-order, and, therefore, the clearance, and thus the variation
in clearance, is also a function of the exposure.
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Figure 5.2.3.2.1. Derivation of the PDF describing individual bioequivalent responses
Sample from a uniform distribution
over 𝐹 and 𝑘 respectively

Predict 𝐶𝑉 and 𝐶𝑉 given 𝐹 and
𝑘 , respectively (see chapter 4)

upper
𝐹
limit

𝐶𝑉 = 𝑓(𝐹 )

Does the expected value for the

upper
𝑘
limit

𝐶𝑉

Calibrated Clinical
Trial Simulation
Platform

Process each set of 𝐹 , 𝐶𝑉 , 𝑘 , and
𝐶𝑉 using the CTS platform

Process each set of 𝐹 , 𝐶𝑉 , 𝑘 , and
𝐶𝑉 using the CTS platform

lower
limit
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lower
limit

= 𝑓(𝑘 )

The first step in the process outlined by Figure 5.2.3.2.1 . was to assign uniform
distributions to the values of 𝐹 and 𝑘 . Samples from this distribution were referred
to as 𝐹

,

and 𝑘

. The goal was that after samples were drawn and processed

,

using the clinical trial simulation platform, the distributions of clinical responses would
cover the interval responses bioequivalent to 𝐹 = 0.78 and 𝑘 = 0.28 hr-1 (i.e. the
values for the reference product Tegretol; see chapter 3). The range of possible
𝐹
-1

,

values was [58% : 98%] while the range for 𝑘

was [0.18 hr -1 : 0.37 hr

,

].
With the ranges of 𝐹

,

and 𝑘

,

defined, the next step was to draw a

random sample from each uniform distribution. Once the 𝐹
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,

and 𝑘

,

values

were sampled, the corresponding intersubject variability for a given 𝐹
𝑘

,

(i.e. 𝐶𝑉

and 𝐶𝑉

,

chapter 4. The set of 𝐶𝑉

,

and

) were determined using the models derived in

,

, 𝐶𝑉

,

,𝐹

,

and 𝑘

,

were then used as

,

inputs to the clinical trial simulation platform. Here, in silico patients were generated
following the procedure described in Chapter 4. Individual values for 𝐹 and 𝑘 being
assigned to each generated patient based on a random draw for a normal distribution
defined by a mean of 𝐹

,

and 𝑘

respectively, and a variance equal to the

,

respective coefficients of intersubject variation as per Chapter 4. This method allowed
the absorption parameter-vs-𝐶𝑉
across all the possible 𝐹

,

and 𝑘

relationship to be preserved
values.

,

Two types of in silico clinical trials were run. The first was similar to a traditional
bioequivalence trial in that it was based on a single 200mg dose. The average 𝐶
and AUC∞ values were assigned to a given set of 𝐹

,

and 𝑘

,

values using

the results of these simulations. The second study was based on dosing of the 200mg
strength three times a day for 30 days. The results of this trial were used to assign a
Css value to a given set of 𝐹

,

and 𝑘

,

values. Both simulations were

performed using 50 trials of 24 patients each drawn from the calibrated population
described in Chapter 4. The number of patients per trial was based on the number of
patients included in the foundational studies performed by Meyer et al and Olling et al.
The number of trials was selected to ensure convergence to a stable distribution of
pooled clinical responses. The resulting distribution of clinical responses for each
𝐹

,

and 𝑘

,

sampled in the first step of this process was saved for subsequent

pooling if it satisfied the criteria described in section 5.2.3.1.
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5.2.4 Comparison of F2-based Clinical Responses to the Encompassing PDF
of BE responses
The product of the clinical trial simulations performed according to sections 5.2.2
and 5.2.3.2 were two distributions of clinical responses.

The first distribution

represented the clinical responses originating from the processing of F2 > 50
dissolution profiles using the IVIVC nested within a physiologically based clinical trial
simulation platform. This was considered the F2 distribution. The second distribution
was the distribution of responses bioequivalent to the performance of Tegretol. This
was considered the reference distribution. The distributions were fit using the fitdist.m
function within Matlab (2016)). Within this function, a kernel function was used to fit
the distributions. For any real values of 𝑥, the kernel density estimator’s formula is
given by,
𝑓 (𝑥) =

1
𝑛ℎ

𝐾

𝑥−𝑥
ℎ

were, 𝑥 , 𝑥 , … , 𝑥 are random samples from an unknown distribution, 𝑛 is the sample
size, 𝐾(·) is the kernel smoothing function, and ℎ is the bandwidth. The kernel estimate
for the cumulative distribution function (CDF) of the results was given by,
𝐹 (𝑥) =

𝑓 (𝑡)𝑑𝑡 =

1
𝑛

𝐺

where
𝐺(𝑥) =

𝐾(𝑡)𝑑𝑡
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𝑥−𝑥
ℎ

Here, a non-parametric kernel smoothing function was selected for 𝐾(·) to minimize
bias. The bandwidth was selected based on assessing the root mean squared error in
cross validation (RMSECV). Using a random 25% hold back of the data, the error
between the predicted CDF value and an observed CDF value was assessed across
varying bandwidth window sizes. The window size ultimately decided upon was 150.
With the F2 and reference probability densities defined, the probability of an
observation over a specific interval could be calculated and the differences between the
two distributions could be assessed. The probability over an interval for a given
distribution was assessed by,
.
The area under the PDF was calculated using the Runge-Kutta algorithm within the
ode45.m function in MATLAB.

The interpretation of probabilistic differences

between two distributions supported the use of Bayesian methologies. In Figure
5.2.4.1, the green PDF represents the encompassing (i.e. maximum) distribution of
bioequivalent responses. It was defined as the reference probability distribution of
equivalent responses centered on the performance of a reference product. The blue
PDF represents the clinical responses (propagated via a clinical trial simulation)
stemming from the use alternative, dissolution based, criteria for equivalence, e.g. the
𝐹2 metric. In this Figure there are three different scenarios examined to identify
exactly how differences will be categorized. All differences were made with respect
to the reference distribution as it was explicitly derived according to observed degrees
of intersubject variability and clinically significant differences in clinical performance
(see sections 5.2.3.1 and 5.2.3.2). The categories used were type I or type II errors
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(failures) for bioequivalence. The Bayesian concept of credible intervals was used for
the assessment of these errors. The intervals for the distributions were defined using
their respective 𝐶𝐷𝐹. The upper and lower 2.5% were excluded resulting in what was
defined as the 95% credible interval for the distribution. These intervals were defined
along

the

x-axis

with

values

of

𝐶𝐼

,

and

𝐶𝐼

where

,

𝑖=

[𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 (𝑟𝑒𝑓), 𝑎𝑙𝑡𝑒𝑟𝑛𝑎𝑡𝑖𝑣𝑒 (𝑎𝑙𝑡)]. Errors were assessed at both ends of the
intervals. Scenarios when either (CIlower,ref – CIlower,alt) or (CIupper,ref - CIupper,alt) was
positive or negative, respectively, type I errors were said to exist. The probability of
type I errors in these cases were ∫

,
,

𝑃𝐷𝐹

and ∫

,

𝑃𝐷𝐹

,

,

respectively. Type I errors represent the false rejection of bioequivalence for a given
clinical response on the basis of excessively tight alternative equivalence criteria at a
given boundary condition (i.e. upper or lower). Type II errors were identified when
either (CIlower,ref – CIlower,alt) or (CIupper,ref - CIupper,alt) was negative or positive,
respectively. The probability of type II errors in these cases were ∫
,

and ∫

,

𝑃𝐷𝐹

,
,

𝑃𝐷𝐹

, respectively. Type I errors represent the false acceptance of

bioequivalence for a given clinical response on the basis of excessively wide alternative
equivalence criteria at a given boundary condition (i.e. upper or lower). In a scenario
where when both (CIlower,ref – CIlower,alt) or (CIupper,ref - CIupper,alt) was negative, the
∫
∫

,

𝑃𝐷𝐹

,

𝑃𝐷𝐹 would represent the probability of type II errors.

,

,

would represent the probability of type I errors while the

Figure 5.2.4.1. Illustration for the interpretation of differences in distributions of clinical responses
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PDFGreen – reference responses

PDFBlue – alt. responses
- n% credible interval

- n% credible interval

P(Type II)

P(Type I)

P(Type II)

P(Type I)

CIn,alt is narrower than CIn,ref.
Therefore, P(CIn,ref) - P(CIn, alt) =

CIn,alt wider than CIn,ref.
Therefore, P(CIn,alt) - P(CIn, ref) =

probability of falsely rejecting
BE based on the “test”
equivalence criteria
(i.e. P(type I error)).

probability of falsely accepting
BE based on the “test”
equivalence criteria
(i.e. P(type II error)).

At the upper limit of CIn,ref:
CIn,alt > CIn,ref resulting in the
occurrence of type II error
At the lower limit of CIn,ref:
CIn,alt < CIn,ref resulting in the
occurrence of type I error

5.2.5 Comparison of F2 Dissolution Specification with IVIVC-based
Specification
The comparison of dissolution profile specifications was performed on the basis of
the area occupied by the respective specifications. The F2 area was calculated by
simulating to convergence a stable population of dissolution profiles whose F2 value
was greater than or equal to 50 when compared to the dissolution profile of Tegretol as
per section 5.2.2. The simulated dissolution profiles were made on a minute-wise basis
up until 2 hours. The area under the minimum amount dissolved for each time point in
the population of simulated responses was calculated using the trapz.m function in
MATLAB. This function uses the trapezoidal method for calculating the area under
the curve. This value was then subtracted from the area under a curve defined by the
minimum value for each time point in the population of responses.
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To calculate the area of a dissolution profile specification defined using the IVIVC,
the range of 𝑘𝑎 and 𝐹𝑎 values that resulted in performances that were bioequivalent to
Tegretol as per section 5.2.3.2 were recalled. With these ranges of the acceptable
absorption parameters, the IVIVC of Chapter 2 could then be used to solve for the of
dissolution parameters that would equal the upper and lower limits of 𝑘𝑎 and 𝐹𝑎.
Simulations were then run across the range of acceptable dissolution parameters to
generate a population of dissolution responses just as before. The area occupied by this
population of dissolution profiles was calculated in the same way as with the F2 > 50
dissolution profiles.

5.2.6 Comparison of F2 Dissolution Design Space with IVIVC-based Space
The comparison of design spaces derived from the dissolution specifications based
on F2 and IVIVC required the development of a knowledge space. The knowledge
space was defined by the binder concentration, disintegrant concentration, and porosity
of a four component tableted carbamazepine drug product. The binder used was
hydroxypropyl methylcellulose (HPC; Nippon Soda Co., Ltd. Tokyo, Japan). The
disintegrant used was crospovidone (CP; BASF Corporation, Ludwigshafen,
Germany). The formulation also included microcrystalline cellulose (MCC; Sigm
Aldrich, St. Louis, MO).

Lastly, the carbamazepine was sourced from Cayman

Chemical (Ann Arbor, MI). Only a single lot of each product was used in the study.
In this study the carbamazepine concentration was held constant at 50%. A 3 x 3
full factorial design was used to define the binder and disintegrant concentrations of
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tableted products used for the dissolution experiments in this study (see Table 5.2.6.1).
Any remaining concentration to reach a total of 100% was made up of MCC.

Table 5.2.6.1. Design of Dissolution experiments

Binder (w/w %)

6.25

Disintegrant (w/w %)
3.75

1.25

17

High [CP]
High [HPC]

Med [CP]
High [HPC]

Low [CP]
High [HPC]

14

High [CP]
Med [HPC]

Med [CP]
Med [HPC]

Low [CP]
Med [HPC]

11

High [CP]
Low [HPC]

Med [CP]
Low [HPC]

Low [CP]
Low [HPC]

Each design point was weighed directly into 100 ml plastic jars to reach a sufficient
quantity of 80 grams. The materials were agitated using a benchtop vortex mixer for
30 seconds and then mixed for 20 minutes using a retrofitted bin blender. To ensure
homogeneity, this process was performed in triplicate.
A direct compaction method was selected to prepare tablet formulations. Tablets of
400 mg (200 mg of carbamazepine) were prepared by a compaction simulator
(Presster®, Metropolitan Computing Co., USA) using a 10-mm flat-faced punch. The
rotary press Korsch 336 with 36 stations was simulated at a speed of 0.5 m/s.
Compaction force was between 6 and 10 kN for all tablets.

The porosity was varied across three levels: 8%, 11% and 14%. This was achieved
by altering the punch distances in the press. Porosity (ε) was calculated according to
the following equation based on volume.
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𝜀 = 1−

𝑚
𝑉 ∙𝜌

100

In the porosity equation, 𝑚 is the tablet mass and 𝑉 the tablet volume, and 𝜌 is the
true density of the powder blends. Density of the powder blends was calculated as the
weighted mean from the true density of each component. True density was assessed by
a gas displacement pycnometer (AccuPyc 1330, Micromeritics, USA).
Tablets were allowed to completely relax (approximately 1 week) before
dissolution tests were performed. Relaxation was verified by measuring the tablet
dimensions over a series of several days until values became stable. All tablets used
for dissolution tests were within + 10% of the target porosity. Additionally, dissolution
tests were performed in triplicate and the mean was used as the response.
The dissolution test was performed with a USP Apparatus II (Distek, Inc., North
Brunswick, NJ). The conditions were set according to the USP monograph for
carbamazepine immediate release tablets. The paddle speed was 75 rpm and media was
900 mL water containing 1% sodium lauryl sulfate (w/v) at 37°C. Samples were
analyzed every 3 minutes by UV-VIS Spectrophotometry (Agilent, Santa Clara, CA)
at 287 nm via an autosampler and flow through cell.
JMP (SAS Institute Inc., Cary, NC) was used to model the percent dissolved as a
function of time, binder concentration, disintegrant concentration, and porosity. Here,
the neural platform was used due to its inherent flexibility (see Hertz et al neural
network theory).330,331

Cross validation of the model was performed by randomly

dividing the original data into the training and cross validation sets. The proportion of
the original data used for cross validation was 20%. The use of up to two layers was
provided by the software with an unlimited number of nodes to either layer. The
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activation functions available to be applied at the nodes of the hidden layers were the
hyperbolic tangent function, a linear function, and the Gaussian function (see Table
5.2.6.2). The models selection was made on the basis of minimizing the negative loglikelihood.

Table 5.2.6.2. Available Activation Functions for Modeling % Dissolved
Title
Hyperbolic
tangent
function
(TanH)

Formula

Linear

identity function

Gaussian
function

𝑒
𝑒

−1
+1

𝑒

Description
Sigmoid function that transforms values to
be between -1 and 1, and is the centered and
scaled version of the logistic function.
The linear combination of the X variables is
not transformed.
Helpful when the response surface is
Gaussian in shape.
𝑥 is a linear combination of the 𝑋 variables

An important step of the modeling process was to assess not only the accuracy, but
also the generalizability of the model. Model generalizability is a concept frequently
invoked in the neural modeling domain. This concept is referred to as the avoidance
of overfitting the model to the data. It was assessed by means of a visual predictive
check as described by Jann et al. using the “prediction profiler” function within JMP.332
The visual predictive check is made not only using the inputs and outputs of the
calibration and cross validation samples, but also using interpolated inputs wherein the
outputs are observed for adherence to trends known a priori.
Accuracy of the final model was accessed on the basis of RMSEC, RMSECV and
R2.

Overfitting of the data was assessed by first selecting binder, disintegrant, and

porosity values that existed between the design points of Table 5.2.6.1.

These

interpolated values were then processed using the model. The generalizability of the
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model was supported if the resulting output of dissolution profiles were similarly
interposed in a consistent manner that followed the classically observed trends (i.e.
porosity, disintegrant ∝ dissolution rate; binder ∝ 1/dissolution rate). Additionally,
overfitting was assessed by profiling the marginal effects of binder, disintegrant and
porosity and examining them across their respective ranges for deviations from smooth,
predictable behavior.
With the generalizability of the model supported, the development of the respective
product parameter design spaces was performed.

The use of the three product

parameters in this work resulted in three dimensional design spaces.

Thus,

comparisons between the design spaces were on the basis of volume. Additionally, a
comparison of the binder vs disintegrant design space area at porosity values of 8, 11,
and 14% was performed.
The

F2

design

space

was

refined

by

nesting

the

% 𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑 =

𝑓(𝑡𝑖𝑚𝑒, [𝐻𝑃𝐶], [𝐶𝑃], 𝑝𝑜𝑟𝑜𝑠𝑖𝑡𝑦) model within the F2 equation. Values for HPC, CP,
and porosity were then randomly sampled and F2 values were calculated. The points
that resulted in F2 > 50 were saved until a stable design space was converged upon as
per section 5.2.2.
The IVIVC based design space was defined using a MATLAB function developed
in-house that a randomly defined a set of binder, disintegrant, and porosity values and
translated them into ka and F values. These absorption parameters were then compared
to the bioequivalent range of ka and F defined after the activities of section 5.2.3.2.
Those sets of binder, disintegrant, and porosity values that resulted in bioequivalent
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performance were then saved and the processes was repeated until a stable design space
was converged upon. The specifics of the routine are described in Figure 5.2.6.1.

Figure 5.2.6.1. Generating a Product Parameter Design Space using IVIVC
Sample from a uniform
distribution for each parameter

Predict dissolution profile using
the model based on the process
parameters

[𝐵𝑖𝑛𝑑𝑒𝑟]

[𝐷𝑖𝑠𝑖𝑛𝑡𝑒𝑔𝑟𝑎𝑛𝑡]

𝑃𝑜𝑟𝑜𝑠𝑖𝑡𝑦

% 𝐷𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑 =
𝑓(𝑡𝑖𝑚𝑒, [𝑏𝑖𝑛𝑑𝑒𝑟], [𝑑𝑖𝑠𝑖𝑛𝑡𝑒𝑔𝑟𝑎𝑛𝑡], 𝑝𝑜𝑟𝑜𝑠𝑖𝑡𝑦)

100
80
60
40
20
0

Model predicted dissolution
profile using Makoid Banakar
Model
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1

Time (hr)

1.5

Makoid Banakar Dissolution Model

5.3 Results and Discussion
5.3.1 Comparison of Dissolution Specifications: F2 vs IVIVC
The combinations of Makoid Banakar dissolution model parameters that resulted
in an F2 of > 50 are demonstrated in Figure 5.3.1.1. The a. pane in the Figure is a
representation of the approximately 8k points satisfying the F2 criteria. The b. pane is
the three dimensional shape that captures these points. The volume of this shape was
9.6716e+04 arbitrary units (A.U.).
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Figure 5.3.1.1. Combinations of Makoid Banakar Dissolution Parameters with F2 > 50
b.

b

a.

A distribution of dissolution profiles was generated by inputting each set of points
from Figure 5.3.1.1 into the Makoid Banakar dissolution model. The resulting profiles
are shown in Figure 5.3.1.2. In this figure, the red dots represent the dissolution
performance of the reference product.

The blue region is the product of each

dissolution profile being plotted on the same graph.

Figure 5.3.1.2. Dissolution Profiles with F2 > 50
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The area occupied by the blue region of Figure 5.3.1.2 was 3.2612e+03 (%*min). It is
important that the y-range not be interpreted as the acceptable range of values. To
demonstrate why, consider two dissolution profiles where one is defined by the minimum
y-values for each timepoint and the other is defined by the maximum values. In either case
the, the F2 metric is far less than 50. This is because the conventional F2 > 50 criteria
assured that the average difference across all the time points is < 10%. Thus the upper and
lower limits of the blue region in Figure 5.3.1.2 are define by dissolution profiles that may
have high error at certain time points but very low error at the others. While the area of
the blue region is useful for comparison is it important to keep in mind that the
interpretation that any dissolution profile falling within the blue region will have an F2 >
50 is incorrect. It is acceptable however, to consider that any combination of dissolution
model parameters that falls within the shape of Figure 5.3.1.1.b. will result in a F2 > 50.
For this reason, the more representative measure of the acceptance space is the volume
metric calculated in Figure 5.3.1.1.b.
To refine dissolution parameter limits using the IVIVC, the first step was to recall the
𝑘𝑎 and 𝐹 terms for Tegretol: Fa = 0.78, ka = 0.28. These terms were then incrementally
varied across the respective ranges of [0.2 : 1.0] and [0.01 : 2.0]. The median response for
𝐴𝑈𝐶, 𝐶𝑚𝑎𝑥, 𝑇𝑚𝑎𝑥, 𝐶𝑠𝑠, 𝐶𝑠𝑠𝑚𝑎𝑥, and 𝐶𝑠𝑠𝑚𝑖𝑛 were assessed using the + 33% window
described in section 5.2.3.1
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Identifying Makoid Banakar dissolution model parameters that were bioequivalent
began with defining the range of F and ka values that would provide 𝐴𝑈𝐶, 𝐶𝑚𝑎𝑥, 𝑇𝑚𝑎𝑥,
𝐶𝑠𝑠𝑚𝑎𝑥, 𝐶𝑠𝑠𝑚𝑖𝑛, and 𝐶𝑠𝑠 values that were bioequivalent to that of Tegretol. The
combination of absorption parameter values is represented by Figure 5.3.1.2.a. In this
figure, the red region represents the bioequivalent values for ka and F. The dissolution
parameters, that (when processed using the IVIVC) returned F and ka values that were
within the bioequivalent region of Figure 5.3.1.2.a are shown in Figure 5.3.1.2.b. The
resulting shape was not tractable in every dimension. However, when Fmax/b, Fmax, and
Fmax,Tmax were plotted against one another a tractable shape emerged (see Figure
5.3.1.2.c.). This allowed a discrete encompassing volume to be calculated. The bounds
were based on the max and min parameter values of the F2 based shape. That decision was
made in order to normalize the volume comparison. As such, the volume of the IVIVC
dissolution parameter acceptance space was 1.2666e+09 A.U. and the volume occupied by
the associated dissolution profiles was 4.6100e+08 A.U. (see Figure 5.3.1.2.d.). From this
data it is evident that the use of the IVIVC provides the opportunity to have a wider
dissolution specification (see Figure 5.3.1.2.e.).

Figure 5.3.1.2. Combinations of IVIVC defined Dissolution Parameters

a.

b.
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a. Bioequivalent region (red)

b. Dissolution parameters that return
bioequivalent combinations of F and ka

d.

c.

d. Ratios of dissolution parameters that return
F2 values >50

c. Ratios of dissolution parameters that return
bioequivalent combinations of F and ka

e.

e. percent dissolved vs. time (min):
F2 > 50 region - red;
Bioequivalent dissolution profiles - blue;
Tegretol dissolution - black points;

5.3.2 Comparison of Product Parameter Design Spaces: F2 vs IVIVC
The IVIVC-vs-F2 comparison of product parameter design spaces began by
establishing a model that predicted the amount dissolved based on binder
concentration, disintegrant concentration, and porosity. The results of the dissolution
tests performed according to the design of experiments in Table 5.2.6.1. are shown in
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Figure 5.3.2.1. In this Figure, the model fits are also superimposed over the observed
dissolution profiles.
The number of dissolution profiles, and time points per profile, was 27 and 11
respectively. Therefore, using 20% random subset cross validation the number of time
points in the cross validation set was 60. The summary statistics for the product
parameter dissolution model demonstrated suitable accuracy. The R 2 for the calibration
and cross validation were both > 0.99. The RMSEC and RMSECV was 0.88% and
1.47% respectively. The final model was built with two hidden layers each consisting
of 3 TanH nodes, 2 linear nodes, and 3 Gaussian nodes. The generalizability of the
model was demonstrated by the ability to predictably interpolate between time points
and design points as demonstrated by Figure 5.3.2.3.

Figure 5.3.2.1. Combinations of IVIVC defined Dissolution Parameters

High (6.25%)

Disintegrant Concentration
Medium (3.75%)

lved

High (17%)
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Low (1.25%)

Observed % Dissolved

Observed % Dissolved

Figure 5.3.2.2. Calibration and Cross Validation Models
Cross Validation
Calibration

Predicted % Dissolved

Predicted % Dissolved
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Table 5.3.2.3. Neural Model for the Prediction of % Dissolved
Calibration
Cross Validation
Measures
Values
0.999
0.998
R2
0.88 %
1.47 %
RMSE
307.6
108.4
-Log Likelihood
237
60
N

% Dissolved

Figure 5.3.2.4. Example Response Surface Interpolated using
Product Parameter Dissolution Model

[Disintegrant] = 1.355%; Porosity = 8.5%
(Black points are observed dissolution time points)

With the demonstration of acceptable accuracy and generalizability of the product
parameter dissolution model, the next step in was to generate product parameter F2 metric
and IVIVC design spaces. After nesting the developed dissolution model inside of the F2
calculation, the design space that resulted is presented in Figure 5.3.2.4. The volume of
this shape was 49.4013 A.U.

Figure 5.3.2.4. Product Parameter design spaced based on F2 > 50
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When the product parameter dissolution model was nested within a bioequivalence
(IVIVC-based) loss function, the volume of the acceptable product parameter shape was
40.8200 A.U. (see Figure 5.3.2.5).

Figure 5.3.2.5. Product Parameter design spaced based on IVIVC

The bioequivalence loss function was constructed by:
i.

Modeling the dissolution profiles generated by the product parameter
dissolution model reported in Figures 5.3.2.2 through 5.3.2.4 using the
Makoid Banakar dissolution model
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ii.

Transforming the dissolution model parameters into absorption rate and
bioavailability terms using the IVIVC from chapter 3

iii.

Identifying whether or not the paired absorption rate and bioavailability
terms existed within the bioequivalence region identified in Figure
5.3.1.2.a. and saving the product parameter values if true

To understand why the IVIVC design space was smaller than the F2 design space despite
the former having a wider dissolution specification, one must evaluate the dissolution
profiles resulting from each model. Figure 5.3.2.6. illustrates the respective dissolution
profile ranges. The red range in this Figure corresponds to the F2 product parameter design
space and the blue range corresponds to the IVIVC design space. Within Figure 5.3.2.6
the most apparent difference was that the F2 criteria allowed for release rates that were
faster than those provided with the IVIVC. By combining this observation with the
information contained within Figure 5.3.2.1. the reason for the differences between the
product parameter design spaces becomes clearer. The earlier Figure demonstrates how
faster dissolution rates can be achieved by a wider variety of product parameter
combinations. This allows the larger F2 design space to align with the observed results of
the faster releasing F2 dissolution profiles.

Figure 5.3.2.6. Dissolution Profile Ranges for the F2 and IVIVC Design Spaces
100

% Dissolution

80

60

40

20

182

An additional feature of the profiles that made up Figure 5.3.2.6 was that when each
profile was fit using the Makoid Banakar dissolution model, the slope parameter (𝑏) was <
1 in all cases. This scenario meant that the profiles were all mono-exponential as opposed
to a combination of mono-exponential and sigmoidal profiles as was the case in Figure
5.3.1.2.e. This was interpreted to mean that, while sigmoidal release rate can occur (as
evidenced by the slowest releasing products of Figure 5.3.1.2.e.) in the ranges of interest
the release characteristics are most realistically represented by Makoid Banakar slope terms
of < 1. This characteristic of the model drug product was carried forward to the simulations
of the next section.

5.3.3 Post hoc Assessment of F2 Dissolution Spec using the PB-IVIVC-CTS
Platform
The population of F2 > 50 dissolution profiles from Figure 5.3.2.6. were processed
using the IVIVC of Chapter 3 coupled with the clinical trial platform of Chapter 4 to
create distributions of pharmacokinetic profiles. The summary metrics for these

lized Frequency

profiles were individually calculated and the results are shown in Figures 5.3.3.1.

a.

Figure 5.3.3.1. Bioequivalent Pharmacokinetic Responses and
Responses Resulting from F2 > 50 Dissolution Profiles
c.
b.
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Interpreting the calculated F2 distributions shown Figures 5.3.3.1. was
accomplished by recalling several concepts:
i)

The observations which made up the distributions were paired

ii)

Errors for bioequivalence were assess at both the upper and lower limits
of the distribution of bioequivalent responses (upper and lower green
lines)
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iii)

F2 associated type I errors for bioequivalence could only occur at the
upper or lower limits if there were no type II errors at those limits for
any of the summary pharmacokinetic metrics

iv)

F2 associated type II errors were defined as red observations made
outside upper and lower boundaries identified by the green lines

v)

If an in silico subject from the red distribution had a single
pharmacokinetic metric that was outside the upper and lower boundaries
for what constituted a bioequivalent response, the subject’s experience
was recorded as type II error for bioequivalence.

In Figure 5.3.3.1.e it is observed that the lower limit for the 95% credible interval
associated F2 (𝐿𝐿

%

,

) distribution is below that of the lower limit for the 95% CI

defined by the distribution of truly bioequivalent responses (𝐿𝐿
area occupied by the region between the 𝐿𝐿

%

,

and 𝐿𝐿

%

%
,

,

). The red

thus constitutes

the probability of type two errors at the lower limit of bioequivalence (𝑃(𝛽 ) =
5.8%).
In graphs a., b., c., d., and f. of Figure 5.3.3.1. it is observed that the upper limit
for the 95% credible interval associated F2 (𝑈𝐿

%

,

) distribution is above that of

the upper limit for the 95% CI defined by the distribution of truly bioequivalent
responses (𝑈𝐿

%

and 𝑈𝐿

thus constitutes the probability of type two errors in bioequivalence

%

,

,

). The red area occupied by the region between the 𝑈𝐿

%

,

at the upper limit (𝑃(𝛽 )). Internal assessment of the paired responses showed that
the greatest occurrence of unique type II errors at the upper limit of bioequivalence
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occurred for the 𝐶

metric. The 𝑃(𝛽 ) for this term was 6.6%. With such errors

for bioequivalence occurring at both the upper and lower limits, it can be stated that
the results of this work indicate that only type II errors for bioequivalence are
associated with the use of the F2 statistic. Furthermore, the probability of
biononequivalence occurring was calculated to be 12.3% (𝑃(𝛽
𝑃(𝛽 )). The significance of 𝑃(𝛽

) = 𝑃(𝛽 ) +

) associated with the use of the F2 statistic can

be placed into context by considering that approximately 3.4 million Americans suffer
from epilepsy, approximately 280k+ adults suffer from trigeminal neuralgia, and
approximately 31 million Americans suffer from mood disorders – all of which can
be treated using carbamazepine.333-336 With an estimated 12.3% of patients being put
at risk for biononequivalence when the F2 statistic is selected to justify similar product
performance, over 400,000 patients could be affected by the strategic decision.
However, if the IVIVC is used to justify similar product performance, the risk of
biononequivalence can be directly controlled.

5.4 Conclusion
The activities of this chapter focused on comparing design spaces and specifications
derived from the use of the F2 statistic with those defined using a physiologically
based IVIVC. This was performed in three steps:
1st) Dissolution specifications were defined using the F2 and IVIVC methods
respectively without constraining the possible parameters for the Makorid
Banakar dissolution model,
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2nd) A product parameter design space was constructed using dissolution profiles
expressed by the product parameter dissolution model, and
3rd) The F2 product parameter design space was processed using the IVIVC and
the distribution of clinical responses were compared against the distribution
of clinical responses explicitly controlled by the use of the IVIVC from the
onset of design space refinement.
The first step showed that IVIVC allowed for a larger range of Makoid Banakar
dissolution model parameters when compared to the F2 range. This lead to an initial
expectation that the IVIVC would similarly allow for a larger space of acceptable
product parameter values.

However, the second step exposed that upon using

dissolution profiles that were based on the performance of a real world tablet system,
the opposite was observed to be true: the IVIVC product parameter design space was
smaller than the F2 design space. This observation was due to the effect of the binder,
disintegrant, and porosity plateauing within the ranges examined by the design of
dissolution experiments. Steps one and two highlighted the importance of using the
principles of experimental design to develop experimentally informed knowledge
spaces for a pharmaceutical tablet.
The final step of this chapter illustrated how in order to minimize the probability of
setting specifications for quality measurements that are excessively wide or
unnecessarily narrow development tools must be linked back to clinical performance.
The F2 statistic did not provide a connection back to clinical performance and resulted
in an expected 12.3% occurrence of biononequivalent events. This expectation could
be avoided, however, through the use of a physiologically based IVIVC as it allows
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the risk of biononequivalence to be directly controlled for through the refinement of
product parameters with the knowledge of their impact on dissolution.

Chapter 6: Summary and Conclusion
Heraclitus (Greek philosopher c. 500 BCE) wrote, “The only thing constant is change.”
This concept is especially true for the development, and lifecycle management, of
pharmaceutical products. Here, change can result from modification to facilities, utilities,
equipment, computer systems, formulations, analytical methods, specifications,
manufacturing and cleaning processes, vendors and components, and documentation. With
the pharmaceutical industry being one of the most tightly regulated industries in the world,
managing change is often a challenging part of a sponsor’s pharmaceutical quality system.337
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Modeling and computer simulation offer significant opportunities for enhancing both
quality and efficiency in our industry. The physiologically-based IVIVC and the F2 method
are mathematical modeling approaches used to bridge product development activities over
changes that can occur to a pharmaceutical product’s formulation or manufacturing process.
It was hypothesized in this work that the use of an IVIVC provided superior estimation of
bioequivalence relative to the F2 statistic. This superiority was posited despite reliance upon
the F2 statistic being more efficient and not requiring a paradigm shift away from
conventional biowaiver strategies. Regardless of the industry’s conventional use of the F2
statistic, and its advantage in efficiency, this work demonstrated a clear performance
advantage for the IVIVC approach.
Since 1997, when the FDA adopted the F2 test proposed by Moore and Flanner, the F2
metric has conventionally been used to assess the test-vs.-reference dissolution performance
similarity.338 Currently, sponsors rely on the historical track record of the F2 metric. Users
of this metric benefit from its efficiency. When a formulation or manufacturing process
change occurs, the F2 metric allows a sponsor to move through the resulting decision point
via a method that is straightforward and thoroughly familiar to regulatory agencies.
However, such practice does not provide a clear link back to clinical significance; thus, the
criticality of such a change cannot be accurately assessed using the F2 metric. The major
limitation of the F2 statistic is that it does not account for the inter-subject variance required
for the effective in vivo assessment of similarity for a test vs. reference comparison.
An IVIVC allows for the direct linkage between a dissolution change and its clinical
effects (see Specific Aim I - Chapter 3). Indeed, by nesting an IVIVC within a clinical trial
simulation platform, as shown by the work herein, the prediction of inter-subject variability
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can also be accomplished. The performance of such simulations has historically required
that a large-scale clinical trial be conducted so that population pharmacokinetic analysis
could be carried out on the results (see discussion on NLME modeling in Chapter 2 section
2.4.1). However, such trials are demanding of resources and require extended timelines. The
work presented demonstrates how the consideration of inter-subject variability was achieved
without the need for such population level clinical trials. Here, physiologically based
pharmacokinetic modeling and DMPK assays were relied upon for the mechanistic
prediction of such variability (Specific Aim II – See Chapter 4). Ultimately, this work
supports the justification of the increased cost associated with IVIVC development by
demonstrating a scenario wherein the use of the F2 was associated with a higher risk of
bioequivalence failures.
The IVIVC method confers equivalence by directly controlling errors for
biononequivalence. Alternatively, the F2 method confers similarity when its value is
> 50. This assures that the average test vs. reference difference between dissolution
profiles is < 10%. However, using the F2 criterion fails to emphasize the link between
a quality measurement and clinical significance. Additionally, it does not directly
control the risk of biononequivalence, nor does it provide sponsors an opportunity to
assess the risk of setting excessively narrow quality measurement specifications. This
work demonstrated how bioequivalence could be directly built into the design space
development process (see Specific Aim III - Chapter 5). The project illustrated the
superiority of a carbamazepine product development strategy based on IVIVC
methods, over F2 methods, by quantifying the increased risk associated with the use of
the F2 (see Specific Aim IV - Chapter 5). Future efforts should be conducted on
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incorporating physiologically based pharmacodynamic models within the PB-IVIVC
for a further, more mechanistic, refinement of clinically significant deviations in
performance. It is intended that this work support the movement of product/process
optimization practices away from methods that result in rigid factors of unknown clinical
significance, and towards those that are focused on efficiently achieving specific clinical
objectives.
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